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Abstract 
 
In patients undergoing adolescent idiopathic scoliosis (AIS) surgery the yield and 
differentiation capacities of mesenchymal stem cells (MSCs) from vertebral body 
(VB) and iliac crest (IC) bone marrow (BM) were investigated comparing the 
effectiveness of two MSC-harvesting procedures [density gradient centrifugation 
(Lymphoprep, LMP) and red cell lysis (Ammonium Chloride, AC)]. The burden of 
surgery of 3 surgical approaches (posterior, posterior-costoplasty, antero-posterior), 
for AIS correction was also quantified. 
 
In 18 patients 10ml of BM were aspirated intraoperatively from IC and VB and MSCs 
were isolated using AC and LMP harvesting procedures. MSCs were enumerated 
and phenotypically characterised using colony-forming-unit-fibroblast (CFU-F), flow 
cytometry and trilineage differentiation assays. For the immuno-inflammatory study 
23 patients were recruited. ELISA-assays were performed on serum from 4ml of 
peripheral blood, at 6 peri-operative time-points (T), measuring 4 cytokines 
[(Interleukin) IL-6, IL-10, IL-18 and Procalcitonin (PCT)]. Surgical parameters and 
gender variability were also analysed. 
  
Both IC and VB exhibited similar concentrations of MSCs, however AC yielded 
significantly more MSC/ml by 1.8-fold (IC, p=0.012) and 1.5-fold (VB, p=0.043), 
compared to LMP. Calcium and glycosaminoglycan (GAG) concentrations were both 
significantly higher from VB MSCs, compared to IC [Calcium: AC 8.7-fold (p=0.001), 
LMP 1.2-fold, GAG: AC 3.8-fold (p=0.0005), LMP 1.9-fold (p=0.003)]. Adipogenesis 
did not show significant differences. VB AC-harvested MSCs presented a 
significantly smaller colony area by 1.9-fold (p=0.039), compared to IC AC. 
 
The post-operative concentrations of IL-6 and IL-10 were always significatintly 
elevated at T2 and T3 points, in all 3 approaches (p<0.01) with antero-posterior 
approach presenting the highest levels followed by posterior-costoplasty and 
posterior approaches. Although prolonged procedures and gender type affected 
cytokine concentrations, their levels were not statistically significant. 
 
In summary, AC isolated more effectively MSCs, without affecting their function. 
VBBM MSCs demonstrated higher osteo- and chondro-genic differentiation 
capacities, representing a valid source of MSCs in spinal surgery. The surgical stress 
reaction quantified with immune-inflammatory markers, was higher in more 
aggressive and extensile procedures, suggesting greater vigilance in identifying and 
preventing complications.  
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 1  
 A) Initial presentation  B) Progression at 9 months  C) Surgical correction of AIS 
 
1. Introduction  
1.1.1 Description of adolescent idiopathic scoliosis (AIS) 
                  
Scoliosis is a three dimensional deformity of the spine. It is characterised by a lateral 
deviation in the frontal plane, rotation and torsion of the vertebral bodies, associated 
also with progression over the years, in a percentage of patients. It is a relatively 
common clinical finding, especially in the less severe grades1. Based on a 
demographic analysis performed by the American National Scoliosis Foundation, 
spinal deformity affects approximately 2-3% of the general population, corresponding 
to an estimation of 7-9 million people in the United States. In the vast majority of 
cases, is not possible to identify a cause and so it is classified as idiopathic. The 
treatment can vary from physiotherapy and use of special braces, to surgical 
correction when scoliosis progression can not be otherwise controlled. From the 
affected population, 38.000 patients undergoing spinal fusion surgery (Figure 1a,b,c) 
every year. Similarly in the UK, one thousand surgical procedures for spinal deformity 
correction are approximately performed anually2. 
 
 
Figure 1: Standing X-Rays of patient presenting scoliosis deformity: A) At initial 
presentation, B) Progression after 9 months of follow-up, C) Antero-posterior and 
lateral projections at post-operative control. The metalwork used in this case was 
bars, pedicle screws and cross connectors. 
 2  
The surgical correction of AIS is a well established procedure, able to deliver 
substantial improvement and subsequently produce dramatic changes in patients' 
quality of life3. 
 
The surgical procedure for AIS is characterised by two fundamental steps: correction 
of the deformity and fusion of the vertebrae involved (arthrodesis), in order to 
preserve the surgical correction. Spinal fusion is a fundamental element of the 
surgical procedure and its success is achieved by two components; the use of 
metallic implants (immediate) and the biological fusion (long term) of the vertebrae 
involved. Metalwork secure the correction achieved intraoperatively, whilst biological 
fusion ensure the preservation of the correction, virtually for the rest of patients' life. 
Implants are made from different metal alloys, to achieve adequate mechanical 
behaviour and desired strength for the human body4,5. Routinely, implants remain in 
situ for patient's lifetime and the only reason to be removed, is in case of 
complications, such as infections, pain or failure of the metalwork2,6.  
 
The instrumentation is lacking of "self-repairing" possibilities and can resist for a 
relatively limited period of mechanical stress cycles. Whilst the biological fusion is 
achieved via the iatrogenic micro-fractures of the posterior elements of the vertebrae, 
in combination with the addition of graft material which incorporates with the patient's 
skeleton. 
A fast biological fusion will ensure a better preservation of the intraoperative 
correction and also will limit the rate of pseudoarthrosis associated with failure of 
metalwork1. For this reason it is crucial to guarantee the earliest bony fusion of the 
vertebral bodies involved within the scoliosis correction construct. Moreover, a fast 
biological fusion will improve the rehabilitation outcome and the prompt return of the 
patients to the previous life standards. A satisfactory bone callus formation is 
radiologically evident within 6-12 months approximately from the date of the surgical 
correction1. 
 
In order to enhance the healing process autograft material is traditionally used from 
the iliac crest (IC) which is considered the gold standard source due to its properties. 
This practice, despite being in use for many years, is not devoid of risks and early or 
late complications. One of the biggest complication, which affect approximately 40% 
of the patients, is the pain from the donor site7,8. Other complications are related to 
superficial or deed infections, formation of seromas or haematomas, neurologic 
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injuries, structural weakness of the iliac wing and delay of the rehabilitation 
process7,8. 
 
In recent years new advances in the field of cellular and molecular mechanisms 
involved in the biology of fracture healing, provided with new solutions able to 
improve the spinal fusion process. These include the use of BM-MSCs combined 
with scaffold materials and also growth factors, like bone morphogenetic proteins 
(BMPs). The use of which has become recently controversial7,9,10. 
Both ICBM and VBBM are rich of stem cells and can be used for augmenting 
vertebral arthrodesis, due to the high potential of proliferation and osteogenic 
differentiation. The potential of BM and in particular of VBBM, as a valid alternative to 
enhance bone fusion in combination with graft8,11-13, is still not adequately explored in 
spinal field. 
 
Scope of this study is to shed more light among the differences between IC- and VB-
MSCs, isolated with two different methods and also focus on the effects of the 
surgical treatment on the immuno-inflammatory system. 
 
 
1.1.2 Bone tissue 
 
Spine, due to its nature and function, combines two apparently opposite 
biomechanical concepts, flexibility and stability14. The skeleton, and in particular 
spine, has a fundamental role in human evolution14. From a biomechanical point of 
view, provides mechanical support, locomotion and protection of vital organs (chest 
cage, brain, medullar canal)14,15. Moreover, from a metabolic point of view, its high 
calcium content, makes it extremely important for calcium homeostasis. Furthermore, 
the bone marrow contained within the cancellous bone, represent the main site for 
the hematopoietic and the mesenchymal stem cells production.  
 
The skeleton, is a connective tissue and its metabolic activity is influenced by a great 
variety of biochemical, biomechanical, cellular and hormonal factors. Under physio- 
logical conditions, the harmonic balance of these factors play an important role in the 
maintenance of bone turnover and they become key players in the reparative 
process16, when a fracture occurs. 
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A bone fracture is defined as a high concentration of forces able to exceed the 
strength/resistance of the bone, causing disruption of its continuity14-16. Given the 
spectrum of fractures there are numerous classification systems, providing a 
common language to describe them accurately. Fractures can be defined based on 
their anatomic location (metaphysis, diaphysis, epiphysis), their relation with joints 
(intra- or extra-articular), based on fracture's three-dimensional configuration of the 
fragments (comminuted displaced, undisplaced, transverse, spiral, etc.). Following a 
fracture, the bone can be exposed to the outside environment (open fracture), which 
is associated with a higher risk of infection and non-union, or in case the skin 
remains intact (closed fracture) the bone is protected and the sterility is maintained16. 
 
From an aetiological perspective fractures can be classified as: 1) caused by a 
sudden injury applied directly or indirectly on a healthy bone, which are the most 
common, and 2) pathological fractures, occurring in subjects where bone tissue is 
already weak, mainly due to local or systemic metabolic condition (fatigue fractures 
osteoporosis, tumours), or also to genetic predisposition14,16. Iatrogenic fractures are 
performed intentionally to correct axial malalignments, or in case of spinal surgery, 
micro-fractures in addition to bone-graft can guarantee the spinal fusion via 
reactivation of the bone healing process (Figure 2). 
 
 
1.1.3 Physiology of the fracture healing 
 
Following a fracture, the bone tissue activates physiologically reparative mechanisms 
regulated by the coordinated action of a variety of mediators and cells. This process 
is characterised by the unique feature of healing without scarring, due to continuous 
remodelling and bone homeostasis, compared to other tissues14-16. Conventionally, 
this process consist of three stages: initial inflammatory response, followed by 
osteogenic/angiogenic repair (soft and hard callus) and finally bone 
remodelling15,16,18, known as indirect (secondary) process (Figure 2). With the 
advances in the orthopaedic field and the use of metalwork in fracture reconstruction, 
through a rigid construct and minimal gaps between bone ends, it was achieved a 
more direct (primary) type of fracture healing minimising the second stage of callus 
formation16,17. In the spinal field, however, the presence of bone callus is paramount 
in order to achieve the desirable biological fusion. In this study will be mainly 
described the secondary fracture healing process. 
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Figure 2: Secondary bone healing process. Schematic representation, following 
iatrogenic fracture. (Adapted from Netter's Orthopaedics, Italian edition, 2007, 
following explicit permission from Elsevier.) 
 
 
The secondary fracture healing process is the most common type of fracture repair 
mechanism and is characterised by the production of callus. It simulates both 
intramembranous and endochondral ossification, depending on the type of fracture 
and the degree of stability, in a multi-step process with many similarities to 
embryogenesis during skeletal development16.  
 
During endochondral ossification, MSCs differentiate into chondrocytes, producing a 
cartilaginous structure, which becomes the "foundation-stone" for the following 
angiogenetic and osteogenetic steps of the healing process. Contrarily, the 
cartilaginous phase is missing during intramembranous ossification (clavicle) and the 
new bone is formed in a more direct manner following inflammation16,17. 
Following a fracture, the hematoma between and around the fracture ends, triggers 
the inflammatory response which peaks within 24 hours and lasts approximately a 
week19 (Figure 2a).  
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During this stage, phagocytes and macrophages are attracted to the fracture site 
removing in a first place the debris, preparing subsequently the ground for the MSCs' 
homing and the beginning of the reconstruction stage. During the inflammatory 
process, the release of mediators, grow factors and cytokines (TNF-α, IL-1, IL-6, IL-
11 and IL-18), promote further the recruitment of more inflammatory cells stimulating 
angiogenesis, MSCs and the extracellular matrix formation18-20. BMPs 2 and 7, but 
also 4, 9 and 14, have a fundamental role in this process, acting on different types of 
cells, including MSCs. BMPs, are known to be responsible for MSCs homing, MSCs 
chondroblastic and later osteoblastic differentiation, following the dynamic pathway of 
the healing process21. 
 
Gradually, at the end of the first week, the inflammatory stage is succeeded by the 
repair stage (Figure 2b, c). MSCs, under the effect of BMPs, signalling molecules 
and growth factors, are differentiated into chondroblasts, which consequently 
become chondrocytes, providing a soft callus22. This offers a temporary mechanical 
support, as well as a scaffold to use during the angiogenesis process. Adequate 
blood supply is a critical phase for the further progression of the healing progress, 
which leads to the transformation of the soft callus into hard callus, through the 
mineralization of the extracellular matrix. This stage lasts approximately 4-6 
weeks16,18-21.  
 
The remodelling of the callus represents the final stage of secondary bone healing 
process. It is performed though the coordinated action between callus resorption 
from the osteoclasts and lamellar bone deposition from the osteoblasts18-21. This is a 
slow process, which may take years to be completed and is influenced by a variety of 
parameters including age, biomechanical stability and metabolic factors at local and 
systemic level.  
 
 
1.1.4 Risk factors affecting bone union 
 
Despite the fact that bone tissue is physiologically predisposed to heal following a 
fracture, sometime fracture healing mechanisms fail. Given the multiple factors that 
can influence the fracture healing process, there is no yet international consensus 
regarding the cut-off point (in terms of timing) between fracture union and non-union. 
However, the US Federal Drug Administration (FDA) council, defines a non-union as 
a fracture which does not present radiological and clinical signs of healing nine 
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months after the initial injury and without signs of further biological activity for the last 
three months22.  
 
On the other hand, fracture union is characterised by the absence of motion and 
tenderness at the fracture site during physiologic biomechanical load. Moreover, from 
a radiological perspective, union is diagnosed when a callus formation is bridging the 
fracture site in a satisfactory manner to ensure stability14-16. Between union and non-
union, lies the delayed union which is the period between the expected time to union, 
for the anatomic site of interest, and the development of a frank non-union14-16.  
 
Several systemic and/or local factors are known to be associated with possibility of a 
fracture progressing to non-union. General factors such as age, dietary habits, 
diabetes and osteoporosis23 can influence the reparative mechanisms contributing to 
the development of non-union14-16. Contrarily, children and young adults, due to a 
better blood supply at local level and grater MSCs potential tend to heal faster18,22. 
 
Another factor affecting negatively bone healing is smoking. Nicotine, present in 
tobacco, apart from the known vasoconstriction effect at local level, is able to 
interfere with osteoblast proliferation during fracture healing24,25. Furthermore, the 
non-union and the post-operative complication rates in spinal surgery is high in 
smokers26,27 and even higher if smoking is associated with excessive alcohol 
consumption28 and poor diet23,29. Alcohol-induced neuropathic pain associated with 
nutritional deficiency is a well known combination, which can increase the rate of pre- 
and post-operative complications30 (pain, infection, pseudoarthrosis) and 
compromise the post-operative compliance with rehabilitation31, in spinal field. 
Additionally, alcohol can delay osteogenesis affecting negatively MSCs function32 
and angiogenesis28.  
 
Despite the diffuse use of non steroidal anti-inflammatory drugs (NSAlDs) on daily 
basis, their administration following a fracture is a double-edged sword solution; has 
the benefit of the pain relief, but also the inconvenient of a higher risk of 
complications. NSAlDs can affect MSC chondrogenic and osteogenic differentiation 
activity, interfering with prostaglandin synthesis and possibly with cyclooxygenase-1 
(COX-1) activity33. Additionally, prolonged administration of NSAID, for more than 
four weeks period, associated with smoking33 can delay the healing progress and 
significatively increase the non-union risk. Another commonly prescribed drug which 
can be of a great utility in spinal field, but also can interfere with the bone metabolism 
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are the steroids34, which are considered the first line drugs in many rheumatic/ 
autoimmune conditions. However, they can delayed bone healing35, lead to vertebral 
body avascular necrosis34,36 and osteoporosis followed by vertebral fractures37, in a 
wide age range of patients and not exclusively on elderly population.  
 
Other local factors including, deep spinal infection, length of the surgical wound and 
soft tissue status, can influence the healing progress and increase the non-union 
risks.  
To ensure spinal fusion, a concept similar to "diamond concept", characterized by a 
biomechanically stable environment, bone graft, presence of MSCs and growth 
factors, from the micro-fractures, are necessary to ensure fusion38. Since healing 
requires an adequate blood supply any interference with angiogenesis (smoking, 
diabetes, multiple revision surgeries) may interfere with the fracture healing process. 
On the other hand, considering the close relation of the bony component of the spine 
with the neurological structures, it is fundamental to achieve the right amount of 
fusion, but without an exuberant callus or ectopic bone formation, which can 
compress the neurological structures surrounding the spine39. Moreover, a genetic 
susceptibility to fracture non-union, may exist, though inhibition of the signalling 
pathways between BMP and SMAD-6, acting synergically to other risk factors40. 
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1.5 Mesenchymal Stem cells  
1.5.1 History and definitions of MSCs 
 
In 1867, the German pathologist Cohnheim demonstrated the presence of a non-
haematopoietic stem cell population in bone marrow. In his experiment, he first 
created wounds in animals for after injecting in bloodstream an insoluble dye 
observing the appearance of dye-containing cells on the wounds' edges. The author 
observed that the great majority of those cells were coming from bone morrow, 
initiating in this way, the idea of bone marrow as a reservoir of fibroblasts capable of 
collagen generation by the wound site41. Two years later, author Goujon (1869) 
documented the presence of mesenchymal progenitor cells with osteogenic 
differentiation capacity within the rabbits' bone marrow, performing heterotopic 
transplantation experiments42. Goujon's experiments were confirmed in the 
transplantation field, by Biakow (1870) and later by Danis (1960), using diffusion 
chambers containing BM in animal models, showing that bone marrow itself 
presented osteogenic characteristics and was not only an inductive or 
chemoattractant factor for osteogenic cells42.  
 
At the beginning of 19th century, the Russian histologist Alexander A. Maximow, 
proposed the existence of a common precursor cell, within the BM, which generates 
different types of blood cells, the hematopoietic stem cell (HSC)42,43. Later on, 
experiments similar to Goujon, Danis and Biakow, but this time guided by authors 
Petrakova (1963), Friedenstein (1966) and Bruder (1990), using diffusion chambers, 
reinforced the concept of BM being capable of osteogenesis and chondrogenesis42. 
In parallel Ernest A. McCulloch and James E. Till, from experiments on mice in the 
1960s, revealed the clonal ability of marrow cells44. Friedenstain's group in 1973 
identified a non-hematopoietic BM-subpopulation, with colony-forming abilities, 
transplantable and able to growth in basic culture medium showing adherent capacity 
on glass flasks. Later in 1980, Friedenstein and his group, observed that every single 
cell was able to generate a colony with fibroblastic-like characteristics. Moreover, the 
colonies were transplantable, with self-renewal abilities and also capable of 
producing, in adequate environment (recipient animals), specific tissues like bone, 
fat, and cartilage indicating their stem cell nature42,43. The term "colony forming unit 
fibroblast, CFU-F" (referring to stromal cells) was coined in that work, and is in use till 
today. 
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In 1978, Owen formally expressed first the concept of BM-derived stem cell. Later on 
in 1985, Owen and his group proposed a model for the "new" non-hematopoietic 
stromal lineage that contained terms like "stem cell", "committed progenitor", 
"maturing cell", with "fibroblastic", "adipogenic", and "osteogenic" end-stage 
phenotypes42. In the same period, Caplan and Prockop were among the first to 
recognize the important discoveries of the Russian scientist Friedenstein in the 
Western world. In 1991, Caplan expanded further the concept of multi-lineage 
differentiation of the CFU-F cells, having the capacity to differentiate into multiple 
mesenchymal phenotypes including adipose, tendon, ligament, and bone coined the 
term "mesenchymal stem cell".  
 
For the following fifteen years an "explosion" of interest and application of MSCs in 
different fields has been observed, changing consequently the MSCs' terminology 
according to new knowledge discovered every time, leading into misunderstandings 
and confusions between the scientific community. To ensure clarity and a 
standardized use of the MSCs' terminology, in 2006 the Mesenchymal and Tissue 
Stem Cell Committee, of the International Society for Cellular Therapy, published a 
position statement69 to define MSCs' features, including; their tri-lineage 
differentiation nature, the adherence to plastic surface, positive expression of surface 
antigens (CD105, CD73, CD90) and lack of expression of others (CD34, CD45, 
CD14, CD11b, CD19, CD79, HLA-DR) which will be discussed in the 3.6, 4.7 
chapters of this manuscript. 
 
The terms "mesenchymal stem cell" and "marrow stromal cell" have been used 
interchangeably in different circumstances. The mesenchymal stem cells, derived 
from mesenchyme, can differentiate into hematopoietic cells, however the term is 
often used to describe "marrow stromal cells"42,45. However, this is not entirely 
accurate because the term "stromal cells" defines supportive and structural function 
rather than cells with reparative function, able to differentiate into bone, fat and 
cartilage. Hence, a better term to describe this type of cells, could be "multipotent 
stromal cells"45. Mesenchyme is a form of loose reticular connective tissue, made 
mainly by collagen type III. It derives from mesoderm, and protects and supports the 
cells, and reticular fibers within an embryo. Cells within mesenchyme can develop 
into haematopoietic (circulatory and lymphatic system) or non-haematopoietic (bone, 
cartilage, connective tissue) mature cells42. Nevertheless, the term "mesenchymal 
stem cell" gained such global usage that it became the most accepted description.  
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Although several different attempts were made, to create a model including all the 
known characteristics of "multipotent stromal cells", prevailed Gimble's model (1996) 
which expressed the stromal and reparative properties of these cells in an 
overlapping manner42 (Figure 3). 
 
 
 
 
 
 
 
 
Figure 3: Gimble's modified model (1996), summarising MSCs features. 
Illustration adapted from Stem cells handbook, Humana Press Inc., 2004. 
 
 
However, Gilbert's model and the terminology used to describe MSCs are all based 
on the BM tissue. Nonetheless, with the advancement of knowledge in the field and 
the discovery of MSCs or MSC-like cells in different tissues (muscle, fat, hair follicles, 
tooth root, placenta, dermis, articular cartilage, umbilical cord, tendon, etc)42, Gilbert's 
model is not expressing satisfactorily any more the MSCs' multipotentiality42 nor 
plasticity42,43, based also on their heterogeneity according to their topography46,47. 
Moreover, tri-lineage differentiation capacity of MSCs, is expressed differently, 
influenced to a certain extent, by their anatomic origin.  
 
The Stochastic Activation/Repression Model was then proposed by Dennis and 
Charbor in 200248, describing better the plasticity, predisposition and multipotentiality 
of MSCs. MSCs are characterised by the plasticity to trans-differentiate or de-
differentiate and re-differentiate into other cell types, generating a "blurring of the 
boundary" effect between phenotypes, based on the cells' predisposition and the 
stimulus received from the surrounding environment42,43. Moreover, in this model, the 
multipotential events are considered to occur within an "MSC compartment", which is 
not intended as physical space, but as a "genetic state" of expression of their 
multipotential nature. Cells within the MSC compartment can exhibit a range of multi- 
or mono-potential differentiation characteristics42,48, while cells in the differentiation 
compartment are expressing those potentials in response to external stimuli42,48 
(Figure 4).  
Stromal 
cells 
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Figure 4: Stochastic activation-repression model, by Dennis and Charbord, in 
2002. Illustration adapted from Stem cells handbook, Humana Press Inc., 2004. 
 
 
1.5.2 Bone marrow harvesting and MSCs isolation techniques 
 
In the orthopaedic field, MSCs are traditionally isolated from BM, nonetheless they 
can be isolated from a great variety of tissues. In this research will be described the 
BM-harvesting and MSCs isolation procedures from ICBM and VBBM. The stem cells 
are typically harvested directly from the iliac crest. Often BM-MSCs may also be 
taken from the sternum, while tibia/heel and umbilical cord are mainly used for infants 
and  newborns sampling. MSCs can be harvested from the. BM-MSCs can be also 
harvested from vertebrae, but given the difficult access this can be performed only 
during spinal surgery. 
 
As it will be discussed more in details in the next paragraphs, in terms of aspiration 
technique, the principle of "small volumes in small syringe", validated by Hernigou49, 
was adopt in order to maximize the BM-MSCs harvesting. The majority of authors 
consider 1-4ml as the ideal aspiration volume per sample50-53. Nevertheless, from 
slightly bigger BM volumes (10ml approx.), it is possible to obtain a higher number of 
MSCs51,53, without affecting significatively the quality of the sample. Indeed, 
according to Muschler, is possible to have up to 70% donor to donor variability, even 
by using the same technique, comparing to only a 20% variability between different 
aspirated volumes51.  
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MSCs can be isolated from BM aspirates mainly by two techniques: the red cells lysis 
with ammonium chloride (AC) followed by gravity centrifugation and leucocytes 
isolation, or by density gradient centrifugation, using Lymphoprep (LMP), and 
mononuclear cell (MNC) isolation. As it will be discussed more in detailed in the 
appropriate section, AC is a salt solution, causing the lysis of the red cells and 
concentrates the remaining white cells (WBCs) composed by lymphocytes, 
monocytes and granulocytes54. Whilst, LMP solution has a specific density (1.077 ± 
0.001 g/ml), which is similar to MNC (monocytes and lymphocytes) and is able to 
"capture" cells within that density range55-57. Despite the wide use of LMP for MSCs-
isolation, for at least 3 decades, its effectiveness, in terms of maximal MSC yield, has 
been recently questioned, in favour of the AC56,57. 
 
Following BM purification, the majority of modern culture techniques are still using 
the CFU-F assay to select MSCs and count the colony-numbers. Additionally, flow 
cytometry can be used to select MSCs based on specific surface and intracellular 
markers, which will be described in the flow cytometry section 3.5, 4.7. An alternative 
method for MSC-isolation, is by magnetic-activated cell sorting (MACS). This method 
utilize magnetic nanoparticles coated with antibodies against particular surface 
antigens of MSCs. With the help of a strong magnetic field, MSCs attached to the 
magnetic nanoparticles expressing the antigen, will stay within the magnetic field, 
while the rest will flow through. In this way its possible to isolate a particular group of 
cells depending of their magnetic charge. 
 
 
1.5.3 In vitro expansion of MSCs for therapeutic purposes 
 
MSCs populations are rare and often culture expansion is fundamental for 
regenerative medicine and bone tissue engineering, in order to produce therapeutic 
concentrations of MSCs to guarantee an effective healing outcome58-60. Nonetheless, 
tissue culture conditions (oxygen concentration, seeding density, medium 
composition, doubling rate), can determine the "in-vitro-age" and affect the way 
MSCs behaving when transplanted in vivo42,43,61. Moreover, the amount of tissue 
culture stress and consequently their chromosomic stability61, can affect the safety of 
MSCs. Additionally, MSC passaging, though trypsinisation, is a laborious and hard to 
control procedure, which put MSCs under extra stress. 
Concerning media composition, the most common ingredient contained in the MSCs 
expansion media is the bovine fetal calf serum (FCS). However, the use of FSC can 
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contain prions and generate unexpected immunological reactions, and MSCs 
behaviors leading currently to extensive research on FSC alternatives62. A possible 
serum alternative can be patient's own serum, combined with autologous MSCs. 
However patient's serum presents donor-to-donor variability and can be affected by 
patient's immuno-inflammatory underlying conditions, influencing consequently MSCs 
behavior and making more difficult comparisons between cultures63,64. For all the 
above reasons, ideally, MSCs should undergo the minimum number of population 
doublings, required to achieve a therapeutic concentration, which is directly related to 
the initial sample concentration and the anatomic/therapeutic requirements. 
 
The use of fresh, autologous and minimally-manipulated MSCs, without been 
subjected to culture expansion, is an attractive alternative. Firstly, because cells 
preserve their relevant biologic characteristics, hence are virtually risk-free for the 
recipient organism; and secondly because are framed under a more flexible human 
tissues legislation, compared to expanded MSCs. United States FDA and also 
European bodies, identifies as "minimally-manipulated MSCs" criteria, only cells 
cryopreservation, centrifugation and separation procedures65. The advantage of 
minimally manipulated MSCs, apart from the medico-legal aspect, is related to the 
recipient's protection from accidental prions contamination, less complex clinical 
management and consequently more cost- effectiveness. Nonetheless, donor-to-
donor variability and potentially low MSCs numbers, are the possible challenges to 
face. However, the intra-operative use of portable volumetric flow cytometry devices, 
cell concentrators and the possibility to harvest vertebral body bone marrow from all 
vertebras included within the spinal instrumentation and additionally access to the 
posterior iliac crests, if needed, are all important elements in an attempt to overcome 
or minimize the possible challenges.  
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1.5.4 Clinical application of MSCs 
 
The ability of MSCs to be expanded in culture, together with their potential to 
differentiate, makes MSCs an excellent source of cells for tissue repair strategies. 
Also the relatively easy harvesting, represent an additional advantage. On the other 
hand, given their physiological presence in the injury site, as part of the healing 
process, their use without further manipulation, is safe and they do not increase the 
risk of tumour formation61, unless subjected to excessive stresses during tissue 
culture expansion. IC remains the gold standard autograft material, given its 
anatomic features, however bone graft harvesting is not devoid of risks and BM 
aspiration is not always assured66,67. Therefore, alternative approaches and MSCs 
sources have been proposed51. VBBM is rich in MSCs which can be used for graft 
augmentation in vertebral arthrodesis7,68 and harvested while preparing the pilot 
holes for pedicle screw implantation; it can therefore open new possibilities in spine 
surgery and minimize the use of ICBM aspirate. Regarding the therapeutic 
concentration for the autologous bone-marrow grafted MSCs, in order to be both 
effective and safe an answer was given by Hernigou70,71, suggesting 50.000 MSCs as 
optimum concentration, at least in relation to atrophic tibial diaphyseal non-union. 
Moreover, the author highlighted the importance of cell concentrators, in order to 
increase MSCs numbers in the recipient site. However, the therapeutic activity of 
MSCs is not only limited to the tri-lineage differentiation capacity within the graft, but 
also though their trophic action which can influence the growth of the surrounding 
structures72. Another point for reflection is that although in orthopaedic field is always 
highlighted the importance of the osteogenic differentiation of MSCs, in some cases 
bone formation may also be inappropriate such as in spondyloarthropathies 
(ankylosing spondylitis)73,269. 
 
In orthopaedic field, a post-operative non-union, is the result of an impaired biology in 
combination with local and/or systemic risk factors. Spinal non-union is often 
associated with significant morbidity, which represents not only a therapeutic 
challenge for the surgeon, but is also an expensive complication for both the health 
care system and consequently the society41,43. The increasing demand for higher 
health-care standards and the higher life-span of the population, increases ultimately 
the clinical challenges. In order to promote bone-fusion, different procedures have 
been developed in an attempt to improve the local biology38 (neo-osteogenesis and -
vascularisation) and reduce the risks factors, maximising the clinical outcome and 
reducing subsequently the health-care-cost43. The strategies adopted include 
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optimisation of the mechanical stability, use of scaffolds74,75, growth factors (BMP 
2,7), and a better utilization of the MSCs which can be harvested directly from VB or 
from IC if needed.  
 
Other orthopaedic conditions where the potential therapeutic properties of MSCs can 
be applied are the age-related musculoskeletal disorders such as osteoarthritis and 
fragility fractures from osteoporosis. Both conditions represent a great challenge from 
a medical and socio-economic point of view43,75. Furthermore, in pioneering 
experiments MSCs have also been tested in cartilage and tendon repair models. 
Although is well known the chondrogenic ability of MSCs, hence the potential use for 
tissue repair, it is also notorious the difficulty of articular cartilage to heal, especially 
in adults43. Similarly following a tendon injury, MSCs loaded on collagen scaffolds 
and implanted within the damaged tendon, showed integration with the native tissue 
and maintenance of the original tendon architecture, given the arrangement of the 
collagen fibers76. 
 
MSCs were also tested as a therapeutic option for peripheral nerve and brain injury 
repair. The promise of MSCs as neuro-regeneration, is the hope of many patients 
with a permanent impairment. Many trials have shown improvement of the 
neurological condition or at least protective role43,77. Nonetheless, because of the 
complex neuro-biology, the restoration of the function depends from many factors, 
including the initial nerve damage, the type on neurological structure involved, as well 
as the local and systemic biology. Although there are several trials covering the main 
categories of diseases (demyelisation/spinal cord injury, amyotrophic lateral 
sclerosis, stroke, Parkinson/Huntington, macular degeneration and peripheral nerve 
diseases), there is no MSCs therapy approved yet for routine use77.  
 
Due to their anti-inflammatory/immunosuppressive characteristics, culture-expanded 
MSCs have shown promising results in the transplantation field, to control the graft 
versus host disease and potentially, to treat rheumatoid arthritis78. MSCs are capable 
of suppressing T and B cell proliferation in a dose dependent manner. Additionally, 
allogenic MSCs are not targeted as "non-self" by T cells and natural killers79, thus, 
they can be administered to patients, even with an intact immune system80. Bone 
marrow can be used from a compatible donor to another (allogenic) or harvested and 
returned into the same original donor at a later stage (autologous). Systemic BM 
transplantation is mainly used in case of severe bone marrow diseases, such as 
autoimmune diseases or malignancies and the procedure is usually associated with 
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radiotherapy and chemotherapy with scope to neutralize recipient's BM and his 
immune system response before transfusion43.  
 
However, a fundamental obstacle to overcome is to retain their physiological 
characteristics during the expansion in artificial culture conditions42,43. Furthermore, a 
second difficulty, is the delivery of MSCs to the site of repair, and the local integration 
and promotion of differentiation toward the appropriate mesenchymal phenotype. In 
orthopaedic field is common practice the direct injection or placement of MSCs into 
the affected site, rather than intravenous transplantation, where MSCs could be  
sequestered mainly by the lung filter. Another important technical limitation with the 
intra-operative use of autologous BM-MSCs, is the lack of possibility to know 
prospectively the amount of MSCs delivered locally. Currently, the way to count the 
MSCs' concentration is retrospectively in the tissue-culture lab, via a BM-sample. In 
order to optimize the therapeutic potential of MSCs, new portable devices using the 
volumetric flow cytometry method, may bridge the current technical gap offering a 
real-time intraoperative quality/quantity control on the BM-sample. 
 
It has been entrusted to regenerative medicine and bone tissue engineering 
disciplines, both using the MSCs' therapeutic potential, to provide solutions in order 
to replace or repair damaged tissue through activation, stimulation or correction of 
reparative mechanisms with scope to restore the function. Although the research into 
MSCs biology and the derived applications play a key role in medicine, is still in its 
infancy. Some of the therapies are already available (osteogenesis in orthopaedic 
field), however for the great majority of them, more work is needed before they can 
be routinely applied. Moreover, there are still several unanswered questions about 
MSCs control in vivo, delivery to the target and their effectiveness. Studying how 
these cells work and interact within the body, is critical for the development of 
effective treatments in the future. 
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1.3 Cytokines and Immuno-inflammatory response      
1.3.1 Host defence response in adults and adolescents 
 
When a traumatic or surgical insult takes place, a series of complex mechanisms are 
activated in order to control and restore the physiological homeostasis under the 
principle of the minimal enthalpy status81. These events can trigger a diversity of 
immuno-inflammatory responses which can gradually increase its complexity and 
grade of severity in response to the amount of pathological or surgical conditions 
involved (second hit phenomenon)82-88.  
 
In particular, a surgical insult can elicit a characteristic response, involving increased 
circulating concentrations of stress hormones (e.g. cortisol and catecholamines) and 
synthesis and release of various humoral mediators (e.g. pro- and anti-inflammatory 
cytokines)89. Moreover, acute-phase proteins like C-reactive protein (CRP) and 
metabolic changes (e.g. lipolysis or hyperglycaemia) can occur90. 
 
More specifically, a traumatic or surgical insult can induce an early 
hyperinflammatory response inducing high concentrations of TNF-α, IL-1a, IL-1b, IL-
6, IL-8 as well as neutrophil and macrophage activation. This condition in turn, leads 
to the activation of anti-inflammatory mediators, such as prostaglandin E2, IL-10, IL-
13, TGF-β, INF-α, INF-γ and a series of endogenous soluble receptor antagonists 
(e.g. IL-1Ra). Inducing in such way, a state of immunosuppression, which can 
interfere with monocytes' activity and shift the Th1/Th2 ratio, to the Th2 dominated 
cytokines pattern94,95. Due to the complexity of these mechanisms and the individual 
response of each patient, the fine balance between pro- and anti-inflammatory 
systems can be compromised, predisposing the host to infections, Systemic 
inflammatory response syndrome  (SIRS), multiple organ dysfunction 
syndrome (MODS) and ultimately death96. Another element which can influence 
patients response, is the immuno-protective role of female steroids and the 
immunosuppression effect of android hormones91,97. Thus, to restore the fine balance 
between inflammatory and anti-inflammatory forces, a holistic clinical approach, has 
become fundamental94,96. 
 
Host defence response has been mainly studied in polytrauma patients, but only few 
publications involve patients with associated spinal injuries91-93. In these studies, 
authors underline the severity of the clinical picture and the additional immuno-
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inflammatory involvement when a spinal lesion is present. However, it is difficult to 
quantify its additive effect, in isolation91-93. 
Host defence responses following a major elective surgery, such as scoliosis 
operation in adolescents is not as widely studied as in adults. Additionally, the 
available literature is often performed retrospectively, increasing up to 3 times the 
possibility to miss short term risks/complications during the data collection, which can 
potentially affect studies' outcome98. 
 
Suzuki et al., analysed the pre- and post-operative cytokines from blood samples of 
adolescents undergoing AIS surgery and compared them to a control knee 
arthroscopy group99. The results showed a decrease of the B-Lymphocyte population 
and transient increase of NK and cytotoxic-T-Lymphocytes in scoliosis group. 
Production of INF-α, INF-γ was also suppressed for 3 weeks and the overall 
postoperative effects lasted up to 3 weeks when the surgery was particularly 
prolonged. In addition, an extensive surgery could lead to a greater incidence of 
infection occurring even 4 years postoperatively98,99. Moreover, Krohn et al., 
concluded that cytokines respond differently at local and systemic level following AIS 
surgical correction100. 
 
In severe forms of scoliosis with structured curves, antero-posterior surgery is 
required in order to release the spine, via anterior discectomies, achieving a better 
correction of the deformity. Therefore it was investigated whether the intervertebral 
disc material can contribute to the overall immuno-inflammatory status, considering 
that physiologically, the intervertebral disc is a privileged structure with a low 
interaction with the immune system, due to its anatomy101. Herniated disc per se, can 
cause immuno-inflammatory effects even before the surgical intervention (e.g. 
discectomy)101. Several studies correlated herniated disc material with disc material 
harvested during scoliosis operation, showing higher concentration of TNF-α, IL-1, IL-
6, IL-8, monocyte chemoattractant protein 1, nitric oxide, metalloproteinases and 
prostaglandin E2 in the herniated disc, compared to scoliosis group. However, the 
data did not always correlate with the clinical symptoms102-107. 
 
Considering the above, it becomes a prerogative to investigate further the immuno-
inflammatory aspects of this major elective operation, in a prospective manner, in 
order to be able to implement our knowledge and patient's care, especially in a 
paediatric setting. 
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1.3.2 Essential cell types and mediators involved in the immuno-
inflammatory response 
 
A dynamic interaction exist between cytokines, complement degradation products, 
eicosanoids, platelet activators, coagulation factors, leukocytes, endothelial cells and 
numerous other chemical factors regulating the inflammatory response108.  
 
Cytokines are markers of trauma and key mediators of host defensive reactions. 
They influence the haemodynamic, metabolic and immune responses97,109. The 
cytokines mainly involved in the response to a traumatic or surgical insult, include 
TNF-α, IL-1, IL-2, IL-6, IL-8, IL-10, IL-17 and IL-13110. Cytokine cascade forms a 
complex biochemical network with various effects on the injured host111,112. Moreover, 
a significant overlap exist in terms of the bioactivity between different cytokines108,110.  
 
Cytokines interfere with several cell types including macrophages113, neutrophils, 
mast cells, endothelial cells114, T and B cells108 and NK115. Furthermore, a mutual 
inter-relationship between cytokines and non-immune cells such as MSCs exists, 
considering that MSCs express surface receptors for cytokines and respond to its 
stimulation116-118. The available literature, analyzing these immuno-biologic effects in 
children, is rather limited.  
 
 
1.4 Proinflammatory and antiinflammatory cytokines 
 
Cytokines can be classified as proinflammatory (TNF-α, IL-1, IL-6, IL-8, IL-18, 
procalcitonin) and antiinflammatory (IL-10, IL-13). Their balance contribute to the 
restoration of the natural homeostasis, promoting the healing process following an 
insult81,94,96,119. For the purpose of this study, the kinetics of IL-6, IL-18, procalcitonin 
and IL-10 were analysed and will be described in detail in the next paragraphs. The 
characteristics of TNF-α, IL-1, IL-8 and IL-13 will be briefly described herein.  
 
TNF-α has a 20 minutes half-life, and following an insult reaches the highest 
concentration within 4 hours. It is produced by activated macrophages, mast cells, T 
and B cells, NK and also hepatocytes and splenocytes115. Trigger molecules for its 
secretion are principally IL-1, IL-6, INF-γ and TNF-α itself. Also its involved in the 
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activation of the coagulation cascade95. TNF-α can increase in case of disc 
herniation106,107, but not necessary following scoliosis operation102. 
 
IL-1 has a 6 minutes half-life, and to a certain extent, presents similar effects with 
TNF-α, having a prominent role in the host defence system. In low concentrations 
can trigger a local inflammatory reaction, activating and promoting the homing 
process, inducing also IL-6, IL-8 and TNF-α secretion120. In high concentrations, i.e. 
in case of traumatic insult or infection, it is able to generate a systemic inflammatory 
response. IL-1 is mainly produced by neutrophils and macrophages and is directly 
involved with bone metabolism113. The cellular receptors for IL-1 are divided in two 
categories, the IL-1RI characterised by a better biological activity and the IL-1RII 
which seems to behave as a decoy receptor neutralising the biological effects of IL-1 
itself. The activity of IL-1 is also controlled by other interleukins like IL-4, IL-10 and IL-
1 receptor antagonist (IL-1Ra)95,114. 
 
IL-8 increases rapidly following an injury and reaches the highest concentration 
within 24 hours. Alongside with IL-6, it is considered to be a key mediator in SIRS 
and ARDS121. IL-8 is produced by endothelial cells and promotes chemotaxis for both 
neutrophils and lymphocytes, especially in the lung103. Moreover, increased levels in 
the peripheral circulation have been reported in trauma and also a 100-fold 
increment, has been documented in patients undergoing scoliosis operation88,102. 
 
The role of IL-13 is to provide and maintain a balance between pro-inflammatory and 
anti-inflammatory functions122, impairing the expression of pro-inflammatory cytokines 
(TNF-α, IL-1, IL-6) and up regulating IL-12, which has a principal role against a broad 
range of intra cellular pathogens123. A functional relation between the anti-
inflammatory cytokines IL-4 and IL-13 has been observed, however several aspects 
of this interrelationship need to be further analysed124. 
 
 
1.4.1 Interleukin-6 
 
Interleukin-6 (IL-6) is a pleiotropic proinflammatory cytokine with a broad range of 
humoral and cellular effects related to inflammation, host defence, and tissue 
injury125. IL-6 is induced by viruses, LPS, IL-1, INF-γ and TNF-α125 and it is produced 
by a variety of cell types including fibroblasts, monocytes, macrophages, 
hematopoietic cells, endothelial cells, and T and B cells108. IL-6 is the major mediator 
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of the acute-phase response, leading the synthesis of C-reactive protein125 by 
hepatocytes. It is also crucial for the thermoregulation and the mucosal production of 
IgA108. 
 
IL-6 apart from its proinflammatory function, can self-control its action in an 
antiinflammatory manner, mediated through its inhibitory effects on TNF-α and IL-1, 
and activation of IL-1Ra and IL-10108. Moreover, IL-6 has a local antiinflammatory 
action at muscle level (myokine). IL-6 is elevated during muscular activity, acting like 
a hormone, facilitating delivery of energy substrates to the myocytes126. Its increment 
during muscular exercise, however, is controlled by the antiinflammatory actions of 
IL-1Ra and IL-10, and defers from infection/inflammation, which is preceded by a 
TNF-α126rise. 
 
IL-6 levels from fresh peripheral blood samples in healthy adults population range 
between 0.01 and 11.5 pg/ml125 or according to other studies between 5-15 pg/ml127. 
Its levels are constantly elevated during infection, in polytrauma patients and also 
following scoliosis surgery102. IL-6 presents a long half-life and correlates to the 
degree of systemic immuno-inflammatory reaction and outcome. Therefore it  is less 
transient and more readily measurable marker than IL-1 or TNF-α and can be 
considered a reliable marker of the magnitude of a traumatic or surgical insult91. In 
addition, IL-6 has a regulatory role in bone metabolism balancing the function 
between osteoblasts and osteoclasts. Moreover, estrogens can down regulate IL-6 
function, limiting osteoclasts' action and this can be used in the treatment of 
postmenopausal osteoporosis91,97. 
 
It was previously hypothesised, that IL-6 together with MMP3 and MTNR1B genes 
could predispose for AIS128-130. Considering that BMP4 and leptin have a key role in 
bone metabolism, and also are directly interacting with melatonin, IL-6 and MMP3, it 
was thought that these genes could be potentially "AIS predisposition genes"128-130. 
Additionally, an association between IL-6 gene expression and bone mineral density 
in the lumbar spine was observed131. However, despite this evidence, all authors tried 
to correlate specific gene patterns with aspects of AIS which are not necessary 
unique to the scoliosis etiopathogenesis itself125. Moreover, factors like 
demographics, geographic location, dietary habits and lifestyle of the populations 
examined, could have influenced these correlations. On the other hand, different 
genetic patterns can be found between different populations, making it difficult to 
replicate and extend this hypothesis to all patients presenting with AIS. Furthermore, 
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in contrast with that hypothesis, other authors129,132 did not identified any correlation 
between IL-6, MMP3, and MTNR1B with AIS, at least at a single gene level. 
Nonetheless, a possible synergistic effect may exist between combination of genes 
and AIS129, however, further studies are needed to rule out this potential association.  
 
 
1.4.2 Interleukin-18 
 
Interleukin-18 (IL-18) is a proinflammatory pleiotropic cytokine, structurally similar to 
IL-1 and its biological activities overlap with those of IL-1 and IL-12. It is produced 
mainly from activated macrophages, Kupffer and dendritic cells, but also T and B 
cells, playing a major role in the inflammatory cascade. Additionally, IL-18 is 
constitutively present in many tissues as an inactive precursor (e.g. keratinocytes, 
epithelial and glial cells)133. 
 
IL-18 amplifies the expansion of Th1 cells and also enchases the activity and 
proliferation of NK134. It was originally described as an IFN-γ–inducing factor, 
because it appears to be essential for IFN-γ production, in synergy with IL-12135. IL-
18, due to its pleiotropic nature, presents unique characteristics which are important 
for its protective role in sepsis, mainly due to its ability to induce IFN-γ, but also TNF-
α.  
 
IL-18 in serum of healthy adults was reported to range between 64±17pg/ml135 and 
126 pg/ml in healthy adults, or 260pg/ml in healthy adolescents135. Its levels can be 
significantly increased in patients with traumatic injuries associated to lethal 
sepsis137, otherwise trauma-induced systemic inflammation itself seems to not 
increase significatively IL-18 concentrations137. Moreover, IL-18 levels correlate with 
the magnitude of injury, the severity of the clinical condition and can represent an 
early predictive marker for MODS and lethal outcome of postoperative sepsis95. 
 
IL-18 has a key role in many human diseases, including pancreatitis138, myocardial 
insult, arthritis, bowel disease and hepatic/renal failure135. Moreover, IL-18 plays an 
important role in interstitial lung disease and pneumonia in adults139 and 
adolescents136, which can represent an important post-operative complication in 
spinal surgery. Particularly in case of costoplasty and antero-posterior scoliosis 
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correction, with iatrogenically controlled pulmonary collapse and consecutive direct 
approach to the spine through the thoracic cavity.  
 
 
1.4.3 Procalcitonin 
 
Procalcitonin (PCT) is an inflammatory marker produced in response mainly to 
bacterial infections, but does not usually rise significantly with viral or low grade non-
infectious inflammation140-143. Determination of the presence or absence of bacterial 
infection is fundamental for patients' management and appropriate use of 
antibiotics141. 
 
Synthesis of PCT is regulated by gene CALC-1 and is the precursor of the hormone 
calcitonin (CT)144. Under normal metabolic conditions PCT and CT are present in the 
thyroid gland C-cells and are secreted in response to hypercalcemia inhibiting bone 
resorption by osteoclasts, minimizing oscillations in serum calcium concentration and 
calcium loss. Moreover, hepatocytes can also produce large amounts of procalcitonin 
following stimulation by TNF-α and IL-6142,145. Although during severe systemic 
inflammation, related particularly to bacterial infection, PCT is secreted in large 
quantities, CT levels do not necessary rise142,145. 
 
PCT serum level in healthy individuals is generally low146,147 (adults and children 
≤0.15ng/ml) and its directly related to the severity of a bacterial infection. Thus when 
levels exceed 0.25ng/ml, is indicative of minor systemic bacterial infection or infection 
at local level. Contrary, when concentrations rise above 0.5ng/ml, could indicate a 
important systemic bacterial infection146-149. PCT level increases from 3 to 4 hours, 
reaches a peak at about 6 hours and then plateau in 24 hours. In blood serum, PCT 
has a half-life between 25 and 30 hours. In contrast, C-reactive protein (CRP) levels 
rise between 12 and 18 hours after a bacterial challenge146-149.  
 
Higher PCT concentrations are more likely related to bacterial infections, thus, PCT 
is useful in differentiating bacteria from other infectious agents (viruses)150-157. Non-
infectious inflammatory stimuli, like cancer (thyroid), major trauma/surgery, acute 
respiratory distress syndrome, graft-versus-host disease, cardiogenic shock, and 
burns, need to be extremely severe to increase PCT levels150-157. In these conditions, 
PCT has a greater sensitivity and specificity for differentiating patients with Systemic 
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Inflammatory Response Syndrome (SIRS) from those with sepsis. Furthermore, it is 
a more specific indicator of a severe bacterial infection rather than other inflammatory 
markers (IL-2, IL-6, IL-8, CRP and TNF-α) and could be considered one of the 
earliest and most specific markers of sepsis145,158,159 . 
 
Moreover, as suggested by the national guidelines141, PCT in combination with other 
diagnostic tools can help to distinguish between an early infection or non-infectious 
condition, leading consecutively to a better rationalise use of antibiotics and 
potentially to a reduction of hospital stay141. Even though these data are mainly 
related to adult patients, there is limited evidence suggesting that similar effects may 
apply to children presenting a bacterial infection. Additionally, recent studies 
concluded that children with bacterial pneumonia had significantly higher 
procalcitonin levels than those with a viral aetiology150,153,156,159. However, due to a 
certain degree of overlap this test should not be used as a primary "stand alone" 
diagnostic tool, but has to be interpreted in correlation with clinical findings and 
additional complementary tests. Nevertheless, when diagnosis is established can be 
utilized as a monitoring tool141. 
 
 
1.4.4 Interleukin-10 
 
Interleukin-10 (IL-10) acts as a pleiotropic antiinflammatory cytokine, in both innate 
and adaptive immunity, producing mainly immunosuppressive, but also 
immunostimulatory effects on various cell types123. IL-10 is structurally similar to INF-
γ, even though acts as a "brake" to inflammatory responses targeting principally 
macrophages, neutrophils, eosinophils and mast cells, by inhibiting genes 
responsible for TNF-α, IL-1, IL-6, IL-8 and IL-12 synthesis. Also can self-regulate its 
production by destabilising its own mRNA115,123,160. IL-10 can also down-regulate Th1 
cells which trigger the production of IL-2, IL-3, IFN-γ and TNF-, rebalancing the 
Th1/Th2 ratio95,161. Additionally, IL-10 presents an important protective function 
against conspicuous cytokine release during endotoxic shock123.  
 
IL-10 synthesis can be triggered not only by pathogens and their products, but also 
by proinflammatory cytokines. Several cell types can secrete IL-10 (hepatocytes, 
mast cells, eosinophils, B cells) but principally it is produced by activated monocytes, 
macrophages and Th2 cells123,162.  
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IL-10 levels in serum of healthy adult individuals162 range from 3-13.7pg/ml or 0-8 
pg/ml according to other studies performed on adolescents100. IL-10 concentrations 
can rise within 3 hours from the insult in polytraumatized patients and in scoliosis 
operations, however IL-10 concentration tend to become significative after the first 
post-operative day163. Nonetheless, IL-10 concentration correlates with the severity of 
injury and also the degree of the post-insult complications, in comparison to patients 
with an uneventful post-insult course102,113,164. 
 
 
1.5 Coagulation cascade and inflammatory response 
 
The pathophysiology of inflammation and haemostasis are interrelated through a 
bidirectional relationship, and both represent different arms of the host defence 
system. A local or systemic insult is able to activate the inflammatory system as well 
as the coagulation cascade. The close interaction and reciprocal control of these two 
systems, under physiological conditions, restores the tissues physiology following a 
traumatic or infectious insult165,166. The inflammation activates the coagulation 
cascade, and is able to shift the haemostatic balance towards a pro-coagulative 
state, increasing fibrogen concentration (higher risk for thrombotic disease) and 
decreasing the activity of the anti-coagulant and fibrinolytic mechanisms165,166. Major 
inflammatory activators of the haemostatic system at the initial stage, are the pro-
inflammatory cytokines like TNF-a, IL-6 and IL-8165. 
 
The coagulation cascade and the clotting process can enhance the inflammatory 
response, releasing mediators from platelets and also through an inter-cellular 
interaction, promoting in this way the inflammatory response165. Within the 
coagulation cascade, the fibrinogen and the thrombin have a strategic importance 
and represent key molecules of the intrinsic, extrinsic and common pathways. The 
partial thromboplastin time (PTT) is a performance indicator of the intrinsic and 
common pathways (coagulation factors XII, XI, IX, VIII, X, V, prothrombin (II), 
fibrinogen (I), prekallikrein, high molecular weight kininogen), whilst prothrombin time 
(PT) is an indicator of the external and common pathways (coagulation factors VII, X, 
V, prothrombin (II), fibrinogen (I)) 165,166. The evaluation of these two indicators is a 
way to monitor bleeding and clotting disorders, and also represent an indirect way to 
understand better the dynamic evolution of the inflammatory cascade. 
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2. Hypotheses and Aims 
 
2.1 Hypotheses 
 
The effectiveness of density gradient concentration technique (LMP) for MSCs 
isolation will be lower compared with red cells lysis (AC) technique, for both ICBM 
and VBBM.  
 
The number of MSCs in VBBM of scoliosis patients is similar or even higher, 
compared ICBM of the same patients. 
 
MSCs isolated from VBBM are expected to show similar or even better proliferation 
and differentiation potentials compared to MSCs from ICBM.  
 
Following scoliosis surgery, a correlation exists between the type and duration of the 
surgical insult with the kinetics of the proinflammatory and antiinflammatory markers, 
as well as with the clinical and biochemical parameters. 
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2.2 Aims 
 
To quantify MSCs in ICBM and VBBM samples, in donor-matched patients. 
 
To compare the effectiveness of MSCs isolation following density gradient technique 
(LMP) and red cells lysis technique, from both ICBM and VBBM in donor-matched 
patients. 
 
To confirm MSCs' nature and to study their characteristics performing enumeration, 
proliferation and trilineage differentiation (chondrogenesis, osteogenesis and 
adipogenesis) assays in addition to flow cytometry for both VBBM- and ICBM-MSCs, 
isolated using two different techniques from donor-matched patients. 
 
To define the correlation between pro-inflammatory and anti-inflammatory markers 
with clinical and biochemical parameters as well as the duration of the surgery.  
 
To measure, for one week, the proinflammatory cytokines (IL-6, PCT, IL-18) and the 
antiinflammatory cytokine (IL-10) in serum of 3 groups of patients, undergoing AIS 
operation with: a) posterior approach, b) posterior approach and costoplasty, c) 
antero-posterior approach.  
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3. Materials and Methods  
3.1 Patient cohort 
 
3.1.1 Recruitment of patients 
 
Patients undergoing Adolescent Idiopathic Scoliosis (AIS) correction in the spinal 
department of Leeds General Infirmary were invited to participate in the study.  
 
External ethics committee approval (06/Q1206/127) has been granted from the 
NRES Committee Yorkshire & The Humber – Leeds East (Appendix), followed by 
Paediatric ethics committee approval, and Research and Development approval of 
Leeds General Infirmary hospital. Given the young age range of the patients 
recruited and the relative legislation, three different categories of informed consent 
were created for patients and parents: a) patient assent document for ages 13-16y, 
b) parental agreement for same age group (13-16y) and c) a separate consent 
document for patients 16-17y. Additionally, according to Good Clinical Practice 
guidelines, a specific pathway has been put in place for patients recruitment (Figure 
5). 
 
Inclusion criteria were considered: 1) age range between 13 to 17 years old, 2) 
indication for the surgical correction of AIS and 3) their willingness to participate in 
the study.  
 
Exclusion criteria from the study were: 1) age below 13 or above 17 years old, 2) 
presence of abnormal hepatic or renal function on routine laboratory analyses, 3) 
patients treated with known immunomodulatory agents (e.g. corticosteroids) and with 
known bleeding disorders.  
 
Considering the young age of donors, it was not-ethically acceptable to recruit a 
group of healthy donors with similar age-range and without AIS, as a control group, 
for peripheral blood harvesting or for bone marrow harvesting. Therefore, for both 
cases, the internal control concept has been applied. Specifically, pre-operative 
peripheral blood sample and iliac crest bone marrow aspirate have been considered 
as reference values for the post-operative peripheral blood analysis and the 
comparison with the vertebral body bone marrow, for each single patient.  
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First approach with  
patient/parents during the pre-
assessment appointment or in 
scoliosis outpatient clinic. 
 
Patients are not 
interested in the study.  
Patient/parents need more time 
to decide. Second approach 
during the hospital admission.  
 
Patients are keen to 
participate in the 
study. 
 
 
The assent/consent 
forms are singed. 
 
 
Patients are not 
interested in the study.  
 
Patients are interested 
in the study. 
Patients will follow 
the routine clinical 
pathway related to 
their condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Algorithm used for patients consent. The process of informed consent, 
in a paediatric setting, is a more complex act, compared to adults and must follow a 
more rigorous structure, as per guidelines.  
 
 
3.1.2 Patients' cohort: MSCs study 
 
From a cohort of 37 patients, randomly recruited, undergoing elective AIS surgery, a 
total of 46 bone marrow samples were harvested from 19 patients (12 females and 7 
males, median age 15.4 years, range 13-17). From all patients 10ml of bone marrow 
were aspirated intraoperatively from the posterior elements of pelvis (iliac crest, IC) 
and the 12th thoracic vertebra (V12), using validated and publish techniques49-53 
(Table 1), as it will be described in section 3.2.  
 
 
3.1.3 Patients' cohort: immuno-inflammatory response study 
 
The same cohort of 37 randomly recruited patient, (29 females and 8 males, median 
age 15.4 years, age range 13-17) undergoing AIS surgery, was divided in three 
groups, based on the type of surgical approach (Tables 1, 2). The posterior approach 
(group1) was predominant, as it was sufficient to correct the deformity in the majority 
of the cases, followed by the less frequent posterior approach with costoplasty 
(group2) and the antero-posterior approach (group3) which are indicated for more 
severe scoliotic deformities. Lenke classification for the AIS was used3. From all 
patients an average of 8ml of peripheral blood (PB) was withdrawn at specific time-
points and following centrifugation serum and plasma were isolated and 
cryopreserved accordingly, as it will be explained in sections 3.2.1, 3.3. 
 31  
Table 1: Overview of all the patients recruited and the main experiments performed. 
  
N. 
Patient 
Code 
Μ/F 
Surgical 
approach 
ICBM V12 BM  
BM from 
other 
vertebra 
Serum/  
Plasma 
from PB 
CFU-F 
Tri-lineage 
Differentiation 
Flow 
Cytometry 
ELISA 
1 AF 01 F Posterior    √    √ 
2 AF 02 F Posterior    √    √ 
3 AF 03 F Posterior    √    √ 
4 AF 05 M 
Antero-
Posterior 
   √    √ 
5 AF 06 F Posterior    √    √ 
6 AF 07 F Posterior    √    √ 
7 AF 08 M Posterior    √    √ 
8 AF 09 F Posterior    √     
9 AF 10 F Posterior    √     
10 AF 11 F Posterior    √     
11 AF 12 F Post.+Cost.    √    √ 
12 AF 14 F Post.+Cost.    √    √ 
13 AF 16 F Posterior    √     
14 AF 17 F Post.+Cost.    √    √ 
15 AF 18 F Posterior    √    √ 
16 AF 19 F 
Antero-
Posterior 
√ √  √ √   √ 
17 AF 20 F Posterior √ √  √ √    
18 AF 21 F Posterior    √     
19 AF 22 F Post.+Cost.    √    √ 
20 AF 23 F Posterior √ √ V11
* √ √   √ 
21 AF 24 F Posterior √ √ L1
* √ √    
22 AF 26 M Posterior √ √  √ √   √ 
23 AF 27 M Posterior √ √  √ √   √ 
24 AF 28 M 
Antero-
Posterior 
√ √  √ √ √ √ √ 
25 AF 29 M Posterior √ √  √ √ √ √ √ 
26 AF 31 F Posterior √ √  √ √    
27 AF 32 M Posterior √ √  √ √    
28 AF 33 F Posterior √ √  √ √   √ 
29 AF 34 F Posterior √ √ L1
* √ √    
30 AF 35 F Posterior √ √ L1
* √ √   √ 
31 AF 39 F Post.+Cost. √ √  √ √ √ √ √ 
32 AF 40 F Posterior √ √  √ √   √ 
33 AF 43 F Posterior √ √ L1
* √ √   √ 
34 AF 47 F Posterior    √     
35 AF 48 F 
Antero-
Posterior 
√ √ L1
* √ √   √ 
36 AF 49 F 
Antero-
Posterior 
√ √  √ √   √ 
37 AF 50 M 
Antero-
Posterior 
√ √ 
V11
*
, 
L1
* √  √ √ √ 
 
* V11, V12, L1 are used as abbreviations of 11th and 12th thoracic, and 1st lumbar 
vertebrae, respectively.   
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Table 2: Distribution of the three groups of scoliosis, based on the different 
surgical approach.  
 
Group Group size Type of approach 
Group 1 (n=26) Posterior 
Group 2 (n=5) Posterior + Costoplasty 
Group 3  (n=6) Anterior + Posterior  
 
 
3.2 Collection of blood and bone marrow 
 
3.2.1 Blood sampling/processing and clinical/biochemical data 
collection 
 
Peripheral blood was withdrawn at the following seven time points: pre-operatively 
baseline (Time 0), 2 hours after the onset of the surgery (Time 1), at the end of 
surgery (Time 2), 24 hours after the surgery (Time 3), at 3 days (Time 4), at 5 days 
(Time 5) and at 7 days (Time 6), post-operatively.  
 
It is well known that patient position during prolonged procedures, is associated with 
predictable changes in organs' physiology167,168, but also with a number of possible 
cardio-pulmonary and abdominal complications, that could be related to the direct 
or indirect compression from the spine and the surgical table to the patient's 
organs6,7. These conditions are usually reversible by posture changing, however, 
may be more common than published167,168, suggesting further evaluation. For this 
reason an additional time-point for PB sampling was added (time-point "Turn") only 
for the antero-posterior approach group, to investigate possible immuno-inflammatory 
changes immediately after intraoperative change from lateral to prone position.  
 
As control group it was considered the Time 0 (post-anaesthetic induction, pre-
surgery) of each patient. Moreover, as an additional level of control, an extra time-
point (Time 0a), (pre-anaesthetic induction, pre-surgery) was considered, for four 
patients, to investigate whether anaesthetic procedure can affect interleukins' (IL-6, 
IL-10, IL-18, PCL) baseline. 
 
Post-operative time points were designed to coincide with the routine blood sampling 
for the clinical monitoring, in order to minimise patients' discomfort. Additionally, 
during the same period, patients' clinical course, blood results, transfusions, and drug 
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prescriptions were recorded, as well as local and systemic complications. Due to the 
early hospital discharge of the majority of the patients, the blood sampling of the 5th 
and 6th time points was often applicable only to a few donors with longer length of in-
hospital stay.  
 
 
3.2.2 Plasma and serum isolation and storage 
 
At each time point, the 8 ml of PB collected, were equally divided into 2 vacutainer 
tubes (Vacuette K2EDTA for plasma and Vacuette Serum Clot Activator for serum). 
Plasma contains: dissolved proteins, antibodies, clotting factors, electrolytes, 
hormones, enzymes and products of metabolism, while serum is similar to plasma, 
but devoid of clotting factors. Following blood collection, tubes were gently inverted 
few times to ensure adequate mixing of the blood with the additive contained in the 
tube. Blood was processed within 2 hours of collection. Samples collected for serum 
were allowed to stand for at least 30min., to ensure clotting. Next centrifugation was 
performed for both vacutainer tubes at 446xg for 15min.169. Serum and plasma were 
extracted, aliquoted in 1ml cryovials and cryopreserved in -80°C. 
 
 
3.2.3 Bone marrow sampling 
 
Considering the young age of donors, to establish the optimum volume of bone 
marrow aspirates, in terms of patient's safety and experimental needs, the relevant 
literature3,7,51-53,167-174 and the World Marrow Donor Association guidelines175,176, were 
taken in account. Two bone marrow samples of 10ml each, were collected from 19 
patients, during scheduled operation for AIS, from IC, and 12th thoracic vertebra 
(V12), as a standard procedure. In addition, from 7 patients an extra bone marrow 
sample of 10ml was aspirated from the thoracic 11th (V11) or the 1st lumbar (L1) 
vertebra, in order to assess possible changes in cells concentration between 
vertebras (Table 1).  
 
The bone marrow aspiration, did not affect the surgical procedure which was carried 
out using the classical posterior approach and midline incision, associating 
thoracotomy or costoplasty according to the indication. The only variation to the 
standard technique was the use of a 13 gauge bevel-tipped trocar (Stryker), under 
fluoroscopic control, to create the typical pilot hole for screw insertion instead of the 
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3-4 cm 
blunt probe instrument which is commonly used. The trocar was inserted at 3-4cm 
depth from the posterior part of the pedicle, in order to just penetrate the cortical 
bone and reach the periphery of the cancellous bone of the vertebral body (Figure 6). 
Subsequently, a 10ml syringe was used to aspirate 10ml of VBBM, using established 
technique validated and published by authors Hernigou et al49 and McLain et al52. 
During the same stage of the operation, 10ml of ICBM from the posterior elements of 
pelvis, were also harvested with the same technique. ICBM aspirate was the only 
additional step during the operation, however, its often used in spinal surgery, when 
BM aspirate is needed for scaffold enrichment to enhance the bone healing 
process177. 
 
The left or right side for the bone marrow aspiration, for both IC and VB, was decided 
based on the convenience of the surgeon, considering also that there is no evidence 
of any anatomic difference7,62,68,170-173.  
 
 
 
 
 
 
 
 
Figure 6: Schematic representation of the vertebral harvesting technique. The 
13 gauge bevel-tipped trocar (in green), was inserted in the vertebra for 3-4cm via 
the pedicle, till the periphery of the vertebral body. Next, a 10ml syringe was 
connected to the trocar, to aspirate 10ml of VB BM (Adapted from Human Anatomy 
Atlas, Netter 3rd edition, 2006, following explicit permission from Elsevier.) 
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3.2.4 Bone marrow processing, with LMP and AC 
 
All the procedures related to BM processing were performed under aseptic conditions 
at the cell-culture facility laboratories using biological safety cabinets, Class II. The 
BM aspirates from IC and VB were placed in vacutainer tubes containing K2EDTA, to 
prevent clotting, and immediately processed at the end of each surgical procedure. 
BM from each anatomic region was subsequently divided in two equal portions and 
cells were isolated using density gradient separation (LMP) and red cells lysis (AC) 
techniques. In case of LMP, the principal is to generate a thin interlayer, after 
centrifugation, which isolates monocytes and lymphocytes. At the end of the 
centrifugation the remaining BM components (red cells and granulocytes), are lying 
on the bottom of the falcon tube used. In contrast, AC solution lyses erythrocytes and 
following centrifugation, the remaining WBCs (lymphocytes, monocytes and 
granulocytes) are concentrated within the cell pellet*.  
 
For cell separation using density gradient separation technique, BM was initially 
diluted with PBS (1:1) and subsequently layered over the LMP solution (10ml of 
diluted BM for 15ml of LMP) (Figure 7a). Following centrifugation at 600xg for 20min. 
at RT, the interface, denoted by an arrow (Figure 7b) and part of the supernatant 
plasma layer was aspirated using sterile pipettes and the rest discarded, (Figure 
7c,d).  Subsequently the solution was centrifuged for 4min. at 600xg to concentrate 
the cell pellet, and the supernatant was discarded. The cell pellet was then 
resuspended, washed twice with 5ml of PBS and finally cells were counted in 1ml of 
PBS solution (Figure 7e).  
 
For cell separation using red cells lysis techniques, a 0.86% AC solution it was 
prepared fresh every time, by dissolving 4.3g of high purity AC salt in 500ml of 
distilled and sterilized water. In a 50ml falcon tube, 8ml of 0.86% AC solution was 
added for every 2ml of BM, (Figure 8a). The solution was then gently mixed and 
placed into an incubator at 37°C in 5% CO2, for 10min. to lyse the erythrocytes. The 
purified cell pellet was obtained following 3 cycles of centrifugation (washing) at 
600xg for 4min. each, (Figure 8b,c) and then cells were counted in 1ml of PBS 
solution (Figure 8d). 
________________ 
*Acronyms LMP and AC, will be used in this manuscript as abbreviations of 
lymphoprep and ammonium chloride, respectively, but also to refer to density 
gradient separation and red cells lysis techniques. 
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Figure 7: Overview of BM processing using LMP. A) Diluted BM laid over LMP, B) 
Supernatant and interlayer (arrow) containing the cells of interest (top). LMP and 
discarded component as appears following centrifugation (bottom), C) Supernatant 
and interlayer containing the cells of interest isolated and ready for further wash, D) 
Discarded component and E) Final cell pellet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Overview of BM processing using AC. A) BM mixed with AC, B) 
Following 10min. incubation, C) Cell pellet is visible following first centrifugation, D) 
Final cell pellet following thee cycles of wash. 
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3.3 Tissue culture techniques 
 
3.3.1 Cell counting and cells' viability estimation, with trypan blue dye 
 
The cell pellet, following centrifugation, was resuspended in 1ml of PBS and cells 
were counted in 0.4% trypan blue solution, loaded on a haemocytometer (improved 
Neubauer type), under an inverted microscope (Leica DMIL090). As per counting 
method protocol, 1:2 dilution (10μl of cell solution were diluted with 10μl of trypan 
blue) or 1:10 dilution (10μl of cell solution were diluted with 90μl of trypan blue) were 
performed according to the number of cells178, before counting.  
 
The viability of cells using trypan blue dye, works based on the integrity of the cellular 
membrane, the dye can not penetrate intracellularly when the membrane is intact, 
therefore the cells appear as a transparent spheroid surrounded by a bright crown 
(Figure 9a), otherwise they appear as a dark-blue disc (Figure 9b). Cell concentration 
was calculated using the following mathematic formula:  
Cells/ ml = Mean cell count from 4 large grid squares x 104 x dilution factor178. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Microscopic view of haemocytometer during cell counting. a) Viable 
cells with intact cellular membrane excluding the dye, b) Non-viable cells absorbing 
the dye. 0.4% trypan blue solution was used. Magnification x40. 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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3.3.2 Cells' cryopreservation  
 
Freezing medium solution was prepared, under sterile conditions, consisting of 10% 
Dimethyl sulfoxide (DMSO), 45% Fetal bovine serum (FBS) and 45% Dulbecco's 
modified eagle's medium (DMEM).  
 
Following counting, 10-20x106 of mononuclear cells or at a later stage 1x106 of 
MSCs, were frozen in each cryovial, appropriately re-suspended into 1ml of freezing 
medium. The cryovials were placed into a freezing container, containing isopropanol 
which allowed cells to freeze gradually, preserving the cellular membrane integrity. 
Subsequently, following 24hours stay in -80°C freezer, cryovials were transferred to -
150°C freezers or into liquid nitrogen for long-term storage178.  
 
 
3.3.3 Cells' resuscitation 
  
DNAse ready solution, Sigma, was prepared by dissolving DNAse in 2.75ml of PBS 
and frozen in aliquots of 20μl at -20°C. This was then added to the medium to 
prevent the "clumping" effect of the DNA released from the dead cells, which can 
aggregate the viable cells together, resulting in cells' loss. To the medium 10% FCS 
was also added, which has a protective and nutrient function, at the first stages of 
cells thawing178. 
 
The frozen cryovials were placed in water-bath at 37°C and as soon as the solution 
was defrosted, the content of a vial was quickly transferred into a 15ml falcon tube 
containing 5ml DMEM, supplemented with DNAse (20μl/10ml of medium), 10% FCS 
and Penicillin/Streptomycin (5ml/500ml medium). Cell pellet was subsequently gently 
re-suspended and washed twice in PBS by centrifugation at 200g for 10 min. At the 
end of the second cycle of wash, the supernatant was discarded and cell pellet was 
resuspended in 1ml of DMEM/FCS. At this stage cells were counted, as described 
above21 and utilized accordingly for CFU-F assay, tri-lineage differentiation or for flow 
cytometry as described in sections 3.5, 3.6, 3.7, respectively.  
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3.3.4 Establishment of MSCs cultures 
 
Following thawing and counting, cells were seeded in flasks with a density of 1x105 
per cm2, using NH® MSCs expansion medium and incubating at 37°C in 5% CO2. 
Cells were left for 2 days to adhere and fed twice weekly by half culture medium 
exchange178. All cultures were regularly examined under the microscope to monitor 
the culture progress and the early detection of colonies.  
 
 
3.3.5 MSCs passaging, trypsinisation 
 
When cells reached 80-90% confluency (passage P0), they were trypsinised for 
further expansion or freezing. Before trypsinisation, medium was discarded and the 
culture was washed using sterile PBS. Next, 0.1% trypsin solution was added in the 
culture, incubating for 2-3min. at 37°C in 5% CO2 (Figure 10a,b)
178. Cultures were 
examined microscopically and once cells were lifted from the plastic surface, cell 
suspension was transferred in equal amount of DMEM/10% FCS solution. Next, cells 
were counted, following two washing cycles (centrifugation/re-suspension at 200xg 
for 5min. in 5ml of DMEM/10% FCS solution). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Microscopic view of trypsinisation process. A) MSCs partially 
detached from the plastic surface of the flask, B) MSCs retracted and floating on the 
trypsin solution, following 3min. of processing. Magnification x100. 
 
 
 
 
 
 
 
A B 
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3.3.6 Evaluation of MSCs colony sizes and population doubling time 
 
The total area of colonies covering a 10cm diameter petri-dish, used for CFU-F 
assays, was calculated with Nikon NIS-Elements software, following scanning of the 
plates at 360dpi, using EPSON Perfection 2580 Photo scanner and imaging 
processing software ArcSoft Photostudio v.5. Briefly, the software following 
calibration, was able to measure the area of the plate covered by colonies and 
differentiate it from the empty space between them, calculating the total colony area. 
The single colony area was next calculated dividing the total area by the number of 
colonies.   
 
Population doubling rates (PD) between passages, were calculated comparing the 
initial number of seeded cells (N1) and the final number of expanded cells (N2), and 
the results were divided by the number of days (D) in culture178, using the formula 
PD=Log2(N2/N1)/D.  
 
 
3.4 CFU-F assays 
 
CFU-F assays were performed, as previously described179,180, in order to quantify 
MSCs from ICBM and VBBM using two isolation methods (LMP and AC). Following 
thawing and counting, 2x106 cells were seeded (in duplicates) in 10cm diameter 
petri-dishes, with 8ml NH® MSCs expansion medium changed twice weekly and 
incubated at 37°C in 5% CO2 for a 14 days period.  
 
On the 14th day, culture was stopped, medium was removed and cells were washed 
twice with PBS and fixed with 7ml of 3.7% formalin (RT for 15min.). Formalin was 
next removed and colonies were stained with 5ml of 1% methylene blue, for 30min. 
at RT, then washed in tap water and air-dried. 
 
Scoring was performed by counting the colonies under direct vision for each 
duplicate 10cm petri-dish. Afterwards the average number of colonies per dish was 
calculated and converted into number of colonies per million of cells plated and 
consequently into number of colonies per ml of BM. 
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3.5 Phenotypic characterisation of MSCs using flow cytometry 
 
Reagents 
Fluorescence-activated cell sorting (FACS) buffer; 
Fixation/permeabilization buffer; 
Permeabilization wash buffer; 
5 ml round-bottom polystyrene FACS™ tubes; 
Antibodies and fluorochromes, as listed below (Tables 3,4,5). 
 
 
Procedure 
Flow cytometry was performed with a two fold aim: first, to confirm the MSCs 
phenotype of cultured BM–derived plastic-adherent cells and secondly to investigate 
further the difference of osteogenic potential between IC and VB BM-MSCs.   
Based on the minimal criteria for defining MSCs published from the International 
Society for Cellular Therapy (ISCT)69, cells must meet three conditions: firstly, be 
capable of plastic-adherence when maintained in standard culture; secondly, be able 
to differentiate into osteoblasts, adipocytes and chondroblasts in vitro; and thirdly, 
express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or 
CD11b, CD79a or CD19 and HLA-DR surface molecules. Furthermore, SUSD2 
surface marker for MSCs characterisation was also investigated in this study181-183. 
Additionally, in order to explore the different potential between IC and VB MSCs, 
especially in terms of osteogenic production, MSCA-1182-186 (extracellular) and 
alkaline phosphatase187,188 (ALP) (intracellular) markers, were also analysed (Tables 
3,4). For technical reasons, flow cytometry experiment was performed in three 
groups (two for surface markers and one for the intracellular marker), as illustrated in 
Table 4.   
 
The fluorochromes used in this particular set of experiments were designed to help 
characterize cells through surface and intracellular markers. Can be presented as a 
single dye (FITC, PE, APC, BV421) or as a tandem dye (PE CY-7). Both 
fluorochromes types following excitation by a laser beam produce a different 
wavelength energy, which is measured by separate detectors. Tandem technology, 
often used in combination with single dyes, in multicolour fluorescence studies, links 
two fluorochromes (a smaller and a bigger size) together, with the aim to increase the 
number of colours that can be produced by a single laser wavelength (Table 5).  
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In order to be able to compare the osteogenic potential between IC and VB BM-
MSCs, same passage (P3) cultured MSCs, were used for flow cytometry and 
differentiation assays, utilising always the same four donors (AF28, AF29, AF39 
AF50). The cells were thawed as described in paragraph 3.4.3, and subsequently 
spun for 10min. at 500xg at 4°C, the supernatant was discarded and the cells were 
resuspended in 1ml of ice cold PBS and counted. Following counting, cells were 
centrifuged again and resuspended in 150μl of ice cold FACS buffer. MSCs were 
divided into two groups for surface staining, and a third group for intracellular 
staining. Moreover, for the haematopoietic lineage, most of the negative markers 
(CD14, CD19, CD34, HLA-DR) were combined into a single tube, as per validated a 
published protocol of Leeds MSCs' laboratory183. 7AAD staining was also utilized, 
prior to acquisition, to exclude dead cells and debris189,190. Non-stained cells (for the 
first two groups of surface staining) and isotype control for intracellular staining (third 
group) were used as negative controls, respectively, to set gates on positive labelled 
cells and exclude non-specific binding. The events analysis and gate strategy used, 
will be illustrated in the results section 4.7.1. 
 
The surface staining was performed via incubation of 50μl of cells suspension with 
the primary conjugated antibodies, for 30min. at RT in dark, using a 96-well rounded 
bottom plate. Following two washes in 200μl FACS buffer and centrifugation for 5min. 
at 500xg at 4°C, the supernatant was discarded and cells were resuspended in 200μl 
of FACS buffer and next moved into 5ml FACS tubes for analysis.  
 
For intracellular staining, 50μl of cells suspension with 100μl fixation/permeabilization 
buffer were mixed, then added into a 96-well rounded bottom plate and incubated on 
ice for 20min. This step was used to permeabilize the plasma membrane allowing the 
antibody to penetrate intracellularly, maintaining the morphological characteristics of 
MSCs for phenotype characterization. Following a wash in 100μl of permeabilization 
wash-buffer and centrifugation for 6min. at 300xg at 4°C, the supernatant was 
discarded and ALT antibody was added, incubating for 30min. at RT in dark. Next, a 
further wash was performed with 100μl of permeabilization wash-buffer, as before, 
and the cells were resuspended in 200μl of FACS buffer and transferred into 5ml 
FACS tubes for analysis. Data were acquired using a LSR II 4 LASER flow cytometer 
(BD, Biosciences), and analysed using FlowJo v7.6.5 software, (Treestar, Oregon, 
USA). 
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Flow cytometry was performed with the valuable assistance of Dr. Jehan El-Jawhari, 
who contributed mainly to data acquisition and technical support with the flow 
cytometer.    
 
 
Table 3: List of the MSCs markers used for flow cytometry and their features.  
 
 
 
 
 
Marker Function 
Standard positive markers for MSCs 
CD105 
Endoglin, is a type I integral transmembrane glycoprotein and is an accessory 
receptor for TGF-β complex. It is highly expressed on vascular endothelial cells, 
chondrocytes, syncytiotrophoblasts of term placenta, and it is also present on 
activated monocytes, MSCs and leukemic cells of lymphoid and myeloid 
lineages
191,192
. 
CD73 
Ecto-5'-nucleotidase, commonly serves to convert AMP to adenosine, at neutral pH. 
Can be also related to stromal interaction and MSC migration. It is used as a marker 
of lymphocyte differentiation
191,194 
. 
CD90 
Originally discovered as a thymocyte antigen (Thy-1). Can facilitate cell-cell 
interactions and participate in adhesion of monocytes and leukocytes to endothelial 
cells and fibroblasts. It is used as a marker of MSCs and mature neurons
191
.
   
Additional positive markers for MSCs 
SUSD2 
Sushi Domain Containing 2, is novel and specific marker for BM-MSCs isolation and 
can be used on cryopreserved MSCs. Also it is expressed on vessel-surrounding 
smooth muscle cells, and a few neoplastic cell lines
181-183
. 
MSCA-1 
W8-B2/MSCA-1 is expressed by BM MSCs, and is identical to tissue nonspecific 
alkaline phosphatase antigen (TNAP). Is also expressed at high levels in human liver, 
bone, kidney, embryonic stem cells and co-expressed on BM CD271
+
 MSCs
182-186
. 
ALP Used for detection of endogenous alkaline phosphatase activity from MSCs
187,188
. 
Standard negative markers for MSCs 
CD14 
Acts as a co-receptor (along with the TLR 4 and MD-2 receptors) for the detection of 
bacterial lipopolysaccharides. It is mainly expressed on monocytes and 
macrophages
69,184
.  
CD19 
Acts influencing the threshold for antigen receptor-dependent stimulation of B-
Lymphocytes
69,184
. 
CD34 
It is a cell surface glycoprotein expressed on hematopoietic progenitors and 
endothelial cells and functions as a cell-cell adhesion factor
69,184
.  
CD45 
Protein tyrosine phosphatase, receptor type, C (PTPRC) is also known as leukocyte 
common antigen (LCA). It is a type I transmembrane protein present on differentiated 
hematopoietic cells, B- and T-Lymphocytes
69,184
. 
HLA-DR 
Human leukocyte antigen complex-DR (HLA-DR) presenting cells. It is present on 
macrophages, B-Lymphocytes and dendritic cells
69,184
. 
Dye to exclude dead cells and debris 
7-AAD 
7-Aminoactinomycin D, is a membrane impermeant dye that is generally excluded 
from viable cells. It binds to DNA by intercalating between base pairs in G-C-rich 
regions
183,193
. 
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Table 4: List of antibodies and dyes used in flow cytometry to confirm MSCs' 
phenotype and their osteogenic potential. 
 
Marker Fluorochrome μl/well Isotype Clone Manufacturer / catalogue number 
First group, surface markers 
CD105       FITC 10 IgG1, K 43A4E1 MACS Miltenyi Biotec 130098774 
CD34 PE 10 IgG1, K 563 BD 550761 
CD14 PE 10 IgG2a, K M5E2 BD 555398 
CD19 PE 10 IgG1, K HIB19 BD 555413 
HLA-DR PE 10 IgG2a, K G46-6 BD 555812 
7ADD Dye 10   BD 559925 
Second group, surface markers 
CD73 BV421 5 IgG1, K AD2 BD 562430 
CD90 FITC 5 IgG1, K F15-42-1 MCA90F ABD Serotec 
CD45 PE Cy-7 5 IgG1, K HI30 BD 557748 
SUSD2 APC 5 IgG1, K W5C5 Bio Legend 327408 
MSCA-1 PE 10 IgG1, K W8B2 MACS Miltenyi Biotec 130093587 
7ADD Dye 10   BD 559925 
Third group, intracellular marker 
ALP PE 15 IgG1, K B4-78 R&D Systems FAB1448P 
 
 
Table 5: List of fluorochromes used for flow cytometry and their spectrum 
range. Information illustrated in this table, has been provided by the manufacturer. 
 
Fluorochromes Absorption/Emission (max) 
FITC: Fluorescein isothiocyanate, is sensitive to pH 
changes and to photo-induced degradation. 
494/520nm 
PE: Phycoerythrin, is an accessory photosynthetic pigment 
found in red algae. 
496/578nm 
PE CY-7: Phycoerythrin coupled to cyanine dye CY-7, is a 
combined fluorochrome, as bright as the PE. Particularly 
sensitive to photo-induced degradation, resulting in loss of 
fluorescence and changes in fluorescence spill-over. 
496, 546/785nm 
BV421: Brilliant violet 421, is a very bright polymer-based 
dye, excited by the violet laser. 
407/421nm 
APC: Allophycocyanine, is an accessory photosynthetic 
pigment found in blue-green algae. It has 6 phycocyanobilin 
chromophores per molecule, which makes it a very bright 
fluorochrome. 
650/660nm 
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3.6 Tri-lineage differentiation assays 
 
3.6.1 Osteogenic differentiation of MSCs  
(Calcium assay, Alizarin red staining, Alkaline phosphatase activity) 
 
3.6.1a Spectrophotometry, calcium assay 
 
Reagents and basic osteogenic medium preparation 
Basal medium was prepared, under sterile conditions, dissolving 50ml of FBS 
(Gibco), for MSCs' nutritional supply and 5ml of penicillin and streptomycin antibiotics 
(Gibco), for infection prevention, in 445ml of DMEM (Gibco). Subsequently, 
dexamethasone, ascorbic-2-phosphate and beta-2-glycerophosphate, inducing 
osteoblastic and mitogenic effects in MSCs, were added, as previously described195. 
 
Dexamethasone (Sigma). 25mg of dexamethasone were dissolved in 1280μl of 
100% ethanol, giving a 50mM stock solution. Next, it was aliquoted into 10μl volumes 
and frozen at -20°C. Subsequently, 1ml of DMEM was added to the 10μl volumes to 
give a solution of 500μM which was then aliquoted in 20μl and frozen at -20°C. The 
final solution was added to the osteogenic medium just before use, at 1:5000 dilution 
(20μl in 100ml medium) to give a final concentration of 10μM. 
 
Ascorbic-2-phosphate (Sigma). 2.57g of ascorbic-2-phosphate were dissolved in 
50ml dH2O, giving a 200mM stock solution. Next, it was aliquoted into 50μl volumes 
and frozen at -20°C. The solution was next added to the osteogenic medium at 
1:2000 dilution (50μl in 100ml medium) to give a final concentration of 0.1mM. 
 
Beta-2-glycerophosphate (Sigma). 10g of beta-2-glycerophosphate were dissolved in 
23ml dH2O, giving a 2M stock solution. This it was next aliquoted into 500μl volumes 
and frozen at -20°C. The solution was next added to the osteogenic medium at 1:200 
dilution (500μl in 100ml medium) to give a final concentration of 10mM. 
 
Sentinel diagnostic calcium kit for spectrophotometric reading (Sigma). The kit 
contains 3 solutions: a) the calcium standard (10mg/dl or 100 μg/ml), which was used 
for the standard curves, b) reagent 1 (2-aminoethanol buffer, MEA) and c) reagent 2 
(Cresolphtalein complex-one, CPC). Reagents 1 and 2 were mixed only before use 
at a rate of 5:2, and the working solution was added to all the wells containing 
standards and samples solution. Thereafter, the different levels of purple colour 
generated, were measured spectrophotometrically.    
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Procedure 
For all differentiation assays, MSCs were expanded up to 3-4 passages (P3/P4), 
using 25-150cm2 flasks, until reaching sufficient number of cells. At every passage 
trypsinisation and counting procedures were performed, as described in chapter 3.4. 
Osteogenic medium was made, supplementing 100ml of basal medium with 50μl of 
ascorbic-2-phosphate, 500μl of beta-2-glycerophosphate and adding before use, 
20μl of dexamethasone. 
 
MSCs osteogenic induction was performed in triplicates seeding 3 x 104 MSCs per 
well using a 6-well plate. In each well were added 5ml of osteogenic medium and half 
medium was changed twice a week, for a total of 14 days, in contrast to published 
osteogenic differentiation protocols which suggest 21 days of induction200-202. The 
reason for this decision was the vigorous growth of MSCs, risking to over-populate 
the plate and compromise the outcome of the assay. 
 
At the end of the osteogenic induction period, the medium was discarded, the 
cultures were washed twice with PBS (Ca++ free) and 1ml of 0.5N HCl was added to 
the plate for 5min. at RT, to extract the Ca++ produced. Subsequently, with the help of 
a cell scraper, calcium deposits and fixed MSCs were lifted from the plates' surface 
and transferred to 1.5ml micro-centrifuge tubes. These, were next loaded on a rotator 
device and left overnight in continuous mixing at 4oC, before storing at -20oC freezer. 
When vials from all 4 donors were collected (a total of 48 vials) calcium assay was 
performed using spectrophotometry. For this purpose, vials were micro-centrifuged at 
976g for 5min. and the supernatant was transferred to new micro-centrifuge tubes. 
Subsequently, a 96-well plate (flat bottom) was used for each donor, loaded with 
serial dilutions of the standard calcium solution, performed in triplicates, and 3 
aliquots of the supernatant from each micro-centrifuge tube, as illustrated in Table 6.  
Each well was loaded first with 4μl of calcium solution (standards and samples) and 
next were added 196μl of the working solution (reagents 1 and 2), generating a 
different grades of purple colour, based on calcium concentration contained in each 
well. Calcium per well was then measured spectrophotometrically using a Mithras LB 
940 reader, at 570nm wavelength. Optical density (OD) readings were then plotted 
using Microsoft Excel 2003 and analysed with GraphPad Prism 6, calculating the 
calcium concentrations per well, and therefore per ml of solution.  
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Table 6: Calcium assay, setup of a 96-well plate for spectrophotometry. Each 
96-well plate was loaded using the same arrangement as illustrated below. The first 3 
columns were for standard curves and the rest of the plate was divided in 4 areas, 
based on the same configuration in triplicates, used for the osteogenic differentiation 
assay (IC AC, IC LMP, VB AC, VB LMP), testing 3 aliquots from each micro-
centrifuge tube. 1:2 and 1:5 dilutions were performed, when OD was above the 
standard curve range. 
 
μg/ml 1 2 3 4 5 6 7 8 9 10 11 12 
A 100μg 100μg 100μg IC AC 1 (Triplicates)  V12 AC 1 (Triplicates)   
B 50μg 50μg 50μg IC AC 2 (Triplicates)  V12 AC 2 (Triplicates)   
C 25μg 25μg 25μg IC AC 3 (Triplicates)  V12 AC 3 (Triplicates)   
D 12.5μg 12.5μg 12.5μg IC LMP 1 (Triplicates)  V12 LMP 1 (Triplicates)   
E 6.25μg 6.25μg 6.25μg IC LMP 2 (Triplicates)  V12 LMP 2 (Triplicates)   
F 3.13μg 3.13μg 3.13μg IC LMP 3 (Triplicates)  V12 LMP 3 (Triplicates)   
G 1.56μg 1.56μg 1.56μg          
H 0μg 0μg 0μg          
 
 
3.6.1b Matrix mineralisation, alizarin red staining 
 
Reagents 
Ammonium hydroxide 10% (Sigma), used for pH neutralisation. A 10% ammonium 
hydroxide solution was prepared with 30ml 28% ammonium hydroxide diluted in 60 
ml of dH2O. 
 
Alizarin red solution (Sigma), used for staining of calcium-rich deposits as previously 
described198. A 40mM alizarin red solution was made by dissolving 2g of alizarin red 
in 100ml dH2O. The solution was next made up to 4.1pH, by adding the necessary 
amount of 10% ammonium hydroxide. 
 
Procedure 
Osteogenic medium composition and culturing procedure were the same as 
described per calcium assay previously in section 3.7.1a.  
 
Alizarin red staining was performed in duplicates, seeding 3 x 104 MSCs per well in a 
6-well plate. At the 14th day of osteogenic induction, the medium was discarded, 
cultures were washed twice with PBS (Ca++ free) and fixed adding 70% cold ethanol 
for 1 hour at RT. Subsequently, ethanol was removed, plates were rinsed 5 times 
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with dH2O and calcium deposits were stained with alizarin red for 10min. at RT. Next, 
plates were rinsed again 5 times, as previously, and allowed to dry before scanning 
using EPSON Perfection 2580 Photo scanner and imaging processing software 
ArcSoft Photostudio v.5. 
 
 
3.6.1c Alkaline phosphate assay, fast blue RR staining 
 
Reagents 
Citrate (Sigma), used as component of fixative solution. A 2% of citrate working 
solution was prepared by dissolving 2ml of citrate concentrate solution, into 98ml of 
dH2O. 
 
Fixative solution, used for MSCs fixation. 2 volumes of citrate working solution were 
mixed with 3 volumes of acetone.  
 
Fast Blue solution (Sigma), used as hystochemical semi-quantitative demonstration 
of alkaline phosphatase activity in MSCs. A fast blue RR dye was prepared using a 
50ml centrifuge tube shielded from light, by dissolving fast blue RR salt capsule (4-
Benzoylamino-2,5-dimethoxybenzenediazonium chloride hemi-zinc chloride) into 
48ml of dH2O, in a 37°C water-bath. Following, 2ml of Naphthol AS-MX phosphate 
alkaline solution (3- Hydroxy-2-naphthoic acid 2,4-dimethylanilide phosphate, Sigma) 
was added to fast blue solution. 
 
Procedure 
Osteogenic medium composition and culturing procedure were the same as 
described per calcium assay and alizarin red staining previously, sections 3.7.1a and 
3.7.1b. Procedure was performed as per Sigma-Aldrich validated and published 
protocol (n85). 
 
Alkaline Phosphatase assay was performed in duplicates, seeding 3 x 104 MSCs per 
well in a 6-well plate. At the 14th day of osteogenic induction, the medium was 
discarded, cultures were rinsed twice with PBS (Ca++ free) and fixed using the fixative 
solution for 30sec and plates were rinsed twice with dH2O. Next plates were 
incubated at RT with fast blue solution for 60min., protected from light. Upon the 
completion of staining, dye was discarded and plates rinsed twice with dH2O allowing 
them to dry at RT, before scanning with an EPSON Perfection 2580 Photo scanner.  
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3.6.2 Adipogenic differentiation of MSCs (Oil red-O, Nile red/DAPI staining) 
 
Reagents and basic medium preparation 
Ready NH® AdipoDiff medium (Miltenyi Biotec), for MSCs adipogenic differentiation 
was used. Medium, was composed by: DMEM, L-Glutamine, FBS, phenol red and 
other not specified supplements, as per manufacturer description. No further 
information regarding the concentration of the single compounds of the solution was 
provided by the manufacturer. 
 
Penicillin/Streptomycin (Gibco/Life Tech) was added to prevent culture infection. 
Antibiotic solution was aliquoted in 5ml and stored at –20ºC. This was added to 
adipogenic medium at a 1:100 dilution (1ml per 100ml of NH® AdipoDiff medium). 
 
Procedure 
MSCs were seeded in a 48 well plate at a density of 4 x 104 cells per well and 
cultured during 21 days in 1ml volume of adipogenic medium, performing half 
medium changes twice a week, as previously described201,203,204. Cell cultures were 
regularly checked under microscope, at every medium change, monitoring the 
cellular growth. A total of 3 wells were utilized per each condition (IC AC, IC LMP, VB 
AC, VB LMP), one well for Oil red-O staining and two for Nile red/ DAPI staining. At 
the 21st day, induction was stopped, culture medium was discarded, wells were 
rinsed with PBS, and stained accordingly. 
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3.6.2a Oil red-O staining 
 
Reagents 
Oil red (Sigma), used to stain the lipid droplets. A 0.5% of Oil red solution was made 
by dissolving 50mg of Oil red powder in 10ml of isopropanol in 37C water-bath for 
30min. Subsequently, 3 parts of Oil Red stock solution was diluted with 2 parts of 
dH2O and next filtered through a 0.8μ pore filter followed by 0.2μ filter to remove 
particles. 
 
Formalin 10% (Sigma), was used to fix cells before staining. A 10% formalin was 
made diluting 27ml of 37% formalin stock solution in 73 ml of dH2O. 
 
Procedure 
At the 21st day of adipogenic induction, medium was discarded, wells rinsed twice 
with PBS and cells were fixed with 10% formalin for 10min. Next, plates were rinsed 
again twice in PBS and 1ml of filtered Oil red-O was added for 10min. Following 
incubation at RT, Oil red-O was removed and wells were rinsed again twice in PBS. 
The red-ruby coloured adipose vesicles, contained in MSCs, were observed and 
photographed using an inverted microscope (Olympus CKX41) and the Olympus 
digital camera attached. 
 
 
3.6.2b Nile red/DAPI staining and spectrophotometric reading 
 
Reagents 
Saponin 0.2% (Sigma), used to increase membrane permeabilization and 
subsequently intracellular staining. A 0.2% of saponin solution was made by 
dissolving 0.2g of saponin powder in 100ml of PBS.  
 
Nile red (Sigma), used to stain the intracellular lipid droplets. Nile red stock solution 
of 10mg/ml in methanol aliquot was made and stored at -20°C. A working solution 
was made adding 1μl of Nile red in 10ml of 0.2% saponin solution, (1:1000 dilution). 
 
4,6-diamidino-2-phenylindole (DAPI) (Invitrogen), used to stain the nucleus. DAPI 
stock solution was made by adding 2μl of dH2O to the entire contents of the DAPI vial 
to make a 14.3mM (5 mg/μl) and stored at –20°C. A working solution was made 
adding 100μl of DAPI in 10ml of 0.2% saponin solution. 
  
Formalin, 3.7% (Sigma), used as fixative it was made by diluting 10ml of 37% 
formalin stock solution in 90ml of dH2O. 
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Procedure 
At the 21st day of adipogenic induction, medium was discarded, cultures were 
washed twice with PBS and next fixed with 3.7% formalin for 30min. Subsequently, 
formalin was removed and 200μl PBS were added to each well. Before Nile red/DAPI 
staining, the background fluorescence was read using excitation and emission filter 
sets for DAPI (355/460) and Nile red (485/535), as per manufacturer’s instructions 
using a Mithras LB 940 reader. Wells were "spot read" in a 5x5 pattern, providing 25 
readings per well. The PBS was then removed from the wells, and 200μl 0.2% 
saponin solution was added along with DAPI and Nile red (10ml of 0.2% saponin 
solution with 1μl/ml of Nile red and 1μl/ml of DAPI). The plate was then protected 
from light and incubated at RT for 15min. Following three washes with PBS, 200μl 
PBS were added, and plates were scanned again as before. The adipogenesis ratio 
was determined, calculating the different fluorescence emitted between Nile red and 
DAPI staining.  
 
Subsequently, fluorescent microscopy was carried out using an inverted microscope 
(Olympus CKX41) combined with a light generator (Olympus U-RFLT50). Images 
were photographed using an attached Olympus digital camera. 
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3.6.3 Chondrogenic differentiation of MSCs  
(Glycosaminoglycan assay, qualitative analysis of chondrogenic pellets) 
 
 
Reagents and basic chondrogenic medium preparation 
Chondrogenic basal differentiation medium, was prepared, under sterile conditions, 
supplementing DMEM-high glucose medium (4.5g/l) (Gibco), with the following 
ingredients, up to 500ml of total product, in order to promote chondroblastic and 
mitogenic effects197,198 in MSCs. 
 
Ascorbic-2-phosphate (Sigma), used to enhance chondrogenic differentiation and 
collagen matrix production of MSCs197,198. A 200mM stock solution was made by 
dissolving 2.895g in 50ml of distilled water. The stock solution was aliquoted into 
0.5ml volumes and stored at -20°C and it was next added to basal chondrogenic 
medium at a 1:1000 dilution (0.5ml to 500ml of basal chondrogenic medium). 
  
Sodium pyruvate (Sigma). A 100mM stock solution was made by dissolving 1.1g 
sodium pyruvate in 100ml of distilled water. The stock solution was aliquoted into 
0.5ml volumes and stored at -20°C and it was next added to chondrogenic medium at 
a 1:100 dilution (5ml in 500ml of basal chondrogenic medium). 
 
Proline (Sigma). Stored at RT, was added to basal chondrogenic medium at 20mg 
per 500ml. 
 
Bovine serum albumin (BSA) (Sigma). Stored at 4ºC. It was added to chondrogenic 
medium, as MSCs' nutritional supply, at 1:5 dilution (50ml per 450ml of basal 
chondrogenic medium). 
 
Penicillin/Streptomycin (Gibco/Life Tech). It was aliquoted in 5ml and stored at –
20ºC. Next, it was added to chondrogenic medium at 1:100 dilution (5ml per 500ml of 
basal chondrogenic medium), to prevent culture infection. 
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Supplements added immediately before use, to complete the basal 
chondrogenic medium 
 
Dexamethasone, TGFβ3 and ITS+ show a synergistic effect enhancing the 
expression of collagen genes and increasing the numbers of differentiated MSCs in 
culture, leading to a higher concentration of a functional cartilaginous tissue197-199.  
 
Dexamethasone (Sigma). A 25mg of dexamethasone were dissolved in 1280μl of 
100% ethanol, giving a 50mM stock solution. This, was next aliquoted into 10μl 
volumes and frozen at -20°C. Subsequently, 1ml of DMEM was added to 10μl 
volumes to give a solution of 500μM which was aliquoted in 20μl and frozen at -20°C. 
The solution was added to the basal chondrogenic medium just before use, at a 
1:5000 dilution (1μl in 5ml of medium). 
 
Transforming growth factor (TGFβ3) (R&D Systems). For the TGFβ3 stock solution, 
the follow steps were performed: 1) 4mM HCl containing 1mg/mL BSA diluent 
solution was prepared (2.15mL HCl were added to 25ml of dH2O, at 1:250 dilution, 
followed by 25mg of BSA). 2) 2μg TGFβ3 were dissolved in 2ml of the previously 
prepared diluent to give 1g/ml TGFβ3 stock solution. It was aliquoted into 20μl and 
stored at –20ºC, and added to basal chondrogenic medium at 1:1000 dilution (50μl in 
5ml of medium).  
  
Insulin-Transferrin-Selenium (ITS+) (Invitrogen). ITS+, was added to chondrogenic 
medium at 1:1000 dilution (50μl in 5ml of basal chondrogenic medium).These 
important supplements are utilized by most mammalian cells. They promote glucose 
and amino acids uptake (insulin) and in combination with essential trace elements 
(transferrin and selenium) enhance MSCs proliferation and chondrogenic 
differentiation, in vitro197-199. 
 
Papain (Sigma) was used at a final stage in order to digest the chondrogenic pellet, 
for the GAG concentration measurement. For the final papain solution at pH 6.5, the 
following steps were performed: 1) a sodium phosphate buffer was made mixing 
100mM Na2HPO4 (7.1g/500mL dH2O) with 10mM EDTA (1.86g/500mL dH2O) till 
reaching the desirable pH. 2) For the papain solution were mixed 125μg/ml papain, 
10mM cysteine (0.035g/20mL) and 50U/mL hyaluronidase with the above buffer and 
filtered using a 0.2μ filter. Then the final product was aliquoted in 1ml vials and stored 
at –20ºC. It was added to chondrogenic pellets at 100μl per vial.  
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3.6.3a Glycosaminoglycan assay  
 
Sulphated glycosaminoglycan (GAG) assay kit (Blyscan™), was used to stain the 
chondroitin 4-sulfate produced from chondrocytes. This kit contained 3 components: 
1) dye reagent containing 1,9-dimethyl-methylene blue in an inorganic buffer, which 
also contains surfactants, 2) dissociation reagent containing the sodium salt of an 
anionic surfactant, formulated to dissociate the GAG-dye complex and enhance the 
spectrophotometric absorption of the dye, and 3) the reference standard solution 
made of bovine tracheal chondroitin 4-sulfate (100µg/ml). 
 
Procedure  
Chondrogenic basal medium was made, supplementing 500ml of DMEM (high 
glucose) with 0.5ml of ascorbic-2-phosphate, 5ml of sodium pyruvate, 20mg of 
proline, 500mg of BSA and 5ml of penicillin/streptomycin. To complete the medium 
the following it was added before use: 1μl of dexamethasone, 50μl of TGFβ3 and 
50μl of ITS in 5ml of chondrogenic basal medium, as described in section 3.7.3. 
 
Chondrogenic induction was performed in quintuplicates seeding 25 x 104 MSCs per 
micro-centrifuge tube. Three samples were dedicated to quantitative analysis of GAG 
content (GAG assay) and two for qualitative analysis cryo-sectioning and staining the 
chondrogenic pellets with toluidine blue dye, which stained purple the GAG 
molecules of the cartilage. To arrange the cells in a three-dimensional spherical 
model (pellet), MSCs were micro-centrifuged in centrifuge tubes at 2.439xg for 5min., 
in a provisional medium (0.5ml of DMEM with 2%FCS), which was replaced 
afterwards by equal amount of compete chondrogenic medium. The latter was 
changed 3 times a week (half medium each time), during the 21 days of 
chondrogenic induction, incubating at 37°C 5%CO2, as per validated and published 
protocols200,205  (Figure 11). 
 
Chondrogenic induction was stopped after 3 weeks, the medium was discarded, the 
pellets were washed twice with PBS and to those intended to use for GAG assay, 
100μl of papain was added in the micro-centrifuge tubes following overnight 
incubation in water-bath at 65°C. Next, centrifuge tubes were micro-centrifuged at 
6.099xg for 5min. and stored at –20ºC. When vials from all 4 donors were collected 
(48 for GAG-assays and 19 for cryo-sectioning, 77 vials in total,) the assay was 
performed using spectrophotometry.  
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For this purpose, from each micro-centrifuge tube 30μl of the dissolved with papain 
chondrogenic pellet, were placed into a new micro-centrifuge tube (in duplicate), 
adjusting the contents to 100µl with dH2O. Thereafter, serial dilutions of the standard 
GAG solution were made in duplicates making each standard up to 100µl with dH2O. 
To each micro-centrifuge tube 100μl of the dye reagent were added, and loaded on 
rotator disc for 30min. in continuous mixing at RT. Following micro-centrifugation at 
14.636xg for 10min., GAG-dye complex formed, precipitating as pellet, and the 
residual unbound dye was next discarded. At this stage, 0.5ml of the dissociation 
reagent was added in each tube and mixed using a vortex device followed by a 
second micro-centrifugation at 14.636xg for 5min. Subsequently, a 96-well plate (flat 
bottom) was loaded with serial dilutions of the standard GAG solution (in duplicates), 
and 3 aliquots of 100µl from each sample to test (in triplicates), as illustrated in Table 
7.  
 
As result of the chemical reaction between the GAG content of each sample and the 
1,9-dimethyl-methylene blue dye, different levels of blue colour were generated. The 
amount of GAG per well, was determined spectrophotometrically using a Mithras LB 
940 reader, at 620nm wavelength. OD readings were then plotted using Microsoft 
Excel 2003 and analyzed with GraphPad Prism 6, calculating the concentrations per 
well, and therefore per ml of solution.  
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Chondrogenic pellets during induction period. A) The lid of the micro-
centrifuge tube was left slightly loose to allow gas exchange. Typical spheroid pellet 
is visible at the bottom of the tube. B) Characteristic change of the chondrogenic 
medium colour around the pellet, due to metabolic activity of the developing 
chondrocytes, following two days from medium change. A total number of 77 
chondrogenic cultures were performed for all four donors. 
A B 
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Table 7: Composition of the 96-well plate for spectrophotometry. The first 2 
columns were dedicated to the standard curves and the rest of the plate was divided 
in groups of 4 areas per patient, based on the same configuration in triplicates, used 
for the previous steps of the GAG assay (IC AC, ICL MP, V12 AC, V12 LMP), testing 
2 aliquots per eppendorf tube. 1:2 and 1:5 dilutions were performed, in case that 
samples' OD was above the standard curve range. 
 
µg/ml 1 2 3 4 5 6 7 8 9 10 11 12 
A 0μg 0μg IC AC1 (Duplicate) IC LMP1 (Duplicate) V12 AC1 (Duplicate) V12 LMP1 (Duplicate)   
B 1μg 1μg IC AC2 (Duplicate) IC LMP2 (Duplicate) V12 AC2 (Duplicate) V12 LMP2 (Duplicate)   
C 2μg 2μg IC AC3 (Duplicate) IC LMP3 (Duplicate) V12 AC3 (Duplicate) V12 LMP3 (Duplicate)   
D 3μg 3μg           
E 4μg 4μg           
F 5μg 5μg           
G             
H             
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3.6.3b Reagents and materials for cryosection and toluidine blue 
staining for qualitative analysis of chondrogenic pellets 
 
Toluidine blue (1% in 50% isopropanol) (Sigma), was prepared by mixing 50ml of 
100% isopropanol with 50ml of dH2O and subsequently 1g of toluidine blue powder 
was added to the solution, adjusting pH to 4. Next, the solution was filtered using a 
0.45μ filter and kept in dark, to preserve the colour and the pH.  
 
Optimisation staining of toluidine blue was performed prior to final staining of the 
pellet-slides. A combination of two different types of pH (2.5 and 4) and two different 
staining incubation times (10min. and 30min.) were tested, in order to determine the 
most appropriate combination for staining. The best result was obtained with a pH4 
for 30min. incubation time (appendix 8.3). Chondrogenic differentiation was assessed 
by the purple stain of cartilaginous extracellular matrix (metachromasia), while 
undifferentiated or fibrous tissue was stained in blue. 
 
Procedure for qualitative analysis of chondrogenic pellets 
After 3 weeks of chondrogenic induction the culture was stopped, medium was 
discarded and pellets were embedded in OCT gel (optimal cutting temperature 
compound), an inert support made of polyethylene glycol and polyvinyl alcohol, 
avoiding bubbles formation, especially near the pellet206. OCT is characterized by a 
fluid nature at RT, which becomes solid, with a density similar to the pellet when 
frozen.  
Next, OCT-pellets were snap-frozen in liquid nitrogen, to reduce ice-crystal formation, 
minimizing the morphologic damage and preventing cracks of the OCT-pellet 
block207. Samples were wrapped in labelled foil, and stored in -80°C.  
 
When chondrogenic pellets from all 4 donors (4 condition per donor) were collected 
(n=16, in duplicates), a Leica CM1950 cryostat was used, to produce multiple 
sections of 4μm thickness. Sections were loaded on SuperFrost® yellow cut edge 
microslides, wrapped in labelled foil and stored in -80°C208. 
 
When ready to perform toluidine blue staining, the frozen sections on microslides 
were moved from –80°C freezer to RT and allowed to thaw gradually for 30min. In 
order to provide a better dye contrast, sectioned pellets were moisturised for 1min., 
by adding few drops of dH2O directly onto the microslides. Subsequently, toluidine 
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blue staining was performed for 30min., adding the dye directly on the sections, at 
RT and protecting from light. Next dye excess was removed by gentle wash with 
dH2O (3x immersions), the excess of water on microslides was wiped and sectioned 
pellets were dehydrated by xylene (3x immersions of 1min. each), under fume 
cupboard206,208. Finally, microslides were air dried for 5–10min., mounted in sub-x 
mounting medium (Leica) and covered by cover-glass applying gently a uniform 
pressure, to avoid air-bubbles207. Chondro-pellet images were captured at 64 and 
160 magnification, using an Eclipse E1000 microscope. 
 
Toluidine blue staining of chondro-pellets was performed with the valuable 
assistance of Dr. Filomena O.G. Esteves, providing mainly lab training and 
performing the quality control of the staining. Additionally, cryosection training and 
lab support has been provided by ex-Lab manager Karen Henshaw. 
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3.7 Enzyme-linked immuno sorbent assay (ELISA) analysis  
 
Serum samples were thawed at RT and ensured to be thoroughly mixed on a roller. 
In order to avoid a long time exposure at RT of cytokines and repetitive freeze-
thawing cycles, which can affect cytokines stability209-211, serum was first aliquoted 
into a transient 96-well plates based on templates previously arranged, and 
cryopreserved at -80°C. Finally, serum was transferred to ELISA kits, at a later stage, 
for the measurement of pro-inflammatory and anti-inflammatory cytokines (IL-6, IL-
18, PCT and IL-10) when ready to perform the assays.  
 
Analysis was carried out with commercially available kits, from R&D Systems, MBL 
and Sigma-Aldrich (Table 8), employing the quantitative sandwich enzyme 
immunoassay technique. To minimize the variability within the different kits used 
ELISA kits with the same lot number were utilised per every molecule studied, (4 
ELISA kits per molecule, for a total of 16 kits). Additionally, in order to be able to 
compare time-points between all four molecules, minimizing the variability, all 
samples from the same time-point of each patient were loaded on the same 96-well 
plate. ELISA kits codes and manufacturers for the protocols used, are located in 
appendix section 8.2.  
 
Briefly, a monoclonal antibody specific for the molecule (IL-6, IL-18, PCT and IL-10) 
has been pre-coated on the micro plates, by the manufacturer. Duplicates of 
standards and serum samples, following appropriate dilutions, were added into the 
wells where the molecules of interest were bound to the corresponding antibodies. 
Following wash to remove any unbound substances, a further enzyme-linked 
polyclonal antibody (conjugate), specific for the molecule in question was 
subsequently added to the well. Following a further wash, to remove any unbound 
antibody/conjugate complexes, a colour reagent (substrate solution) was added and 
a different intensity of colour was developed in proportion to the test molecule 
concentration present in serum. The colour reaction was then stopped by adding 
sulphuric acid (stop solution) and the OD was measured within 30min. by a Mithras 
LB 940 spectrophotometer. The appropriate wavelength and the correction reading, 
when required (to neutralize plastic-ware, lamp and optical fluctuation effects), was 
set as per manufacturer instructions and every plate underwent a duplicate scanning. 
OD values were then transferred to Microsoft Excel software for analysis. The 
duplicate readings were averaged and subtracted to the averaged correction 
wavelength, obtaining the final absorbance. Standard curves were linearized using 
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log or 4-pl transformation based on manufacturer manual. Final concentrations were 
calculated considering the dilution factor used for each ELISA kit. Graphics were 
generated using GraphPad Prism for Windows. As every different molecule analysed 
with ELISAs, present variations in protocol, Table 8 summarises the differences for 
all the 4 molecules studied. 
 
 
Table 8. Summary of ELISA protocols. The information illustrated in this table, has 
been provided by the manufacturer. 
 
 IL-6 IL-6 HS IL-18 PCT IL-10 HS 
Assay/Sample 
dilution 
1:2 dilution 1:2 dilution 1:5 dilution No dilution 1:1.2 dilution 
Addition of standard 
/sample per well 
100μl 100μl 50μl 100μl 200μl 
1
st
 incubation at RT 2 hours 2 hours 1 hour 2.5 hours 2 hours 
Wash after 1
st
 
incubation 
4 times 6 times 3 times 4 times 6 times 
Addition of conjugate 
solution per well 
200μl 200μl 100μl 100μl 200μl 
2
nd
 incubation at RT 2 hours 2 hours 1 hour 1 hour 2 hours 
Wash after 2
nd
 
incubation 
4 times 6 times 3 times 4 times 6 times 
Addition of substrate 
solution per well 
200μl 50μl 100μl 100μl 50μl 
3
rd 
incubation at RT 20min. 60min. 30min. 45min. 1 hour 
Addition of amplifier 
solution per well 
No 50μl No 100μl 50μl 
4
th
 incubation at RT N/A 30 min. N/A 30min. 30min. 
Stop solution per well 50μl 50μl 100μl 50μl 50μl 
OD reading 
OD correction 
450nm 
540nm 
490nm 
650nm 
450nm 
620nm 
450nm             
--------- 
490nm 
650nm 
Standard Range 
3.13-300 
pg/ml 
0.156-10 
pg/ml 
36.1-257.8 
pg/ml 
27.43-2x104 
pg/ml 
0.78-50 pg/ml 
Manufacturer 
R&D 
Systems 
R&D 
Systems 
MBL Sigma-Aldrich 
R&D 
Systems 
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3.8 Statistics 
 
Statistical analysis and graphing were performed using Windows Excel 2003 and 
Graph Pad Prism v6 for Windows (San Diego California, USA). Median, mean 
values, along with interquartile ranges were calculated throughout all the 
experiments. All statistical analysis were based on mean or median values, 
depending on the Gaussian distribution of the data analyzed. Gaussian distribution 
was determined using Shapiro-Wilk and D'Agostino & Pearson omnibus normality 
tests. For paired values presenting Gaussian distribution, paired t test was 
performed, otherwise Wilcoxon test was used. For unpaired values showing 
Gaussian distribution unpaired t test was performed, applying additionally Welch’s 
correction in case of different standard deviation between the compared groups. For 
unpaired values without Gaussian distribution Mann-Whitney U test was used. The 
cut-off value for significance was p<0.05.  
 
Variability of the results, including  intra-assay and inter-assay variability, was 
measured analyzing the coefficient of variation (CV) by dividing the standard 
deviation (SD) by the mean and multiplying by 100, CV = (SD/mean) x 100). 
Furthermore, to determine the relationship between two variables, Spearman’s rank 
correlation coefficient test (R values) with a two tailed p-value was calculated using 
the Graph Pad Prism v6 software. 
 
For the immuno-inflammatory component of the thesis, due to the limitations of 
GraphPad Prism v6 to support two-way nonparametric analysis of variance 
(ANOVA), was used the IBM SPSS v23 software. Nevertheless, in order to present  
the data with consistency throughout the thesis, the final analysis and graphics were 
performed using GraphPad Prism v6 and presented as mean ± SEM. 
 
Moreover, given the lack of peripheral blood sampling (especially at T5, T6) for part 
of the cohort due to the early hospital discharges or their challenging clinical 
management, the missing data were treated by mean regression imputation 
generating unbiased estimates of means, using IBM SPSS v23 software. 
Additionally, prior to the final analysis, a pilot analysis was conducted to examine the 
assumptions of the statistical tests. Subsequently, polynomial regression coefficients 
were calculated and the missing values were substituted by the predicted mean for 
each time point (Appendix 8.1).  
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Given the GraphPad Prism v6 limitations to support a two-way ANOVA calculations, 
nonparametric analysis were performed at each time point using Friedman test 
(nonparametric equivalent of a repeated measure), Kruskal-Wallis test 
(nonparametric equivalent of one way ANOVA) and Mann-Whitney U test 
(nonparametric equivalent of independent samples t-test) separately. 
 
Friedman test was used to examine differences in outcomes over one-week period in 
each approach, gender and duration of surgery on all four molecules examined (IL-6, 
IL-18, PCT and IL-10). Moreover, Kruskal-Wallis test was conducted to test for 
differences among the three surgical approaches (Posterior, Posterior-Costoplasty 
and Antero-Posterior) at each time point, while Mann-Whitney U test was conducted 
to test for differences of outcomes between genders and different durations of 
surgery (fast and slow groups) at each time point.  
 
The one-way ANOVA section of the GraphPad Prism v6 in a first place determined 
whether there is an overall significance for Kruskal-Wallis and Friedman methods, 
without specifying the exact point. In case of statistically significant results, via the 
Dunn's multiple comparisons test, the exact points were located. However, in few 
occasions due to cohort limitations, even though an overall significant difference was 
present, multiple comparison could not determine where was the significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 63  
4. Results 
4.1 Patients' recruitment 
 
Research with minors presents some unique challenges, compared to adults, related 
mainly to their difficulty, to express their needs or defend their interests212. Moreover, 
the recruitment and consenting process involves minimum two individuals and often 
the entire family, increasing the complexity of the interactions and patient's 
management. It is also fundamental to gain their confidence and of their parents, who 
are not always familiar with a research process. Despite the additional difficulties, 
medical research involving children is essential for advancing child health and 
wellbeing, because often it is not scientifically or ethically appropriate to apply adult 
research findings into children necessities212. 
 
To all children involved in this research, it was given the possibility to express 
themselves unbiased. It was asked to family members or legal representatives to 
have a neutral role and understand that they should not attempt to influence or 
interpret the responses of participants, as it is also described in the article 12 of the 
United Nations Convention on the Rights of the Child (UNCRC) "all children and 
young people who are capable of forming their own views, have a right to express 
those views freely in all matters affecting them, with the views of the child being given 
due weight in accordance with their age and maturity"213. 
 
For children under 16 years old, consent was obtained from parents or legal 
representatives and also assent was required from the child involved. For 
adolescents between 16-17 years old, consent was obtained from them directly, 
however parents or legal representatives were present.  
 
During all stages of recruitment, data collection and blood sampling, type of language 
and approaches utilized were adapted accordingly, to generate a more productive 
researcher-child rapport213-215. Also, almost always it was asked to parents or legal 
representatives to stay during data collection or peripheral blood sampling in order to 
guarantee a more comfortable environment for the child214. 
 
MRC Ethics Guide212,Research with Children and Young People213 and Good Clinical 
Practise (paediatrics) guidelines, were followed for the whole duration of the project. 
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4.2 Overview of patient's demographics 
 
Over a 20 months period (09/2012-06/2014), 55 patients satisfying the 
inclusion/exclusion criteria were approached and 50 of them were successfully 
recruited. The remaining five patients did not agree to participate in this study, merely 
for personal reasons. Out of the 50 patients recruited, it was not possible to harvest 
BM and peripheral blood (PB) from 13 patients, due to unexpected circumstances or 
hospital organization issues, (5 patients decided to postpone the surgery until a later 
date and 8 patients were lost due to last minute changes of the theatre operation 
lists). 
 
From the remaining 37 patients, PB was collected in different time points, isolating 
both plasma and serum. ICBM and VBBM were also harvested from 19 patients 
(14F/5M). Additionally, in seven patients BM was harvested from a second vertebra, 
usually the thoracic 11th (V11), or the first lumbar (L1), to investigate whether the cell 
concentration, is similar from adjacent vertebrae, and if it can be affected by 
differences in vertebral size. An overview of the PB and BM harvested and related 
assays performed (enumeration, differentiations, flow cytometry and ELISA), is 
shown in Table 9. Patients' availability, for PB sampling, was often limited for the 5th 
and 6th time points, due the early hospital discharge.  
 
Twenty-six patents were operated with posterior approach (21F/5M), 5 patients with 
posterior approach and costoplasty (5F), and 6 patients (3F/3M) with antero-posterior 
approach. For the purpose of the immuno-inflammatory component of this study a 
total of 23 patients have been selected. Serum from 12 patients (9F/3M) having 
posterior approach was analysed and compared to the remaining two groups 
(posterior approach and costoplasty (5F), and antero-posterior approach (3F/3M).  
 
The overall age and sex distribution of the recruited patients is shown in Table10. A 
female predominance (29F/8M, F/M-ratio:3.6) was observed, as expected1. The age 
range was 13-17.8 years (median 15.4 years).   
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Table 9: Patient's overview. Blood sampling (time points), BM enumeration, 
proliferation and differentiation assays, phenotypic characterization and ELISA 
assays are illustrated.  
 
N. 
Patient 
Code 
P            
P+Costoplasty     
AP 
Time 
0a 
Time 
0 
Time 
1 
Time 
2 
Time 
Turn 
Time 
3 
Time 
4 
Time 
5 
Time 
6 
Bone 
Marrow 
Harvesting 
CFU-F 
assay 
Differenti-
ation assay 
Flow-
cytometry 
ELISA 
assay 
1 AF 01 P  √ √ √  √ √ √ √     √ 
2 AF 02 P √ √ √ √  √ √       √ 
3 AF 03 P √ √ √   √ √       √ 
4 AF 05 AP  √ √ √  √ √ √      √ 
5 AF 06 P  √ √ √  √ √  √     √ 
6 AF 07 P  √ √ √  √ √       √ 
7 AF 08 P √ √ √ √  √ √       √ 
8 AF 09 P  √ √ √  √         
9 AF 10 P  √ √ √  √ √        
10 AF 11 P  √ √ √  √         
11 AF 12 P+Costoplasty  √ √ √  √  √      √ 
12 AF 14 P+Costoplasty  √ √ √  √        √ 
13 AF 16 P  √ √ √  √ √        
14 AF 17 P+Costoplasty  √ √ √  √ √       √ 
15 AF 18 P  √ √ √  √  √      √ 
16 AF 19 AP  √ √ √ √ √ √ √ √ √ √   √ 
17 AF 20 P  √ √ √  √ √   √ √    
18 AF 21 P  √ √ √  √ √        
19 AF 22 P+Costoplasty  √ √ √  √ √ √ √     √ 
20 AF 23 P  √ √ √  √ √ √  √ √   √ 
21 AF 24 P  √ √ √  √ √   √ √    
22 AF 26 P  √ √ √  √ √   √ √   √ 
23 AF 27 P  √ √ √  √ √ √ √ √ √   √ 
24 AF 28 AP  √ √ √ √ √ √ √  √ √ √ √ √ 
25 AF 29 P  √ √ √  √    √ √ √ √ √ 
26 AF 31 P  √ √ √  √ √   √ √    
27 AF 32 P  √ √    √   √ √    
28 AF 33 P  √ √ √  √ √ √  √ √   √ 
29 AF 34 P √ √ √ √  √ √   √ √    
30 AF 35 P  √ √ √   √ √  √ √   √ 
31 AF 39 P+Costoplasty  √ √ √  √ √ √  √ √ √ √ √ 
32 AF 40 P  √ √ √  √ √ √ √ √ √   √ 
33 AF 43 P  √ √ √  √ √   √ √   √ 
34 AF 47 P  √ √ √  √ √        
35 AF 48 AP  √ √ √ √ √ √ √  √ √   √ 
36 AF 49 AP  √ √ √ √ √ √ √ √ √ √   √ 
37 AF 50 AP  √ √ √ √ √ √ √  √ √ √ √ √ 
 
The blank boxes indicate assays, peripheral blood and BM sampling, that were not 
performed. 
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Table 10. Patients' demographics, at the time of recruitment.  
 
N. 
Patient 
Code 
Gender 
Age                                         
(At recruitment) 
1 AF 01 Female 13.19 
2 AF 02 Female 17.07 
3 AF 03 Female 15.27 
4 AF 05 Male 17.21 
5 AF 06 Female 14.99 
6 AF 07 Female 15.71 
7 AF 08 Male 16.37 
8 AF 09 Female 14.70 
9 AF 10 Female 15.81 
10 AF 11 Female 14.98 
11 AF 12 Female 17.03 
12 AF 14 Female 15.91 
13 AF 16 Female 15.43 
14 AF 17 Female 16.43 
15 AF 18 Female 15.56 
16 AF 19 Female 13.15 
17 AF 20 Female 15.89 
18 AF 21 Female 14.56 
19 AF 22 Female 15.32 
20 AF 23 Female 13.78 
21 AF 24 Female 14.66 
22 AF 26 Male 14.73 
23 AF 27 Male 16.98 
24 AF 28 Male 14.25 
25 AF 29 Male 15.60 
26 AF 31 Female 15.73 
27 AF 32 Male 16.66 
28 AF 33 Female 16.04 
29 AF 34 Female 14.36 
30 AF 35 Female 15.39 
31 AF 39 Female 15.33 
32 AF 40 Female 16.83 
33 AF 43 Female 16.29 
34 AF 47 Female 14.27 
35 AF 48 Female 13.29 
36 AF 49 Female 15.20 
37 AF 50 Male 17.60 
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4.3 Power and Sample Size Calculation 
 
For power analysis and sample size of the MSCs component of the study, normality 
was assumed, based on the Gaussian distribution of the CFU-F assay data, tested 
with D'Agostino and Pearson omnibus normality test. Null hypothesis mean (μ0=1.5), 
type I error rate, (α=5%), and power (1-β=0.80), have been setup accordingly; also 
true mean value (μ) and standard deviation, (σ) were determined based on the 
anatomic site and the cells-isolation method used. Consequently, sample size (n=19) 
satisfied the statistic criteria. Moreover, sample size and study power, were 
considered to represent an appropriate balance between a statistically significant 
difference and a scientific/clinical meaningful difference.  
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4.4 Total cells/ml from IC BM and VB BM: Comparison of AC and LMP 
 
it was evident, since the first stages of BM processing (from both anatomic sites) 
using AC and LMP, the remarkable difference in terms of cell pellet volume, when AC 
was used (Figure 12). The different outcome between both techniques, it was 
expected for the ICBM54-57,216,217, however to best of our knowledge, it was never 
tested before on VBBM.  
 
AC following red cells lysis, concentrates the leukocyte fraction (WBCs) of the BM, 
resulting in a bigger cell pellet, compared to LMP which concentrates only the MNC 
fraction, having density 1.077 ± 0.001 g/ml, without the voluminous part of the 
granulocytes. 
 
 
 
 
 
 
 
 
 
 
Figure 12: Falcon tubes containing cell pellets. (A,B) Harvested from ICBM and 
(C,D) from VBBM of the same donor (AF 48), using AC and LMP, respectively. 
 
These differences were also confirmed quantitatively by counting total cells per ml of 
BM aspirate. From ICBM, using AC, a significantly higher number of cells was 
recovered (median 20x106/ml total cells) compared to LMP (7.23x106/ml total cells). 
This 2.8-fold difference was statistically significant, p=0.0080, (Table 11, Figure 13). 
Similarly, from VBBM, using AC, a significantly higher number of cells was recovered 
(median 15x106/ml total cells) compared to LMP (5x106/ml total cells). In this case 
also the 3-fold difference was statistically significant, p=0.0002, (Table 11, Figure 13). 
Despite the higher numbers of total cells yielded using AC, compared to LMP, no 
statistical significance was observed between VB and IC.   
 
 
 
A                       B         
      B 
C                       D                          
b 
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Table 11: Total cells/ml isolated from ICBM and VBBM using AC and LMP. 
 
Patient  
Code 
# Cells / ml of        
IC AC (106) 
# Cells / ml of             
IC LMP (106) 
# Cells / ml of           
VB AC (106) 
# Cells / ml of   
VB LMP (106) 
AF 28 12.36 2.43 9.25 2.67 
AF 29 12.88 8.05 17.6 8.9 
AF 31 32.89 24.47 8.33 3.83 
AF 32 23.1 7.83 18.67 12.25 
AF 35 18.2 5.89 17.9 10.2 
AF 40 18.18 4.91 7.56 2.67 
AF 43 27.08 8.27 20.89 12.22 
AF 24 16 4 10.4 4.4 
AF 23 25.26 16.8 33.87 20.82 
AF 19 (n/a) 3.7 (n/a) 5 
AF 20 18 3 20 3.1 
AF 26 20 10 15.6 5 
AF 27 15.3 7 15 3.4 
AF 33 23.9 3.67 14 2.75 
AF 34 7.63 7.46 7,5 4.2 
AF 39 22.91 7.55 16 7.45 
AF 49 24.50 12.19 12.84 4.84 
AF48 30.11 5.26 14.74 5.26 
AF50 28 44 38.38 15.79 
MEAN 20.79 9.94 16.62 7.09 
SD 6.87 10.09 8.52 5.06 
MEDIAN 20 7.23 15 5 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Comparison of total number of cells, recovered from 1ml of BM, 
using AC and LMP. IC AC (n=18, p=0.0080) and VB AC (n=18, p=0.0002), showed 
significantly higher concentrations, compared to IC LMP and VB LMP. Box & 
whiskers with min to max range and Wilcoxon matched-pairs test were used. 
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4.5 Cells recovery following thawing 
 
CFU-F, proliferation, differentiation and phenotypic assays were performed using 
fresh-frozen total cells and expanded MSCs. Therefore cells recovery following 
thawing for both locations ICBM and VBBM, were compared for both isolation 
techniques used (AC and LMP). During cryopreservation, approximately 20x106 cells 
were placed in each cryovial; this was considered as a reference value (100%) and 
the number of recovered cells, following thawing, was calculated as percentage. 
Comparisons based on 19 patients' samples, were made in order to assess whether 
the isolation technique used, can influence the thawing outcome (Figure 14, Table 
12). 
 
These findings show a significative loss of cells as a result of the cryoinjury, as 
expected218. Moreover, no statistically significant differences were found between 
anatomic sites (ICBM and VBBM) or cell-isolation methods (AC and LMP), 
suggesting that any numeric differences of MSCs observed, following thawing, are 
unlikely to be related to the cell-isolation method used. 
 
 
 
 
 
 
 
 
 
Figure14: Cells recovery, following cryopreservation. ICBM, presents a 23% and 
17.5% of cells recovery, from AC and LMP, respectively, whilst VBBM, presents a 
17.14% and 19.33% of cells recovery, from AC and LMP, respectively. Box & 
whiskers with min to max range and Wilcoxon matched-pairs test were used. 
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Table 12: Total cells/vial cryopreserved and recovered, from ICBM and VBBM using 
AC and LMP. 
 
 
 
 
 
 
 
 
Patient 
Code 
IC AC 
Frozen 
cells/vial 
(10
6
) 
IC AC 
Recovered 
cells/vial 
(10
6
) 
% of 
Recovery 
IC LMP 
Frozen 
cells/vial 
(10
6
) 
IC LMP 
Recovered 
cells/vial 
(10
6
) 
% of 
Recovery 
VB AC 
Frozen 
cells/vial 
(10
6
) 
VB AC 
Recovered 
cells/vial 
(10
6
) 
% of 
Recovery 
VB LMP 
Frozen 
cells/vial 
(10
6
) 
VB LMP 
Recovered 
cells/vial 
(10
6
) 
% of 
Recovery 
AF 28 22.6 7 30.88 17 5.6 32.94 18.5 9 48.65 16 5.5 34.38 
AF 29 20.6 15 72.82 21.5 6.5 30.28 22 8.2 37.27 22.25 4.3 19.33 
AF 31 21.14 5.32 25.16 21 6.7 31.76 16.7 4 24.00 12.5 1 8.00 
AF 32 18.48 3.8 20.56 15.6 2.4 15.32 18.7  3.2 17.14 18.38 1.8 9.80 
AF 35 18.2 6 32.97 20.6 9.4 45.63 17.9 12 67.04 20.4 4 19.61 
AF 40 20 17.6 88.00 13 8.9 68.46 17 14 82.35 6 5 83.33 
AF 43 20.1 2 9.94 14.33 2.4  16.74 18.8 2.4 12.77 18.33 1.8 9.82 
AF 24 16 4.4 27.63 20 3.5 17.50 20.8 4.18 20.10 16.5 5.52 33.45 
AF 23 20 2.7 13.50 20 2.5 12.50 21.8 3.55 16.31 23.35 3.2 13.70 
AF 19 (n/a) (n/a) (n/a) 37 14.6 39.46 (n/a) (n/a) (n/a) 25 9 36.00 
AF 20 23.63 2.8 12.02 15.8 8.5 53.97 32 5.3 16.56 12.4 6.4 51.61 
AF 26 46.66 10.3 21.99 35 2.8 7.86 33 5 16.27 16.25 4.2 25.85 
AF 27 54.83 6.2 11.22 22.8 3.4 15.12 32 3.4 10.46 11.05 2 18.10 
AF 33 19.12 3.2 16.47 12 7 0.58 17.5 3 17.14 8.25 1.5 18.18 
AF 34 15.25 5.6 36.72 18.7 3.8 20.38 15 2.8 18.67 12.6 3.2 25.40 
AF 39 21 5.2 24.76 20.8 5 24.10 17.6 3.6 20.45 20.5 4.4 21.46 
AF 49 21.43 7.5 35.00 21.33 2.4 11.25 20.3 3.2 15.76 11.5 1.5 13.04 
AF48 20.43 2.57 12.58 12.5 2.1 16.80 17.5 2.42 13.83 12.5 2.1 16.80 
AF50 20 2.8 14.00 36.6 1.39 3.80 30.36 2 6.59 25 0.75 3.00 
Mean 23.31 6.11 28.12 20.81 4.84 24.44 21.59 5.1 25.63 16.25 3.54 24.26 
SD 10.28 4.287 21.03 7.60 3.55 17.61 6.1 3.45 20.44 5.57 2.15 18.44 
Median 20.27 5.26 23.37 20 3.5 17.50 18.73 3.58 17.14 16.25 3.2 19.33 
CV % 44 70  37 73  28 68  34 61  
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1 2 
  AF32 IC LMP 
1 2 
  AF32 VB LMP 
1 2 
AF32 IC AC AF32 VB AC 
V12 
1 2 
4.6 Colony forming unit fibroblast (CFU-F) assays 
 
As mentioned previously, one of the characteristics of MSCs is the ability to adhere 
on plastic surface and proliferate in standard culture conditions optimized for MSCs. 
These features have been exploited in the CFU-F assay. In this study, BM cells were 
separated by differential gradient centrifugation (LMP) and also red cells lysis 
techniques (AC), followed by centrifugation, isolating MNCs and WBCs, respectively. 
Each colony has been shown to originate from a single colony-forming cell or CFU-
F219 and traditionally, MSCs are enumerated as CFU-Fs based on this assay219,220. 
MSCs' colonies from ICBM and VBBM were found in all samples tested (Figure 15) 
and manually counted (Figure 16). 
 
 
 
 
 
 
 
 
 
 
Figure 15: Microscopic images showing the characteristic aspect of a BM-MSCs 
colony, after 10 days in culture. Magnification x200. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Example of CFU-F assay. MSCs colonies stained with methylene blue in 
10cm petri-dishes. All experiments were performed, in duplicates.  
200x 
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4.6.1 MSCs/106 from MNCs / WBCs: Comparison of ICBM and VBBM 
 
A comparison of CFU-F colonies from ICBM and VBBM samples was performed, 
based on the isolation and plating of 2x106 mononuclear cells (MNCs) and 
leucocytes (WBCs), respectively, normalising subsequently the data to a million of 
cells seeded, (Tables 13, 14). Despite the young age of the subjects and the 
consistency of techniques and conditions used for all patients, some of them 
presented relatively low numbers of MSCs. 
 
From both anatomic regions, LMP-harvested cells gave more colonies per million of 
seeded cells, with 1.3-fold and 1.2-fold, respectively, nearly missing statistical 
significance (Tables 4, 5, Figure 17).  
 
 
Table 13. MSCs /106 of cells in ICBM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC LMP (n=19) IC AC (n=18) 
Patients 
Code 
CFU-F/ 2x10
6
 CFU-F/2x10
6
   CFU-F/10
6
 
of MNCs 
CFU-F /2x10
6
 CFU-F/2x10
6
 CFU-F/10
6
 
of WBCs 1
st
 petri-dish 2
nd
 petri-dish 1
st
 petri-dish 2
nd
 petri-dish 
AF28 131 229 90 62 57 29.75 
AF29 14 6 5 31 33 16 
AF31 7 2 2.25 7 6 3.25 
AF32 29 26 22.92 133 138 71.32 
AF35 273 265 134.50 158 202 90 
AF40 6 6 3 4 4 2 
AF43 18 13 12.92 12 15 13.50 
AF34 98 108 54.21 11 9 5 
AF48 65 74 66.19 53 46 38.52 
AF24 325 400 207.14 195 170 91.25 
AF23 6 7 5.20 12 13 9.26 
AF33 1 1 2.86 4 10 4.44 
AF27 29 28 16.57 89 72 40.25 
AF26 57 54 40.36 223 201 106 
AF39 193 206 99.75 200 228 107 
AF19 232 230 115.50 (n/a) (n/a) (n/a) 
AF20 186 181 91.75 82 81 57.39 
AF49 97 104 83.75 115 104 54.75 
AF50 16 28 31.43 20 11 11.7 
Mean   55.29   41.71 
SD   56.18   37.47 
Median   40.36   34.14 
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Figure 17: CFU-F/106 of cells harvested from IC and VB using both AC and 
LMP. VBBM presented a higher number of colonies per million of cells when LMP 
was used, compare d to VB AC, however without statistical significance. Box & 
whiskers with min to max range and Wilcoxon matched-pairs test was used. 
 
Table 14. MSCs/106 of cells in VBBM.  
VB LMP (n=19) VB AC (n=18) 
Patients 
Code 
CFU-F/ 2x10
6
 CFU-F/2x10
6
 CFU-F/10
6
 
of MNCs 
CFU-F/ 2x10
6
 CFU-F/2x10
6
 CFU-F/10
6
 
of WBCs 1
st
 petri-dish 2
nd
 petri-dish 1
st
 petri-dish 2
nd
 petri-dish 
AF28 134 117 62.75 20 23 10.75 
AF29 92 94 46.50 33 31 16 
AF31 19 20 19.50 31 25 14 
AF32 11 14 13.89 45 45 28.13 
AF35 102 175 69.25 53 60 28.25 
AF40 4 2 1.50 3 5 2 
AF43 4 2 3.33 3 6 3.75 
AF34 81 86 52.19 79 61 50 
AF48 100 68 80 44 47 37.60 
AF24 550 504 263.50 363 459 205.50 
AF23 83 59 44.38 117 97 60.28 
AF33 107 66 115.33 170 173 114.33 
AF27 257 259 258 130 114 71.76 
AF26 46 33 19.75 193 191 96 
AF39 246 262 127 201 195 110 
AF19 289 280 142.25 (n/a) (n/a) (n/a) 
AF20 121 131 63 104 123 56.75 
AF49 39 46 56.67 9 11 6.25 
AF50 8 19 27 60 77 68.5 
Mean   77.15   54.44 
SD   75.81   52.08 
Median   56.67   43.80 
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4.6.2 MSCs/ml from ICBM and VBBM: Comparison of AC and LMP 
 
The total number of MSCs (CFU-F) per ml of BM harvested from both IC and VB, 
using LMP and AC, was calculated by the following equation: CFU-F/ml of BM = 
CFU-F/106 x Cells/ml (Tables 15, 16). Both IC and VB showed a significatively higher 
number of MSCs when AC was utilized (IC AC p=0.0009, VB AC p=0.0038), by 2.6-
fold and 1.9-fold, respectively (Figure 18). These results suggested a loss of MSCs 
following LMP processing. This finding was consistent with previous studies on IC 
BM, showing loss of LMP-harvested MSCs (compared to AC-harvested MSCs), in 
the residual cell pellet mixed with erythrocytes and granulocytes54,55,57.  
 
Concerning MSCs' gender variability, given the demographic characteristics of 
scoliosis, this cohort presents an uneven female/male distribution (15F/4M) which did 
not allow a robust statistical comparison. However, the only possible trend noticed 
within the male cohort, was a higher concentration of MSCs, for both VB AC (2.6-
fold) and IC AC (4.4-fold), compared to females. Nevertheless, a bigger evenly 
distributed cohort is needed for a definitive answer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: CFU-F/ml of BM harvested from IC and VB using both AC and LMP. 
A) AC-harvested MSCs presented a statistically higher number of colonies from both 
ICBM (p=0.0009) and VBBM (p=0.0038). Column bar-graph with range and mean 
values was used. Gaussian distribution was assumed. Paired t-test was performed. 
B) Representative example of CFU-F assays showing MSCs colonies per anatomic 
site and cells-isolation method used. 
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Table 15. MSCs/ml from ICBM, comparing LMP and AC. 
IC LMP (n=19) IC AC (n=18) 
Patients 
Code 
CFU-F/10
6
 
of MNC 
MNC of BM 
(10
6
/ml) 
MSCs/ml 
of BM 
CFU-F/10
6
 
of WBC 
WBC of BM 
(10
6
/ml) 
MSCs/ml 
of BM 
AF28 90 2.43 218.70 29.75 12.36 367.71 
AF29 5 8.05 40.25 16 12.88 206.08 
AF31 2.25 24.47 55.06 3.25 32.89 106.89 
AF32 22.92 7.83 179.44 71.32 23.1 1647.39 
AF35 134.50 5.89 792.21 90 18.2 1638 
AF40 3 4.90 14.70 2 18.81 37.62 
AF43 12.92 8.27 106.82 13.50 27.08 365.58 
AF34 54.21 7.46 404.41 5 7.63 38.15 
AF48 66.19 5.26 348.16 38.52 30.11 1159.88 
AF24 207.14 4 828.57 91.25 16 1460 
AF23 5.20 16.84 87.57 9.26 25.26 233.89 
AF33 2.86 3.69 10.54 4.44 23.9 106.22 
AF27 16.57 7 115.99 40.25 15.3 615.83 
AF26 40.36 10 403.64 106 20 2120 
AF39 99.75 7.55 753.11 107 22.91 2451.37 
AF19 115.50 3.70 427.35 (n/a) (n/a) (n/a) 
AF20 91.75 3 275.25 57.39 18 1033.10 
AF49 83.75 12.20 1021.75 54.75 24.5 1341.38 
AF50 31.43 22 691.43 11.07 140 1550 
Mean   356.58   915.50 
SD   317.21   779.55 
Median   275.25   824.46 
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Table 16. MSCs/ml from VBBM, comparing LMP and AC. 
VB LMP (n=19) VB AC (n=18) 
Patients 
Code 
CFU-F/10
6
 
of MNC 
MNC of BM 
(10
6
/ml) 
MSCs/ml  
of BM 
CFU-F /10
6
 
of WBC 
WBC of BM 
(10
6
/ml) 
MSCs/ml  
of BM 
AF28 62.75 2.67 167.54 10.75 9.25 99.44 
AF29 46.50 8.9 413.85 16 17.6 281.60 
AF31 19.50 3.83 74.69 14 8.33 116.62 
AF32 13.89 12.25 170.14 28.13 18.67 525.09 
AF35 69.25 10.2 706.35 28.25 17.9 505.68 
AF40 1.50 2.67 4.01 2 7.56 15.12 
AF43 3.33 12.22 40.73 3.75 20.89 78.34 
AF34 52.19 4.2 219.19 50 7.5 375 
AF48 80.00 5.26 420.80 37.60 14.74 554.27 
AF24 263.50 4.4 1159.40 205.50 10.4 2137.20 
AF23 44.38 20.82 923.89 60.28 33.87 2041.74 
AF33 115.33 2.75 317.17 114.33 14 1600.67 
AF27 258.00 3.4 877.20 71.76 15 1076.47 
AF26 19.75 5 98.75 96 15.6 1497.60 
AF39 127.00 7.45 946.15 110 16 1760 
AF19 142.25 5 711.25 (n/a) (n/a) (n/a) 
AF20 63 3.1 195.30 56.75 20 1135 
AF49 56.67 4.84 274.27 6.25 12.84 80.25 
AF50 27 7.5 202.50 68.50 18.2 1246.70 
Mean   417.01   840.38 
SD   356.57   728.53 
Median   274.27   539.68 
  
 
 
4.6.3 CFU-F: Colony size of ICBM and VBBM, using AC and LMP 
 
In line with other authors171,219,221, the CFU-F colony sizes varies between different 
donors or different anatomic regions of the same donor, but could also vary within the 
same culture (petri-dish). Hence, larger colony sizes, may represent a higher 
proliferative potential or alternatively a bigger size of MSCs in culture. In order to 
study the colonies' morphology further, dishes were scanned using an Epson 2580 
digital scanner and digital images were analyzed using NIS elements BR 2.20 
imaging software (Nikon, Tokyo, Japan). The dish area (A=70.88cm2) was 
determined by using the formula A=π x r2 (π=3.14159, r(radius)=4.75). Furthermore, 
total colony area per dish was calculated, allowing next to determine the average 
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surface area per single colony, using the formula: Single colony area (cm2)=Total 
area of colonies (cm2)/number of colonies (Table 17). 
 
VB AC-harvested MSC presented a significantly smaller colony area, compared to IC 
AC, (p=0.0039). Moreover, similarly to other authors171, it was noticed a trend from 
VBBM to produce smaller colonies with a faster doubling rate, even though it was not 
statistically significant (Figures 19, 20). 
 
Table 17. MSCs' total colonies area. 
Patients 
Code 
IC AC  
area (%) 
IC AC   
area (cm2) 
IC LMP 
area (%) 
IC LMP 
area (cm2) 
VB AC 
area (%) 
VB AC 
area (cm2) 
VB LMP 
area (%) 
VB LMP 
area (cm2) 
AF 28 10.31 7.31 31.62 22.41 7.59 5.38 23.61 16.73 
AF 29 8.19 5.80 9.56 6.78 4.22 2.99 24.47 17.34 
AF 31 3.38 2.39 3.15 2.23 3.24 2.29 5.09 3.60 
AF 32 23.06 16.34 10.78 7.64 9.97 7.06 6.59 4.67 
AF 35 15.30 10.84 30.61 21.69 8.13 5.76 26.10 18.50 
AF 40 3.55 2.52 4.28 3.03 4.52 3.20 3.51 2.49 
AF 43 3.98 2.82 4.17 2.95 3.57 2.53 1.35 0.96 
AF 34 5.06 3.58 21.98 15.58 14.76 10.46 11.00 7.80 
AF 48 10 7.08 12.52 8.87 9.14 6.48 13.49 9.56 
AF 24 14.44 10.24 58.75 41.64 27.09 19.20 61.10 43.30 
AF 23 5.15 3.65 4.75 3.36 15.12 10.72 15.13 10.72 
AF 33 5.27 3.73 1.70 1.20 11.22 7.95 11.48 8.14 
AF 27 8.56 6.06 4.84 3.43 19.52 13.84 64.61 45.79 
AF 26 54.74 38.80 10.14 7.19 16.86 11.95 4.35 3.08 
AF 39 24.06 17.05 45.10 31.97 18.50 13.11 37.26 26.41 
AF 19 (n/a) (n/a) 30.93 21.92 (n/a) (n/a) 11.48 8.14 
AF 20 12.30 8.71 17.07 12.10 19.00 13.47 17.24 12.22 
AF 49 13.46 9.54 10.49 7.44 6.39 4.53 7.10 5.03 
AF50 7.34 5.20 6.90 4.89 11.90 8.43 5.80 4.11 
Mean 12.67 8.98 16.81 11.91 11.71 8.30 18.46 13.08 
SD 12.15 8.61 15.82 11.21 6.68 4.73 18.16 12.87 
Median 9.28 6.57 10.49 7.44 10.59 7.51 11.48 8.14 
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Figure 19: MSCs colony area, following CFU-F assay. IC AC presented a 
significatively bigger colony area, compared with VB AC (p=0.039). Additionally, a 
trend was noticed for VBBM-harvested MSCs to generate smaller colonies, with 
median values of ICBM: LMP 0.15 cm2, AC 0.23 cm2, VBBM: LMP 0.13 cm2, AC 0.12 
cm2. Box & whiskers with min to max range and Wilcoxon matched-pairs test were 
used. 
 
 
4.6.4 MSCs' population doubling for ICBM and VBBM, using AC and LMP 
 
MSCs were passaged at approximately 80% of confluence and then counted, as 
described previously, on section 3.4.1. Population doubling (PD) rates were 
calculated from eight donors, using the formula PD=Log2(N2/N1) (N2 # of cells at P1, 
N1 # of cells seeded), and the results were divided by the number of days (D) in 
culture. No statistically significant differences were observed within the 4 groups 
(Figure 20). 
 
During the proliferation assay, a trend was noticed for VBBM-MSCs to grow slightly 
faster compared to ICBM, as also described by other authors62,171, however this trend 
did not reach a statistical significance, at least with the number of donors examined. 
Moreover, LMP-harvested MSCs, tended to grow slightly faster, compared to AC, 
however no statistical significance was observed, (median values of ICBM: AC 1.94 
D, LMP 1.89 D, VBBM: AC 1.89 D, LMP 1.82 D). 
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Figure 20: MSCs DP rates, following tissue culturing. A trend was observed for 
VBBM-MSCs and LMP-harvested MSCs to proliferate faster, from both sites, 
however without a statistical significance. Box & whiskers with min to max range and 
Wilcoxon matched-pairs test were used. 
 
 
 
 
 
 
 
 
 
 
 
 
IC LMP IC AC VB LMP VB AC 
0
1
2
3
4
D
a
y
s
/P
D
 o
f 
M
S
C
s
1.89 Days 
1.94 Days 
1.82 Days 1.89 Days 
 81  
4.7 Flow cytometry  
 
4.7.1 Phenotypic characterisation of MSCs 
 
Flow cytometry was performed with scope to confirm MSCs nature, based on the 
ISCT criteria69,222, in addition to CFU-F and differentiation assays. Furthermore, the 
aim of the flow cytometry was to investigate whether ICBM-MSCs differ from VBBM-
MSCs, with regards to standard (CD105, CD73, CD90) and novel (SUSD2, MSCA1 
ALP) MSCs' markers, considering also that different isolation methods were 
employed. Moreover, although CFU-F assay, represent the most common method for 
MSCs analysis, is a plastic adherence–based cultivation method, which may lead to 
the loss of some poorly adherent, but highly potent MSCs223. Contrarily flow 
cytometry is based on superficial and intracellular markers detection, hence is not 
affected by tissue culturing techniques allowing the same cells to be studied, from a 
different perspective. 
 
For MSCs phenotypic characterization, were analysed the same donors, used also 
for differentiation assays, (AF28, AF29, AF39, AF50). All MSCs were culture-
expanded at P3 and their phenotype was investigated as explained in paragraph 3.6. 
Cultures were expanded and cryopreserved as described in section 3.4. In order to 
avoid variation of the fluorescent intensity, which is sensitive to experimental 
conditions, (e.g. laser fluctuations) all cultures (4 conditions/donor, 16 cultures in 
total) were thawed simultaneously189,190. Moreover, to exclude dead cells, debris and 
aggregates, 7-AAD dye193 was used. Gating strategy is illustrated below, in Figure 
21. 
 
The flow cytometric analysis is illustrated using histograms with the marker recorded 
on the x-axis, and the total count on the y-axis (appendix 8.4). The latter was gated 
between 102-105 of positive staining cells. Grouped-bars graphics, present an 
overview of median florescent intensity (MFI), positive events detected and 
percentage of positively stained cells. Results, showed positive expression of the 
common MSCs' markers (CD105, CD73, CD90) and negligible levels of 
hematopoietic cell markers (CD34, CD45, CD14, CD19 and HLA-DR) for all donors 
examined (Figures 22-25). 
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CD271 represent an ideal marker for the identification of fresh-harvested MSCs, as 
showed in previous publications191,193,223,224.However, in this study culture-expanded 
MSCs were used, which tend to adapt physiologically their function, based on the 
culturing conditions in vitro, decreasing the concentration of the CD271 
marker183,193,223,225. Hence, in this study, the novel MSCs' surface markers SUSD2181-
183, MSCA1182-186 and also intracellular marker ALP188,226 were used, in order to 
investigate possible differences between IC- and VB-harvested MSCs, isolated 
utilising two different techniques (AC, LMP)54,57.  
 
 
 
 
 
 
 
 
 
 
Figure 21: Flow cytometric analysis dot plot, gating strategy. A) Cell debris were 
excluded based on their forward and side scatter, B) 7-AAD dye was also used to 
exclude dead cells, C) Filtered population of MSCs was then examined for surface 
and intracellular markers. Each dot represents a cell, (an ‘event’) recorded from the 
laser detectors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A                                       B                                 C 
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4.7.2 Individual analysis of each donor  
 
First donor, AF 28, (14.3y, M).  
 
The intracellular marker ALP presented a higher MFI with LMP-harvested MSC, from 
both IC and VB by 1.4-fold and 2.1-fold, respectively. With regards to the anatomic 
location, ALP presented a higher MFI from VB for both AC and LMP-harvested 
MSCs, by 1.2-fold and 1.8-fold difference, respectively (Figure 22, Table 18). 
 
Conversely to ALP, the extracellular marker MSCA1, presented a higher MFI with 
AC-harvested MSCs, from both IC and VB by 3.5-fold and 1.8-fold, respectively. 
Concerning the anatomic site, MSCA1 presented an overall better outcome from VB, 
for both AC- and LMP-harvested MSCs, by 1.2-fold and 2.3-fold, respectively (Figure 
22, Table 18).  
 
Marker SUSD2, showed a higher MFI for AC-harvested MSCs from IC by 1.5-fold, 
whereas LMP-harvested MSCs from VB by 1.2-fold difference. With regards to the 
anatomic site, the overall expression appeared to be similar for both IC and VB, 
however IC presented a higher MFI from AC-harvested MSCs, by 1.5-fold difference 
(Figure 22, Table 18).  
 
The CD90 presented the highest MFI, compared to CD105 and CD73 standard MSC 
characterization markers. For both IC and VB, AC-harvested MSCs showed a higher 
MFI, in both cases by 2.1-fold. In terms of the anatomic site, the overall expression 
appeared to be similar for both IC and VB (Figure 22, Table 18).  
 
Marker CD105, presented a higher MFI from VB LMP-harvested MSCs, by 1.5-fold, 
whilst IC gave similar results for both isolation methods. In terms of the anatomic site, 
VB presented a higher outcome for both AC and LMP-harvested MSCs, by 1.8-fold 
and 1.2-fold, respectively (Figure 22, Table 18).  
 
CD73 presented a similar to CD90 trend. For both IC and VB, AC-harvested MSCs 
showed a slightly higher MFI, by 1.2-fold and 1.1-fold, respectively. In terms of the 
anatomic site, VB presented a slightly better outcome by 1.2-fold, from both LMP and 
AC-harvested MSCs (Figure 22, Table 18). 
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Figure 22: Graphics of median fluorescent intensity, and percentage of 
positively stained MSCs for donor AF 28. MFI results illustrated, are limited only to 
the positive markers characterising MSCs, due to the negligible values of the 
haematopoietic markers (CD14, CD19, CD34, HLA-DR and CD45). The percentage 
of positive MSCs was determined based on the negative controls, applying the 
isotype control concept for all the fluorochromes used. Data are illustrated as 
grouped bars, median values are calculated. The legend for both graphics is showed 
at bottom figure. 
 
 
Table 18. MFI values of donor AF 28. 
 
AF 28 ALP MSCA1 SUSD2 CD105 CD90 CD73 
IC AC 9790 2392 1020 1544 11396 2231 
IC LMP 13623 693 689 2350 5543 1918 
VB AC 11807 2839 667 2824 12558 2667 
VB LMP 24337 1597 822 2743 5638 2333 
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Second donor, AF 29, (15.6y, M). 
 
The intracellular marker ALP, presented a higher MFI from LMP-harvested MSCs, 
from both IC and VB by 6- and 3.5-fold difference, respectively. With regards to the 
anatomic location, ALP presented a higher MFI from IC, for both AC and LMP-
harvested MSCs, by 4.4-fold and 7.5-fold difference, respectively (Figure 23,Table 
19). 
 
Extracellular marker for ALP, MSCA1, concerning the isolation method used, 
presented a higher MFI from IC LMP-harvested MSCs by 1.5-fold and from VB AC-
harvested MSCs by 3-fold difference. Concerning the anatomic site, MSCA1 
presented an overall better outcome from IC, by 1.6-fold, using AC-harvested MSCs 
and 7.3-fold, using LMP-harvested MSCs (Figure 23,Table 19).  
 
Marker SUSD2, showed a higher MFI for LMP-harvested MSCs from VBBM by 1.4-
fold, whereas ICBM presented a similar outcome from both MSCs-isolation methods. 
Concerning the anatomic site, the overall expression was similar for both ICBM and 
VBBM (Figure 23,Table 19).  
 
Also in this case, CD90 presented the highest MFI, compared to CD105, and CD73 
standard MSC characterization markers. Both IC and VB, presented similar results 
from both AC and LMP-harvested MSCs. In terms of the anatomic site, IC showed 
the highest outcome, by 1.5-fold and 1.6-fold difference, from AC and LMP-harvested 
MSCs, respectively (Figure 23,Table 19).  
 
CD105, presented a higher MFI for LMP-harvested MSCs, from IC by 1.5-fold, 
whereas VB presented a similar outcome for both MSCs-isolation methods. In terms 
of the anatomic site, VB presented the highest outcome, by 1.7-fold and 1.2-fold 
difference for both AC and LMP-harvested MSCs, respectively (Figure 23,Table 19).  
 
CD73 presented a similar trend to CD90. LMP-harvested MSCs presented a higher 
MFI, by 1.2-fold from IC and 1.3-fold for AC-harvested MSCs from VB, respectively. 
In terms of the anatomic site, IC presented the highest outcome, by 1.3-fold and 2.2-
fold, from both AC and LMP-harvested MSCs, respectively (Figure 23,Table 19). 
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Figure 23: Graphics of median fluorescent intensity and percentage of 
positively stained MSCs for donor AF 29. MFI results illustrated, are limited only to 
the positive markers characterising MSCs, due to the negligible values of the 
haematopoietic markers (CD14, CD19, CD34, HLA-DR and CD45). The percentage 
of positive MSCs was determined based on the negative controls, applying the 
isotype control concept for all the fluorochromes used. Data are illustrated as 
grouped bars, median values are calculated. The legend for both graphics is showed 
at bottom figure. 
 
 
Table 19. MFI values of donor AF 29. 
 
AF 29 ALP MSCA1 SUSD2 CD105 CD90 CD73 
IC AC 3688 1743 656 1650 24878 5715 
IC LMP 22194 2624 715 2445 24282 7103 
VB AC 841 1090 591 2730 16380 4247 
VB LMP 2964 360 814 2818 15094 3165 
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Third donor, AF 39, (15.3y, F). 
 
The intracellular marker ALP, presented a higher MFI from IC LMP-harvested MSCs, 
by 1.3-fold and from VB AC-harvested MSCs by 1.7-fold, respectively. Regarding the 
anatomic site, ALP presented a higher MFI from IC, for both AC and LMP-harvested 
MSCs, by 1.4-fold and 3.2-fold difference, respectively (Figure 24,Table 20). 
 
The extracellular marker for ALP, MSCA1, presented a higher MFI from AC-
harvested MSCs, from both IC and VB by 1.3-fold. Regarding the anatomic site, 
MSCA1 showed a better outcome from IC, for both harvesting methods used by 1.6-
fold (AC) and 1.7-fold (LMP) (Figure 24,Table 20).  
 
Marker SUSD2, presented a higher MFI for LMP-harvested MSCs from ICBM by 1.3-
fold, whereas VBBM presented a similar outcome from both MSCs-isolation 
methods. Regarding the anatomic site, the overall expression was similar for both 
ICBM and VBBM (Figure 24,Table 20). 
 
CD90 presented, also in this case, the highest MFI, compared to the other standard 
MSCs characterization markers. AC-harvested MSCs, from both IC and VB 
presented a higher MFI, by 1.9- and 1.2-fold difference, respectively. Regarding the 
anatomic site, IC presented a higher outcome, by 1.6-fold from AC-harvested MSCs, 
whilst VB showed a better outcome, by 1.2-fold from LMP-harvested MSCs (Figure 
24,Table 20). 
 
CD105, presented a higher MFI for AC-harvested MSCs from IC by 1.7-fold, whereas 
VB presented a better outcome from LMP-harvested MSCs, by 1.6-fold. Concerning 
the anatomic site, VB showed the highest outcome from LMP-harvested MSCs, by 3-
fold, while AC-harvested MSCs gave similar results from both IC and VB (Figure 
24,Table 20).  
 
CD73 presented, also in this case, a similar trend to CD90. AC-harvested MSCs 
presented a higher MFI, by 1.8-fold from IC and 1.2-fold for LMP-harvested MSCs 
from VB. In terms of the anatomic region, IC presented a similar outcome for both 
MSCs-harvesting methods, while VB presented a better outcome form LMP-
harvested MSCs, by 1.9-fold difference (Figure 24,Table 20). 
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Figure 24: Graphics of median fluorescent intensity and percentage of 
positively stained MSCs for donor AF 39. MFI results illustrated, are limited only to 
the positive markers characterising MSCs, due to the negligible values of the 
haematopoietic markers (CD14, CD19, CD34, HLA-DR and CD45). The percentage 
of positive MSCs was determined based on the negative controls, applying the 
isotype control concept for all the fluorochromes used. Data are illustrated as 
grouped bars, median values are calculated. The legend for both graphics is showed 
at bottom figure. 
 
Table 20. MFI values of donor AF 39. 
 
AF 39 ALP MSCA1 SUSD2 CD105 CD90 CD73 
IC AC 2893 322 421 2790 15115 5231 
IC LMP 3805 252 565 1625 7843 2918 
VB AC 2012 204 582 3157 9225 4633 
VB LMP 1201 152 570 4901 11231 5550 
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Forth donor, AF 50, (17y, M). 
 
Intracellular marker ALP, presented a better MFI from both IC and VB LMP-
harvested MSC, by 4.7-fold and 6.8-fold, respectively. With regards to the anatomic 
site, ALP presented the same MFI, from both IC and VB, when AC-harvested MSC 
was used, however, VB presented a higher MFI with LMP-harvested MSC, by 1.5-
fold difference (Figure 25,Table 21). 
 
The extracellular marker for ALP, MSCA1, presented a better MFI with AC-harvested 
MSC, from both IC and VB by 5.2-fold and 2.3-fold, respectively. Concerning the 
anatomic site, MSCA1 presented an overall better outcome from VB, by 1.9-fold, 
using AC-harvested MSCs and 4.3-fold, using LMP-harvested MSCs (Figure 
25,Table 21). 
 
Marker SUSD2, presented a higher MFI for AC-harvested MSCs from IC by 1.9-fold, 
whereas LMP-harvested MSCs from VB showed better results by 1.5-fold difference. 
From the anatomic point of view, the overall expression was similar from both ICBM 
and VBBM (Figure 25,Table 21). 
 
Similarly to all the previous donors, CD90 presented the highest MFI, compared to 
CD105, and CD73 standard MSC characterization markers. Both IC and VB, AC-
harvested MSCs presented a higher MFI, by 1.7-fold and 1.3-fold, respectively, 
compared to LMP. Concerning the anatomic site, VB presented the highest outcome 
for CD90, by 3.5- and 2.1-fold from LMP and AC-harvested MSCs, respectively 
(Figure 25,Table 21). 
 
CD105, presented a higher MFI from LMP-harvested MSCs, for both IC and VB, by 
1.7-fold and 1.6-fold, respectively. With regards to the anatomic site, IC presented 
the highest outcome, by 1.2-fold for both LMP and AC-harvested MSCs (Figure 
25,Table 21). 
 
In line with all the above donors, CD73 presented a similar to CD90 trend. Both IC 
and VB, AC-harvested MSCs showed a higher MFI, by 1.2-fold and 1.4-fold, 
respectively. Regarding the anatomic region, VBBM shown the higher outcome, by 
1.9-fold and 1.6-fold, from both AC and LMP-harvested MSCs, respectively (Figure 
25,Table 21). 
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Figure 25: Graphics of median fluorescent intensity and percentage of 
positively stained MSCs for donor AF 50. MFI results illustrated, are limited only to 
the positive markers characterising MSCs, due to the negligible values of the 
haematopoietic markers (CD14, CD19, CD34, HLA-DR and CD45). The percentage 
of positive MSCs was determined based on the negative controls, applying the 
isotype control concept for all the fluorochromes used. Data are illustrated as 
grouped bars, median values are calculated. The legend for both graphics is showed 
at bottom figure. 
 
Table 21. MFI values of donor AF 50. 
 
AF 50 ALP MSCA1 SUSD2 CD105 CD90 CD73 
IC AC 348 569 689 2126 12041 4555 
IC LMP 1634 110 450 3596 7204 3859 
V12 AC 349 1064 369 1784 25354 8556 
V12 LMP 2379 469 689 2900 20340 6243 
 
 
 
 
 
 
 
 
 
 
 
 
 
 91  
4.7.3 Overall comparison (anatomic sites and isolation methods) 
 
The ALP intracellular marker presented a higher MFI from LMP-harvested MSCs 
from all donors, compared to AC, for both anatomic sites (IC 2.6-fold, VB 1.9-fold). 
APL presented the highest MFI from IC LMP (8714), followed by IC AC (3290.5), VB 
LMP (2671.5), and VB AC (1426.5). Despite the trend of IC to show a higher MFI, 
compared to VB, for both AC and LMP by 2.3-fold 3.3-fold, respectively, no statistical 
significance was observed (Figures 26-28, Table 22).  
 
Conversely, the extracellular marker for ALP, MSCA1, presented a higher MFI from 
AC-harvested MSCs, compared to LMP, from the majority of donors (AF28, AF29, 
AF50), for both anatomic sites (IC 2.4-fold, VB 2.6-fold). MSCA1 presented the 
highest MFI from IC AC (1156), followed by VB AC (1077), IC LMP (472.5), and VB 
LMP (414.5). Concerning the anatomic location, the overall expression was similar 
from both IC and VB (Figures 26-28, Table 22). 
 
SUSD2 did not show any substantial trend, regarding the harvesting method used or 
the anatomic site. VB LMP-harvested MSCs presented a slightly higher MFI (751.5), 
compared to VB AC (586.5) by 1.3-fold difference, followed by IC AC (672.5), and IC 
LMP (627) (Figures 26-28, Table 22). 
 
In relation to MSCs standard characterization markers, CD90 and CD73 presented a 
similar pattern throughout all donors. In particular, IC AC-harvested MSCs, presented 
a higher MFI for both CD90 (1.8-fold) and CD73 (1.4-fold), compared to IC LMP. 
Moreover, both presented a similar MFI from VB regardless the MSCs-harvesting 
method used. Additionally, CD90 was the only marker to present statistical 
significance (p=0.048) from IC AC-harvested MSCs, compared to IC LMP. Also 
CD90 presented always the highest MFI independently from the harvesting method 
used or the anatomic site. CD105 presented the higher MFI from VB LMP-harvested 
MSCs (2859), followed by VB LMP (2777), IC LMP (2397.5) and IC AC (1888). IC 
LMP presented a higher MFI by 1.3-fold difference, compared to IC AC. (Figures 26-
28, Table 22).  
 
The overall expression of all three markers CD105, CD90 and CD73, concerning the 
anatomic site, was similar for both IC and VB. Moreover, VB did not present any 
substantial difference between harvesting methods used, for CD105, CD90 and 
CD73, (Figures 26-28, Table 22). 
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Figure 26: Comparison of MFI values between AC- and LMP-harvested MSCs. 
Data are illustrated as before/after-type of graphics. No statistical significance was 
found, except from IC AC harvested-MSCs CD90 marker (p=0.048). 
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Figure 27: Comparison of MFI values between anatomic sites VB and IC MSCs. 
Data are illustrated as before/after-type of graphic. No statistical significance was 
found. 
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Table 22. Overview of MFI values, for all the donors tested with flow cytometry. 
Due to a non Gaussian distribution, median values were used for analysis. 
 
Donors ALP PE CD105 FITC CD90 FITC CD73 BV 421 SUSD2 APC MSCA1 PE 
AF28 IC AC 9790 1544 11396 2231 1020 2392 
AF29 IC AC 3688 1650 24878 5715 656 1743 
AF39 IC AC 2893 2790 15115 5231 421 322 
AF50 IC AC 348 2126 12041 4555 689 569 
Median 3290.5 1888.0 13578.0 4893.0 672.5 1156.0 
SD 4002.3 567.9 6228.7 1543.2 246.5 978.4 
Mean 4179.75 2027.5 15857.5 4433 696.5 1256.5 
       
AF28 IC LMP 13623 2350 5543 1918 689 693 
AF29 IC LMP 22194 2445 24282 7103 715 2624 
AF39 IC LMP 3805 1625 7843 2918 565 252 
AF50 IC LMP 1634 3596 7204 3859 450 110 
Median 8714.0 2397.5 7523.5 3388.5 627.0 472.5 
SD 9483.2 814.9 8763.1 2246.8 122.2 1163.0 
Mean 10314 2504 11218 3949.5 604.75 919.75 
       
AF28 VB AC 11807 2824 12558 2667 667 2839 
AF29 VB AC 841 2730 16380 4247 591 1090 
AF39 VB AC 2012 3157 9225 4633 582 204 
AF50 VB AC 349 1784 25354 8556 369 1064 
Median 1426.5 2777.0 14469.0 4440.0 586.5 1077.0 
SD 5414.9 589.0 6960.2 2502.5 128.0 1106.0 
Mean 3752.25 2623.75 15879.25 5025.75 552.25 1299.25 
       
AF28 VB LMP 24337 2743 5638 2333 822 1597 
AF29 VB LMP 2964 2818 15094 3165 814 360 
AF39 VB LMP 1201 4901 11231 5550 570 152 
AF50 VB LMP 2379 2900 20340 6243 689 469 
Median 2671.5 2859.0 13162.5 4357.5 751.5 414.5 
SD 11102.1 1042.3 6206.6 1870.2 119.2 648.5 
Mean 7720.25 3340.5 13075.75 4322.75 723.75 644.5 
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Figure 28: Overall comparison of median fluorescent intensity for all four 
donors. Median fluorescent intensity was performed only on markers characterising 
MSCs. CD90 from IC AC-harvested MSCs, was the only marker to present statistic 
significance (p=0.048). Data are illustrated as grouped bars, median values were 
calculated and Wilcoxon matched-pairs test were used. 
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4.8 Tri-lineage differentiation: Osteogenesis 
4.8.1 Osteogenesis, introduction. 
 
Following 14 days of osteogenic induction, osteogenesis was compared between the 
different groups; quantitatively (in triplicates), with spectrophotometric measurement 
of calcium production and qualitatively (in duplicates) by detection of alkaline 
phosphatase (ALP) activity with fast blue RR staining and matrix mineralization assay 
using alizarin red (AR) dye (Figures 29,30). All MSCs cultured under osteogenic 
conditions stained positively for all donors, with the only exception of a single 
contaminated well. 
 
ALP activity was more pronounced from VB with no significant deference between 
AC and LMP. Contrarily, within the IC group the colour was less marked, meaning a 
slightly lower ALP activity. In particular, IC LMP presented a slightly more intense 
activity compared to IC AC. Concluding, VB AC presented remarkably higher levels 
of ALP activity compared to IC AC, in all the donors studied. Whilst IC LMP gave 
better results from donors AF 39, AF 50 and only donor AF 29 expressed more ALP 
activity from VB LMP. Donor AF 28 presented similar activities for both harvesting 
methods (Figure 29). 
 
Similarly, matrix mineralization was higher from VB and in particular from VB AC-
harvested MSCs (donors: AF 29, AF 50), compared to VB LMP. Similarly to Figure 
34, the colour from IC was less marked, meaning a lower calcium deposition. In 
particular, IC LMP presented a slightly more intense activity compared to IC AC, 
especially for donors AF 39, AF 50. Concluding, VB AC presented the highest levels 
of matrix mineralization compared to VB LMP, IC AC and IC LMP, which present 
comparable levels between them (Figure 30). 
 
Despite the thorough tissue culture techniques, the staining presented an 
heterogeneous distribution within the same well. VB AC showed a more uniform 
colour distribution for both ALP and matrix mineralization (Figures 29,30). As it was 
expected, donor-to-donor variability was observed. This is a constant characteristic 
among similar studies and it is vastly documented in the literature51. 
 
All osteogenic cultures were stopped prematurely at the 14th day (instead of the 21st 
as per standard protocols), due to their high proliferation capacity, having almost 
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reached confluency of the well-plate at the end of the second week. Further 
extension of the culture, could have led to MSCs detachment from the plastic surface 
prejudging the outcome of the assay (Figure 31).  
 
 
 IC AC IC LMP VB AC VB LMP 
AF28 
    
AF29 
    
AF39 
    
AF50 
    
 
Figure 29: ALP colourimetric assay at 14 days post-induction. Overall 
comparison of the entire surface of the well plate (3.5 cm diameter) showing ALP 
activity, stained with Fast blue RR salt dye. 
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Figure 30: AR colourimetric assay at 14 days post-induction. Overall comparison 
of the entire surface of the well plate (3.5 cm diameter) showing mineral deposition, 
stained with AR dye. 
 
 
 
Figure 31: Bone marrow MSCs in osteogenic environment at passage 3. At this 
stage of MSCs' differentiation, the typical growth at radial pattern is less pronounced, 
however MSCs are still characterized by a high doubling rate, due to the young 
donors' age. A) Proliferation at the end of the 1st week. B) Reached confluency by the 
end of the 2nd week. Images at x200 magnification.  
7 Days 
X 200 X 200 
14 Days 
A B
b 
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Validation of calcium assay performance 
 
Variability between calcium assay triplicates was assessed to establish its accuracy. 
The CV was calculated at two different stages: 1) intra-variability within the triplicates, 
used for the spectrophotometric analysis (cut-off point ≤ 10%) and 2) inter-variability 
between the three different dishes used for the MSCs osteogenic induction (cut-off 
point ≤ 30%).  
 
Moreover, calcium concentrations were compared with the staining outcomes of 
colourimetric assays (ALP activity and AR), adding an additional level of validation to 
the results. 
 
Calcium assay performance (spectrophotometry) 
 
Standard curves have been produced using standard calcium values (Sigma kit) 
showing satisfactory linearity and consistent results across the different experiments 
performed (Figure 32). Following 144 readings, the optical density was analyzed and 
the overall CV was 2.63% (range 0%-10%), showing satisfactory intra-experimental 
performance with minimal pipetting error.  
 
Calcium assay performance (osteogenesis) 
 
Total calcium concentration was calculated in µg/ml, from each group of triplicates for 
all the different test cultures. Following 47 osteogenic assays, the average CV was 
16.1 (range 8.1%-24.7%) remaining, for all the cases, below the cut-off level of 30% 
for this type of assay.  
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Figure 32: Spectrophotometric readings of calcium assays. A-D) Standard 
curves and calcium concentrations in each set of triplicates, using 96-wells plate. E, 
F) Repetition of the assays performing 1:2 dilution of the samples, due to calcium 
concentrations, above the standard curves. 
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4.8.2 Individual analysis of each donor  
 
First donor, AF 28, (14.3y, M).  
 
CVs of the triplicates, following spectrophotometry (OD) and total calcium 
concentration (μg/ml), were 2.2% and 15.9%, far below the cut-off points of 10% and 
30% respectively, showing satisfactory intra- and inter-assay accuracy (Tables 23, 
24). 
 
The first donor exhibited higher calcium concentrations from VBBM (Figure 33a) and 
both AC and LMP harvesting methods performed better from VBBM. However, 
calcium concentrations from VB LMP-harvested MSCs, were higher compared to VB 
AC, IC LMP, and IC AC, as illustrated in Table 24. Additionally, considering the 
15.9% of the overall CV, the differences between the values of VB AC, IC LMP and 
IC AC were within the intra-experimental variability, therefore were not significant 
(Table 24, Figure 33).  
 
Matrix mineralization assay outcome, was consistent with the above 
spectrophotometric results confirming in such way the accuracy of both tests (Figure 
33b). Similarly, ALP activity assay, showed also a trend to be slightly more 
pronounced within the VBBM group, but without a marked difference between AC 
and LMP (Figure 33c).  
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Table 23: First donor, variability between triplicates of Calcium assay. OD 
readings, in triplicates. Mean, SD and CV were performed per single group. 
 
AF 28  Optical density in 96well-plate (x3) 
  1 2 3 MEAN SD 
CV 
(%) 
IC AC 
1 dish 0.159 0.159 0.158 0.159 0.00 0.36 
2 dish 0.162 0.166 0.161 0.163 0.00 1.62 
3 dish 0.146 0.141 0.143 0.143 0.00 1.76 
      CV Mean 1.25 
        
IC LMP 
1 dish 0.135 0.133 0.136 0.135 0.00 1.13 
2 dish 0.137 0.135 0.138 0.137 0.00 1.12 
3 dish 0.136 0.134 0.138 0.136 0.00 1.47 
      CV Mean 1.24 
        
VB AC 
1 dish 0.225 0.222 0.221 0.223 0.00 0.93 
2 dish 0.194 0.194 0.199 0.196 0.00 1.48 
3 dish  contaminated CV Mean 1.21 
        
VB LMP      
(1:2 dilution) 
1 dish 0.497 0.548 0.577 0.541 0.04 7.49 
2 dish 0.674 0.638 0.689 0.667 0.03 3.93 
3 dish 0.595 0.573 0.555 0.574 0.02 3.49 
      CV Mean 4.97 
     Total CV Mean 2.17 
 
 
Table 24: First donor, total calcium concentrations and experimental variability. 
A) Calcium concentration in triplicates, SD and intra-donor CV within the groups, B) 
Intra-donor comparisons of calcium concentrations, in fold-difference.  
 
A Total Calcium (µgr/ml) 
 IC AC IC LMP VB AC VB LMP 
1 dish 7.947 3.709 19.249 155.271 
2 dish 8.713 4.062 14.481 202.019 
3 dish 5.24 3.944 16.865 167.729 
MEAN 7.3 3.905 16.865 175.007 
SD 1.825 0.18 3.372 24.209 
CV (%) 24.998 4.605 19.991 13.833 
Mean of Overall CV 15.86 
     
B 
Intra-donor 
comparison based 
on total calcium 
Fold-difference 
 IC AC - IC LMP 1.9 
 VB AC - VB LMP 10.4 
 IC AC - VB AC 2.3 
 IC LMP - VB LMP 23.97 
 103  
IC  AC  IC  L M P  V B  AC  V B  L M P  
0
5 0
1 0 0
1 5 0
2 0 0
C
a
+
+

g
/m
l
AF 28 ♂ 14.3y 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: First donor, comparison between calcium concentration, AR and 
ALP results. A) Calcium concentration was higher in VB, compared to IC. VB LMP 
showed remarkably higher results, among all groups. B) Calcium deposits stained 
with AR, confirmed the spectrophotometric readings. C) ALP activity was similar in all 
groups. The text box indicates donor's details. B, C) Illustration of the entire surface 
of the wells. Graphic presented as bars with mean and SD. 
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Second donor, AF 29, (15.6y, M). 
 
In this case also, CVs of the triplicates, following spectrophotometry (OD) and total 
calcium concentration (μg/ml), were 2.3% and 18%, far below the cut-off points of 
10% and 30% respectively showing satisfactory intra- and inter-assay accuracy 
(Tables 25, 26). 
 
The second donor also exhibited higher concentrations of calcium from VBBM 
(Figure 34a) and both AC and LMP harvesting methods performed better from 
VBBM. Nevertheless, calcium concentration from VB AC-harvested MSCs, was 
higher compared to VB LMP, IC LMP, and IC AC as illustrated in Table 26. 
Additionally, considering the 18% of the overall CV, the differences between the 
values of VB AC, IC LMP and IC AC were within the intra-experimental variability, 
therefore were not significant (Table 26, Figure 34).  
 
Matrix mineralization assay outcome, was consistent with the above 
spectrophotometric results, confirming in this manner the accuracy of both tests 
(Figure 34b). Similarly, ALP activity assay, was also remarkably more pronounced 
within the VBBM group, but without difference between AC and LMP (Figure 34c).  
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Table 25: Second donor, variability between triplicates of Calcium assay. OD 
readings, in triplicates. Mean, SD and CV were performed per single group. 
 
AF 29  Optical density in 96well-plate (x3) 
  1 2 3 MEAN SD CV (%) 
IC AC 
1 dish 0.132 0.133 0.132 0.132 0.00 0.44 
2 dish 0.137 0.135 0.139 0.137 0.00 1.46 
3 dish 0.133 0.136 0.134 0.134 0.00 1.14 
      CV Mean 1.01 
        
IC LMP 
1 dish 0.133 0.132 0.131 0.132 0.00 0.76 
2 dish 0.131 0.132 0.133 0.132 0.00 0.76 
3 dish 0.129 0.127 0.128 0.128 0.00 0.78 
      CV Mean 0.77 
        
VB AC          
(1:2 dilution) 
1 dish 0.451 0.457 0.415 0.441 0.02 5.15 
2 dish 0.520 0.462 0.516 0.499 0.03 6.49 
3 dish 0.557 0.588 0.648 0.598 0.05 7.74 
      CV Mean 6.46 
        
VB LMP 
1 dish 0.149 0.147 0.152 0.149 0.00 1.69 
2 dish 0.138 0.137 0.135 0.137 0.00 1.12 
3 dish 0.138 0.138 0.138 0.138 0.00 0.00 
      CV Mean 0.93 
     Total CV Mean 2.29 
 
 
Table 26: Second donor, total calcium concentrations and experimental 
variability. A) Calcium concentration in triplicates, SD and intra-donor CV within the 
groups, B) Intra-donor comparisons of calcium concentrations, in fold-difference. 
 
A Total Calcium (µgr/ml) 
 IC AC IC LMP VB AC VB LMP 
1 dish 2.816 2.758 118.391 5.758 
2 dish 3.335 2.758 139.976 3.566 
3 dish 3.162 2.066 176.363 3.797 
MEAN 3.104 2.527 144.91 4.374 
SD 0.264 0.4 29.3 1.205 
CV (%) 8.517 15.815 20.219 27.545 
Mean of Overall CV 18.02 
     
B 
Intra-donor 
comparison based 
on total calcium 
Fold-difference 
 IC AC - IC LMP 1.2 
 VB AC - VB LMP 33.1 
 IC AC - VB AC 46.7 
 IC LMP - VB LMP 1.7 
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Figure 34: Second donor, comparison between calcium concentration, AR and 
ALP results. A) Calcium concentration was higher in VB, compared to IC. VB AC 
gave the highest results, among all groups. B) Calcium deposits stained with AR, 
confirmed the spectrophotometric results. C) ALP activity was higher in VB group. 
The text box indicates donor's details. B, C) Illustration of the entire surface of the 
wells. Graphic presented as bars with mean and SD. 
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Third donor, AF 39, (15.3y, F). 
 
CVs of the triplicates, following spectrophotometry (OD) and total calcium 
concentration (µg/ml), were 1.7% and 17.9%, below the cut-off points of 10% and 
30% respectively, showing satisfactory intra- and inter-assay accuracy (Table 27, 
28). 
 
The third donor, in contrast with the previous cases, did not show any significant 
difference between the compared groups and both harvesting methods, AC and 
LMP, performed slightly better from VBBM (Figure 35a). In particular, calcium 
concentration from VB AC-harvested MSCs, was higher compare to VB LMP, IC 
LMP, and IC AC as illustrated in Table 28. Additionally, considering the 17.9% of the 
overall CV, the differences between VB LMP, IC AC and IC LMP were within the 
intra-experimental variability (Table 28, Figure 35). 
 
Comparison between matrix mineralization assay and ALP activity, showed similar 
colourimetric results (Figure 35b,c). This donor did not present a strong relation, 
between spectrophotometric and colourimetric assays, however it is still possible to 
identify a trend, which correlates between the tests (Figure 35a,b,c). This difference 
from the rest of the donors, maybe is related to the different gender of this donor. 
From the anatomic point of view, both sites presented a similar outcome.  
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Table 27: Third donor, variability between triplicates of Calcium assay. OD 
readings, in triplicates. Mean, SD and CV were performed per single group. 
 
AF 39  Optical density in 96well-plate (x3) 
  1 2 3 MEAN SD CV (%) 
IC AC 
1 dish 0.139 0.142 0.136 0.139 0.00 2.16 
2 dish 0.127 0.129 0.130 0.129 0.00 1.19 
3 dish 0.124 0.127 0.128 0.126 0.00 1.65 
      CV Mean 1.66 
        
IC LMP 
1 dish 0.148 0.150 0.150 0.149 0.00 0.77 
2 dish 0.148 0.149 0.148 0.148 0.00 0.39 
3 dish 0.162 0.161 0.160 0.161 0.00 0.62 
      CV Mean 0.60 
        
VB AC 
1 dish 0.140 0.135 0.134 0.136 0.00 2.36 
2 dish 0.132 0.139 0.134 0.135 0.00 2.67 
3 dish 0.144 0.143 0.150 0.146 0.00 2.60 
      CV Mean 2.54 
        
VB LMP 
1 dish 0.135 0.135 0.129 0.133 0.00 2.60 
2 dish 0.132 0.130 0.134 0.132 0.00 1.52 
3 dish 0.127 0.127 0.130 0.128 0.00 1.35 
      CV Mean 1.82 
     Total CV Mean 1.66 
 
 
Table 28: Third donor, total calcium concentrations and experimental 
variability. A) Calcium concentration in triplicates, SD and intra-donor CV within the 
groups, B) Intra-donor comparisons of calcium concentrations, in fold-difference. 
 
A Total Calcium (µgr/ml) 
 IC AC IC LMP VB AC VB LMP 
1 dish 7.355 3.463 6.876 6.277 
2 dish 5.498 3.295 6.636 6.097 
3 dish 5.079 5.424 8.552 5.378 
MEAN 5.977 4.060 7.355 5.917 
SD 1.211 1.184 1.044 0.475 
CV (%) 20.263 29.150 14.198 8.033 
Mean of Overall CV 17.91 
     
B 
Intra-donor 
comparison based 
on total calcium 
Fold-difference 
 IC AC - IC LMP 1.5 
 VB AC - VB LMP 1.2 
 IC AC - VB AC 1.2 
 IC LMP - VB LMP 1.4 
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Figure 35: Third donor, comparison between calcium concentration, AR and 
ALP results. A) Calcium concentration was slightly higher in VB, compared to IC, but 
without any substantial difference. B) Calcium deposits stained with AR, did not 
present a strong correlation with the spectrophotometric results. C) ALP activity was 
similar in both anatomic regions. The text box indicates donor's details. B, C) 
Illustration of the entire surface of the wells. Graphic presented as bars with mean 
and SD. 
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Forth donor, AF 50, (17y, M). 
 
In the fourth donor, CVs of the triplicates, following spectrophotometry (OD) and total 
calcium concentration (μg/ml), were 4.4% and 11.2%, far below the cut-off points of 
10% and 30% respectively, showing satisfactory intra- and inter-assay accuracy 
(Tables 29, 30). 
 
The forth donor, exhibited higher concentrations of calcium from IC LMP-harvested 
MSCs followed by VB AC. AC-harvesting method performed better from VBBM, but 
contrary to the rest of the cases, LMP performed better from ICBM (Figure 36a). In 
particular, calcium concentration from IC LMP-harvested MSCs, was higher 
compared to VB AC, VB LMP, and IC AC as illustrated in Table 30. Additionally, 
considering the 11.2% of the overall CV, the difference between IC LMP and VB AC 
was above the intra-experimental variability, and the difference between VB LMP and 
IC AC was within the intra-experimental variability (Table 30, Figure 36).  
 
Matrix mineralization and ALP activity assays showed consistent colourimetric 
outcome, coinciding with the above spectrophotometric results, confirming the 
accuracy of both tests (Figure 36a,b,c).  
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Table 29: Forth donor, variability between triplicates of Calcium assay. OD 
readings, in triplicates. Mean, SD and CV were performed per single group.  
 
AF 50  Optical density in 96well-plate (x3) 
  1 2 3 MEAN SD 
CV 
(%) 
IC AC 
1 dish 0.195 0.211 0.208 0.205 0.01 4.15 
2 dish 0.172 0.185 0.183 0.180 0.01 3.89 
3 dish 0.191 0.207 0.201 0.200 0.01 4.05 
      CV Mean 4.03 
        
IC LMP          
(1:2 dilution) 
1 dish 0.562 0.567 0.626 0.585 0.04 6.08 
2 dish 0.514 0.574 0.558 0.549 0.03 5.66 
3 dish 0.524 0.526 0.561 0.537 0.02 3.87 
      CV Mean 5.21 
        
VB AC          
(1:2 dilution) 
1 dish 0.424 0.424 0.424 0.424 0.00 0.00 
2 dish 0.477 0.517 0.556 0.517 0.04 7.65 
3 dish 0.439 0.417 0.446 0.434 0.02 3.49 
      CV Mean 3.71 
        
VB LMP 
1 dish 0.254 0.251 0.270 0.258 0.01 3.95 
2 dish 0.219 0.229 0.240 0.229 0.01 4.58 
3 dish 0.248 0.243 0.270 0.254 0.01 5.66 
      CV Mean 4.73 
     Total CV Mean 4.42 
 
 
Table 30: Forth donor, total calcium concentrations and experimental 
variability. A) Calcium concentration in triplicates, SD and intra-donor CV within the 
groups, B) Intra-donor comparisons of calcium concentrations, in fold-difference. 
 
A Total Calcium (µgr/ml) 
 IC AC IC LMP VB AC VB LMP 
1 dish 19.153 172.676 112.368 28.795 
2 dish 14.721 159.324 146.390 23.584 
3 dish 18.254 155.036 115.800 27.956 
MEAN 17.376 162.345 124.853 26.779 
SD 2.343 9.200 18.731 2.798 
CV (%) 13.483 5.667 15.002 10.448 
Mean of Overall CV 11.15 
     
B 
Intra-donor 
comparison based 
on total calcium 
Fold-difference 
 IC AC - IC LMP 9.3 
 VB AC - VB LMP 4.7 
 IC AC - VB AC 7.2 
 IC LMP - VB LMP 6.1 
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Figure 36: Forth donor, comparison between calcium concentration, AR and 
ALP results. A) Calcium concentration presented similar results between both 
anatomic regions, however, IC LMP yielded the highest outcome compared to VB 
AC, VB LMP and IC AC, respectively. B, C) Calcium deposits stained with AR and 
ALP activity was in line with the spectrophotometric results. The text box indicates 
donor's details. B, C) Illustration of the entire surface of the wells. Graphic presented 
as bars with mean and SD. 
 
 
4.8.3 Osteogenesis, overall comparison  
 
The overall analysis of 16 different cultures from a cohort of 4 donors (3 males and 1 
female) showed higher calcium concentrations from VBBM MSCs, compared to 
ICBM, with both harvesting methods (VBBM: AC 73.5μg/ml, LMP 53μg/ml, ICBM: AC 
8.4μg/ml, LMP 43.21μg/ml, mean values). In particular, VB AC-harvested MSCs 
showed significantly higher calcium concentration, compared to IC AC-harvested 
MSCs by 8.7-fold difference, p=0.001 (Figure 37). Contrarily, comparing the calcium 
production between VB LMP and IC LMP, the difference was only 1.2-fold and 
without any statistical significance. 
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Matrix mineralization assay, showed a higher calcium deposition from VBBM, 
especially from the VB AC-harvested MSCs' group (Figure 30), which was consistent 
with the spectrophotometric results in all the above experiments.  
 
ALP activity was also higher from the VBBM and especially from VB AC-harvested 
MSCs' group, however it was not always matching the spectrophotometric outcomes 
with the same accuracy as the AR staining (Figure 29). This is because, although 
spectrophotometry and matrix mineralization assays use different techniques, both 
measure calcium deposition following its staining. Contrarily ALP assay, represents a 
qualitative assessment of the ALP expression, detecting its enzymatic activity. 
Therefore, they show different aspects of the same process and for this reason they 
present a similar pattern, but is not exactly identical. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Summarized data from all 4 donors. Average values of total calcium 
production (μg/ml), showing a statistically significant difference between VB AC- and 
IC AC-harvested MSCs (***, p=0.001). Values processed with Wilcoxon T test and 
are represented as Box & Whiskers graphic. Mean and median are illustrated as "+" 
and "bar" symbols, respectively. 
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4.9 Tri-lineage differentiation: Chondrogenesis 
4.9.1 Chondrogenesis, introduction 
 
Following 21 days of MSCs chondrogenic induction, cultures stained positively for all 
donors. Chondrogenesis was compared between the different groups; quantitatively, 
with spectrophotometric measurement of glycosaminoglycan (GAG) production and 
qualitatively by toluidine blue staining of sectioned chondrogenic pellets at 10°C 
temperature using an oscillo-cryotome (Figure 38).  
 
However, despite the thorough tissue culture technique used, MSCs-chondrogenic 
induction, presented a more complex management compared to osteogenesis and 
adipogenesis, resulting in three contaminated eppendorf tubes, subsequently 
excluded from the assay. This higher rate of infection, compared to other assays, 
could be possibly related to a more complex medium composition and manipulation 
of the numerous eppendorf tubes used (5 eppendorf tubes per condition, 77 in total) 
to reproduce the 3D culture model.  
 
Similarly to osteogenesis, donor-to-donor variability was also noticed, however, 
similar patterns between donors were observed, and will be discussed in the 
following paragraphs.  
 
Comparing chondrogenesis from a quantitative perspective, VBBM showed a 
significantly higher production of GAG from all patients, regardless the harvesting 
technique used. Contrarily, within the ICBM group, were statistically significant 
differences between AC and LMP-harvested MSCs, resulting in a higher production 
of GAG from IC LMP-harvested MSCs (Figure 44).  
 
In particular, VB LMP presented slightly higher concentration of GAG from donors 
AF29 and AF50 (Figures 41, 43), while donors AF28 and AF39 (Figures 40, 42) gave 
higher concentration of GAG from VB AC. Therefore, no statistical significance was 
found between VBBM harvesting method. Regarding ICBM MSCs, a consistent 
performance was observed across all donors, presenting always a higher 
concentration of GAG from LMP-harvested MSCs, which was statistically significant 
(Figure 40-44). 
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Validation of GAG assay performance 
 
Variability between the different groups of GAG assay was assessed to establish its 
accuracy. The CV was calculated at two different stages: 1) between the two 
samples tested from each eppendorf tube, between each group of triplicates (cut-off 
point of OD, ≤ 10%) and 2) between the total GAG concentrations (cut-off point, ≤ 
30%).  
 
Moreover, the quantitative outcomes of GAG concentrations were compared with the 
qualitative analysis of the staining patterns of chondrogenic pellets (Figure 38), 
performed in duplicates, adding an extra level of validation of the results. 
 
 
GAG assay performance (spectrophotometry) 
 
Standard curves were produced, in duplicates, using standard GAG values 
(Blyscan™ s-GAG assay kit) showing satisfactory linearity and consistent results 
across the different experiments performed (Figure 39). Following 
spectrophotometry, OD was analyzed and the overall CV was 3.03% (range 1.29%-
4.24%), showing satisfactory intra-experimental performance. 
 
 
GAG assay performance (chondrogenesis) 
 
Total GAG concentration was calculated in µg/ml, from each group of triplicates. The 
average CV was 17.78% (range 13.24%-21.08%) remaining below the cut-off level of 
30% for this type of assay.  
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 IC AC IC LMP VB AC VB LMP 
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AF39 
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Figure 38: Qualitative analysis of chondrogenic pellets. Overall comparison of 
the pellets sectioned into 0.04μm in OCT and stained with toluidine blue dye, 
following 21 days post-induction. GAG is stained in purple and fibrous tissue is 
stained in blue. Microphotography was performed under consistent photographic 
parameters to allowed comparison of the results. Magnification x64. 
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Figure 39: Spectrophotometric readings of GAG assays. A-D) Standard curves 
and GAG concentrations performed in duplicates, per each condition examined, 
using 96-flat bottom well plates. 
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4.9.2 Individual analysis of each donor. 
 
First donor, AF 28, (14.3y, M).  
 
Following spectrophotometry (OD) and calculation of total GAG concentrations 
(µg/ml), the CVs were 3.99% and 21.81%, far below the cut-off points of 10% and 
30% respectively, showing satisfactory intra- and inter-assay accuracy (Tables 31, 
32). 
 
The first donor produced overall the lowest amount of GAG, however, presented a 
similar pattern compared to the rest of the donors, showing higher GAG 
concentrations from VBBM either using AC or LMP (Figure 40a). More specifically, 
VB AC-harvested MSCs produced the highest amount of GAG followed by VB LMP, 
IC LMP and IC AC with 1.3-fold, 1.7-fold and 32.2-fold difference, respectively (Table 
32). Additionally, considering the 21.8% of the overall CV, the differences between 
GAG values of IC LMP and IC AC, were above the intra-experimental variability, 
contrarily the difference between IC LMP and VB LMP, was within the intra-
experimental variability (Table 32, Figure 40).  
 
Moreover, this donor did not present a strong relation, between spectrophotometric 
and colourimetric assays (Figure 40b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119  
Table 31: First donor, variability between duplicates of GAG assay. OD 
readings, with Mean, SD and CV were calculated per single group. 
 
AF 28  Optical density in 96well-plate (x2) 
  
1 2 MEAN SD 
CV 
(%) 
IC AC 
1 eppendorf 0.081 0.083 0.082 0.001 1.72 
2 eppendorf 0.084 0.081 0.083 0.002 2.57 
3 eppendorf 0.084 0.082 0.083 0.001 1.70 
     CV Mean 2.00 
       
IC LMP 
1 eppendorf 0.125 0.121 0.123 0.003 2.30 
2 eppendorf 0.117 0.107 0.112 0.007 6.31 
3 eppendorf  contaminated CV Mean 4.31 
       
VB AC 
1 eppendorf 0.155 0.159 0.157 0.003 1.80 
2 eppendorf 0.129 0.137 0.133 0.006 4.25 
3 eppendorf contaminated CV Mean 3.03 
       
VB LMP 
1 eppendorf 0.119 0.133 0.126 0.010 7.86 
2 eppendorf 0.129 0.133 0.131 0.003 2.16 
3 eppendorf 0.127 0.146 0.137 0.013 9.84 
     CV Mean 6.62 
    Total CV mean 3.99 
 
 
 
 
Table 32: First donor, total GAG concentrations. GAG production in triplicates 
(µg/ml), SD and intra-donor CV within groups were calculated.  
 
Total GAG (µg/ml) 
 IC AC IC LMP VB AC VB LMP 
1 eppendorf 0.340 10.788 19.453 11.553 
2 eppendorf 0.595 7.985 13.337 12.827 
3 eppendorf 0.595 contaminated contaminated 14.356 
MEAN 0.510 9.387 16.395 12.912 
SD 0.147 1.982 4.325 1.404 
CV (%) 28.867 21.117 26.379 10.870 
Mean of Overall CV 21.81 
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Figure 40: First donor, comparison between GAG concentrations A) GAG 
concentration was higher in VB, compared to IC, showing slightly higher results from 
VB AC, among all groups. B) It was not possible to identify a strong correlation, 
between GAG deposits stained with toluidine blue and the spectrophotometric 
results. The text box indicates donor's details. A) Graphic presented as bars with 
mean and SD, B) Microphotography of chondrogenic pellet slides. Magnification 
x160. 
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Second donor, AF 29, (15.6y, M). 
 
In this case also, following spectrophotometry (OD) and calculation of total GAG 
concentrations (µg/ml), the CVs were 4.24% and 16.05%, far below the cut-off points 
of 10% and 30%, respectively, showing satisfactory intra- and inter-assay accuracy 
(Tables 33, 34). 
 
The second donor also exhibited higher concentration of GAG from VBBM, especially 
from VB LMP-harvested MSCs (Figure 41a). In particular, VB LMP-harvested MSCs 
produced the highest amount of GAG followed by IC LMP, VB AC and IC AC with 
1.3-fold, 1.4-fold and 2.8-fold difference, respectively. In addition, considering the 
16.05% of the overall CV, the differences between the GAG values of VB AC, IC 
LMP and IC AC, were all above the intra-experimental variability (Table 33, Figure 
41). 
 
GAG staining outcome was similar with the above mentioned spectrophotometric 
results, showing satisfactory correlation between colourimetric and 
spectrophotometric assays (Figure 41b). 
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Table 33: Second donor, variability between duplicates of GAG assay. OD 
readings, with Mean, SD and CV were calculated per single group. 
 
AF 29  Optical density in 96well-plate (x2) 
  1 2 MEAN SD CV (%) 
IC AC 
1 eppendorf 0.158 0.153 0.156 0.004 2.27 
2 eppendorf 0.123 0.138 0.131 0.011 8.13 
3 eppendorf 0.114 0.13 0.122 0.011 9.27 
     CV Mean 6.56 
       
IC LMP 
1 eppendorf 0.236 0.223 0.230 0.009 4.01 
2 eppendorf 0.193 0.183 0.188 0.007 3.76 
3 eppendorf 0.193 0.195 0.194 0.001 0.73 
     CV Mean 2.83 
       
VB AC 
1 eppendorf 0.19 0.192 0.191 0.001 0.74 
2 eppendorf 0.192 0.181 0.187 0.008 4.17 
3 eppendorf  contaminated CV Mean 2.46 
       
VB LMP 
1 eppendorf 0.23 0.216 0.223 0.010 4.44 
2 eppendorf 0.241 0.274 0.258 0.023 9.06 
3 eppendorf 0.225 0.231 0.228 0.004 1.86 
     CV Mean 5.12 
    Total CV mean 4.24 
 
 
 
 
Table 34: Second donor, total GAG concentrations. GAG production in triplicates 
(µg/ml), SD and intra-donor CV within groups were calculated. 
  
Total GAG (µg/ml) 
 IC AC IC LMP VB AC VB LMP 
1 eppendorf 19.198 38.056 27.863 36.273 
2 eppendorf 12.827 27.353 27.098 45.192 
3 eppendorf 10.533 28.882 contaminated 37.547 
MEAN 14.186 31.431 27.480 39.670 
SD 4.489 5.789 0.541 4.824 
CV (%) 31.646 18.418 1.967 12.160 
Mean of Overall CV 16.05 
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Figure 41: Second donor, comparison between GAG concentrations. A) GAG 
concentration was higher in VB, compared to IC; showing higher results from VB 
LMP, among all groups. B) GAG deposits stained with toluidine blue were in line with 
the spectrophotometric results. The text box indicates donor's details. A) Graphic 
presented as bars with mean and SD, B) Microphotography of chondrogenic pellet 
slides. Magnification x160. 
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Third donor, AF 39, (15.3y, F). 
 
Following spectrophotometry (OD) and calculation of total GAG concentrations 
(µg/ml), the CVs were 2.26% and 13.24%, far below the cut-off points of 10% and 
30% respectively, showing satisfactory intra and inter-assay accuracy (Tables 35, 
36). 
 
Likewise, AF 39 also exhibited a higher concentration of GAG from VBBM (Figure 
42a). In particular, V12 AC-harvested MSCs produced the highest amount of GAG, 
followed by VB LMP, IC LMP, and IC AC with 1.3-fold, 3.8-fold and 5.2-fold, 
difference, respectively. In addition, considering the 13.24% of the overall CV, the 
differences between the GAG values of VB LMP, IC LMP and IC AC, were all above 
the intra-experimental variability. However, the difference between IC LMP and IC 
AC, was within the intra-experimental variability (Table 36, Figure 42). 
 
Similarly to osteogenic assay, this donor did not present a strong relationship, 
between spectrophotometric and colourimetric assays, however is still possible to 
identify a trend (Figure 42b). This difference from the rest of the donors, possibly 
could be related to the different gender of this donor. 
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Table 35: Third donor, variability between duplicates of GAG assay. OD 
readings, with Mean, SD and CV were calculated per single group. 
 
AF 39  Optical density in 96well-plate (x2) 
  1 2 MEAN SD CV (%) 
IC AC 
1 eppendorf 0.117 0.119 0.118 0.001 1.20 
2 eppendorf 0.123 0.121 0.122 0.001 1.16 
3 eppendorf 0.142 0.143 0.143 0.001 0.50 
     CV Mean 0.95 
       
IC LMP 
1 eppendorf 0.153 0.151 0.152 0.001 0.93 
2 eppendorf 0.138 0.136 0.137 0.001 1.03 
3 eppendorf 0.147 0.146 0.147 0.001 0.48 
     CV Mean 0.82 
       
VB AC 
1 eppendorf 0.31 0.345 0.328 0.025 7.56 
2 eppendorf 0.315 0.322 0.319 0.005 1.55 
3 eppendorf 0.311 0.341 0.326 0.021 6.51 
     CV Mean 5.21 
       
VB LMP 
1 eppendorf 0.251 0.238 0.245 0.009 3.76 
2 eppendorf 0.291 0.277 0.284 0.010 3.49 
3 eppendorf 0.258 0.27 0.264 0.008 3.21 
     CV Mean 3.49 
    Total CV mean 2.61 
 
 
 
 
Table 36: Third donor, total GAG concentrations. GAG production in triplicates 
(µg/ml), SD and intra-donor CV within groups were calculated. 
 
Total GAG (µg/ml) 
 IC AC IC LMP VB AC VB LMP 
1 eppendorf 9.514 18.179 63.031 41.879 
2 eppendorf 10.533 14.356 60.737 51.818 
3 eppendorf 15.885 16.905 62.521 46.721 
MEAN 11.978 16.480 62.097 46.806 
SD 3.422 1.946 1.204 4.970 
CV (%) 28.572 11.811 1.939 10.618 
Mean of Overall CV 13.24 
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Figure 42: Third donor, comparison between GAG concentrations. A) GAG 
concentration was higher in VB, compared to IC, showing higher results from VB AC, 
among all groups. B) It was not possible to identify a strong correlation for all the 
groups, between GAG deposits stained with toluidine blue and the 
spectrophotometric results. The text box indicates donor's details. A) Graphic 
presented as bars with mean and SD, B) Microphotography of chondrogenic pellet 
slides. Magnification x160. 
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Forth donor, AF 50, (17y, M). 
 
The forth donor, following spectrophotometry (OD) and calculation of total GAG 
concentrations (µg/ml), the CVs were 1.29% and 20.09%, below the cut-off points of 
10% and 30% respectively, showing satisfactory intra- and inter-assay accuracy 
(Tables 37, 38). 
 
The fourth donor, produced the highest amount of GAG among all donors, 
maintaining in the meantime a similar pattern like the previous donors. Also in this 
case, the highest concentration of GAG was from VBBM (Figure 43a). In particular, 
VB LMP-harvested MSCs produced the highest amount of GAG, followed by VB AC, 
IC LMP, and IC AC with 1.1-fold, 1.2-fold and 2.4-fold, difference, respectively. 
Additionally, considering the 20.09% of the overall CV, the difference between the 
GAG value of VB AC, VB LMP and IC LMP were within the intra-experimental 
variability, with exception of IC AC which was above it (Table 38, Figure 43).  
 
GAG staining outcome was similar with the above mentioned spectrophotometric 
results, showing satisfactory correlation between colourimetric and 
spectrophotometric assays (Figure 43b). 
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Table 37: Fourth donor, variability between duplicates of GAG assay. OD 
readings, with Mean, SD and CV were calculated per single group. 
 
AF 50  Optical density in 96well-plate (x2) 
  1 2 MEAN SD CV (%) 
IC AC 
1 eppendorf 0.24 0.244 0.242 0.003 1.17 
2 eppendorf 0.34 0.347 0.344 0.005 1.44 
3 eppendorf 0.227 0.223 0.225 0.003 1.26 
     CV Mean 1.29 
       
IC LMP 
1 eppendorf 0.493 0.491 0.492 0.001 0.29 
2 eppendorf 0.493 0.496 0.495 0.002 0.43 
3 eppendorf 0.382 0.389 0.386 0.005 1.28 
     CV Mean 0.67 
       
VB AC 
1 eppendorf 0.591 0.632 0.612 0.029 4.74 
2 eppendorf 0.429 0.439 0.434 0.007 1.63 
3 eppendorf 0.497 0.499 0.498 0.001 0.28 
     CV Mean 2.22 
       
VB LMP 
1 eppendorf 0.581 0.584 0.583 0.002 0.36 
2 eppendorf 0.505 0.492 0.499 0.009 1.84 
3 eppendorf 0.551 0.557 0.554 0.004 0.77 
     CV Mean 0.99 
    Total CV mean 1.29 
 
 
 
 
Table 38: Fourth donor, total GAG concentrations. GAG production in triplicates 
(µg/ml), SD and intra-donor CV within groups were calculated. 
  
Total GAG (µg/ml) 
 IC AC IC LMP VB AC VB LMP 
1 eppendorf 41.115 104.825 135.406 128.016 
2 eppendorf 67.108 105.590 90.044 106.609 
3 eppendorf 36.782 77.812 106.354 120.625 
MEAN 48.335 96.075 110.601 118.417 
SD 16.402 15.821 22.977 10.873 
CV (%) 33.934 16.468 20.775 9.182 
Mean of Overall CV 20.09 % 
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Figure 43: Four donor, comparison between GAG concentrations. A) GAG 
concentration was higher in VB, compared to IC, showing higher results from VB 
LMP, among all groups. B) GAG deposits stained with toluidine blue were similar with 
the spectrophotometric results. The text box indicates donor's details. A) Graphic 
presented as bars with mean and SD, B) Microphotography of chondrogenic pellet 
slides. Magnification x160. 
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4.9.3 Chondrogenesis, overall comparison 
 
The overall analysis of 16 different groups of cultures from a cohort of 4 donors (3 
males and 1 female), showed consistently higher GAG concentrations from VBBM-
MSCs, compared to ICBM-MSCs (VBBM: AC 44.3μg/ml, LMP 43.5μg/ml, ICBM: AC 
11.7μg/ml, LMP 22.8μg/ml) (Figure 44). In particular, GAG production from VB AC- 
and LMP-harvested MSCs was statistically higher, compared to IC AC- and LMP-
harvested MSCs, by 3.8-fold (p=0.0005) and 1.9-fold (p=0.0030) difference, 
respectively.  
 
Regarding ICBM, all four donors presented a consistently higher production of GAG 
from LMP-harvested MSCs by 1.9-fold difference (p=0.0005), compared to AC-
harvested MSCs. Contrarily, VBBM donors showed an equal GAG production 
between AC and LMP-harvested MSCs, without any statistical difference.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: Summarized data from all 4 donors. Average values of total GAG 
production (μg/ml), showing statistical significant differences between IC LMP - IC 
AC (***, p=0.0005), IC LMP - VB LMP (**, p=0.0030), and IC AC - VB AC (***, 
p=0.0005). Values processed with Wilcoxon T test and are represented as Box & 
Whiskers graphic. Mean and median are illustrated as "+" and "bar" symbols, 
respectively. 
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4.10 Tri-lineage differentiation: Adipogenesis 
4.10.1 Adipogenesis, introduction 
 
Following 21 days of adipogenic induction (Figure 45), adipogenesis was compared 
between the different groups, using Oil red-O and Nile red/DAPI staining.  
Oil red-O dye binds lipids present in cells and represents one of the most commonly 
used staining method for adipogenically-differentiated MSCs227,228 (Figure 46). 
Additionally, this method can be used to assess the differentiation of MSCs through a 
semi-quantitative grading system227 (Figure 47).  
 
Moreover, Nile red and DAPI staining, combined together in the same well, provide a 
series of advantages for the adipogenesis study. Firstly, it allows the 
spectrophotometric measurement of fat content (Nile red). Secondly, DAPI staining of 
the nuclei, provides information on the cells' proliferation rate during the induction 
period. Moreover, the combination of two dyes allows to determine the relationship 
between proliferation and differentiation rate, calculated by dividing DAPI by Nile red 
fluorescence.  
 
Finally, the spectrophotometric results were compared to fluorescent images of the 
same cultures. This offered a visual verification of the fat content (Figure 48). In this 
manner, further information could be gathered from the analysis of the fat droplets 
distribution per cell and their levels of fluorescence. For example, it allowed to 
distinguish between cultures presenting equal fluorescence, but with a different 
pattern of fat distribution.  
 
 
Figure 45: Progress of adipogenic differentiation of MSCs over a 21 days 
period. Fat droplets begin to be visible from the second week onwards. In the third 
week, fat content tends to cover a larger area of the cytoplasm. For the same time-
course of adipogenic induction, were noticed cells presenting different size of fat 
droplets (3rd week). Images illustrated are from donor AF28 IC LMP before staining. 
1
st  
week 2
nd  
week 3
rd  
week x 40 x 40 x 100 
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Figure 46: Oil red-O staining of MSCs. Representative images of MSCs from all 
four donors following 21 days of adipogenic induction. Intracellular fat droplets 
stained red for all cultures, except AF50 IC AC where dye didn't bind the fat content 
of the droplets, which however it is still visible. The bigger and more uniform size of 
fat droplets is evident in IC AC compared to IC LMP which appear to be slightly 
smaller. MSCs from VB AC presented a bigger variety of fat droplet sizes containing 
prevalently medium size droplets, while VB LMP presented mainly smaller size fat 
droplets. Images were taken using an Olympus inverted microscope in x40 and x200 
(inserts) magnifications.  
 
 
 
 
 
 
 IC AC IC LMP VB AC VB LMP 
AF28 
    
AF29 
    
AF39 
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Figure 47: Semi-quantitative scoring system of adipogenic differentiated MSCs' 
using Oil red-O staining. MSCs were counted and scored in 3 different areas of the 
well, and ranked into four grades, based on their fat content; Grade 1 (0-24%), Grade 
2 (25-49%), Grade 3 (50-74%), and Grade 4 (75-100%). Magnification x200. 
 
 
From the morphologic point of view, all cultures showed heterogeneous distribution 
of the differentiated MSCs within the well (Figures 46, 48). Moreover, differences 
between the fat droplets' size and their distribution within the cells were observed. 
Furthermore, there were dissimilar differentiation patterns, as well as the failure of 
differentiation of a subset of MSCs, within the same well. 
 
In particular, regardless the staining technique used, IC AC presented the biggest 
size of fat droplets with the most uniform distribution within the MSCs. Additionally, 
the differentiation rate was almost uniform within the culture. VB AC presented a 
smaller size droplets, compared to IC AC, and slightly more size variety of fat 
droplets within the MSCs, with an almost uniform differentiation pattern within the 
culture. Both IC LMP and VB LMP, presented smaller fat droplets (compared to IC 
AC and VB AC) with a more variable fat droplet size within the same cell and a less 
uniform differentiation pattern within the culture. VB LMP showed a smaller size of fat 
droplets within the cells, compared to VB AC. Generally, LMP-harvested MSCs 
presented a smaller size of fat droplets, which frequently gave a "gold dust" like 
appearance, especially under fluorescent microscopy (Figure 49). 
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Figure 48: Nile red staining of MSCs under florescence microscopy. Images of 
differentiated MSCs from all four donors following 21 days of adipogenic induction. 
Intracellular fat droplets are stained in yellow/gold, and the MSCs' nucleus appear as 
a dark brown spheroid structure. The bigger and more uniform size of fat droplets is 
evident in IC AC, followed by VB AC-harvested MSCs, which presented a more 
varied pattern, with prevalence of medium size fat droplets. Both IC LMP- and VB 
LMP-harvested MSCs presented prevalently smaller size fat droplets, appearing like 
"gold dust". Images were taken using an Olympus inverted microscope in x40 and 
x200 magnifications. 
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In terms of the staining procedures, all cultures stained positively with Oil red-O and 
Nile red/DAPI dyes. However, AF50 IC AC culture failed to bind the Oil red-O dye, 
despite the presence of big intracellular fat droplets visible under microscope even 
without staining (Figure 46). As it was expected, donor-to-donor variability was also 
observed. This is a constant characteristic among similar studies and it is widely 
reported in the literature51.  
 
  
 
 
 
 
 
 
 
Figure 49: Same type of fine cytoplasmic lipid droplets in MSCs stained with 
Nile red (A), and Oil red-O (B). A) Characteristic gold dust like appearance of small 
fat droplets observed mainly in cultures of LMP-harvested MSCs. The nucleus of 
MSCs appear as dark brown colour. B) LMP-harvested MSCs from the same donor, 
stained with Oil red-O. Images illustrated are from the same donor (AF 28 IC LMP) 
and taken using an Olympus inverted microscope at x200 magnification. 
 
 
Validation of adipogenic assay performance 
 
The variability within the adipogenic assays (Nile red/DAPI duplicates), was 
assessed to establish its accuracy. The CV within the duplicates was calculated 
separately for Nile red and DAPI based on the spectrophotometric analysis. The cut-
off point of optical density was established at ≤ 10%. Additionally, ratios between Nile 
red and DAPI were analyzed. The results were also compared to semi-quantitative 
scoring system of MSCs stained with Oil red-O dye (performed in single well).  
 
 
 
 
 
 A B 
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Semi-quantitative scoring system for adipogenic differentiated MSCs using Oil 
red-O staining  
 
For this grading system, 500 differentiated MSCs were measured in a dish following 
Oil red-O staining, as previously described227. The level of adipogenic progression 
was next ranked between grades 1-4, (Figures 46, 47, Table 39) based on the 
percentage of fat droplets occupying the cytoplasm of mature adipocytes (grades 2-
4) using the following formula: 
[# cells (grade 2) + # cells (grade 3) + # cells (grade 4)/500] x 100 = % of mature fat 
cells. 
 
Correlations between Nile red spectrophotometry and Oil red-O semi-quantitative 
scoring system were performed. However, given the similar percentages of 
adipogenesis from all donors (average 88%, range 80%-96%), it was not possible to 
show any correlation between semi-quantitative scoring system and Nile red 
absorbance, except for VB LMP (Table 39, Figure 52).  
 
Grading adipocytes it was complex and subjective, because equally graded MSCs 
can contain different sizes of fat droplets within the cells, which is not accounted by 
the semi-quantitative scoring system (Figure 50). Additionally the heterogeneous 
growth pattern within the same culture, increased the degree of complexity of this 
method (Figure 51).  
 
Both semi-quantitative scoring and Nile red absorbance methods could be 
complementary, to a certain extent, offering important morphologic information. 
However, Nile red in combination with DAPI staining (microscopic observation and 
spectrophotometric reading), is faster, consistent and not operator dependent 
method, hence can be easily reproduced and is comparable between different 
studies. 
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Table 39: Semi-quantitative scoring system. Percentages of MSCs' fat content, 
based on the fat accumulation within the cytoplasm. A) Individual analysis per 
donor showing the different percentages of fat content per grade. Grades 2-4, 
represents the mature population of fat-cells within the cultures. Their sum was 
calculated following 21 days of induction. MSCs from all donors presented an 
average of 88% (80%-96%) of fat content. B) Summary of overall grade distribution, 
from all four donors, is illustrated as a bar graphic. 
 
A 
AF 28 IC AC IC LMP VB AC VB LMP 
 
AF 29 IC AC IC LMP VB AC VB LMP 
Grade 1  10 10 20 10 Grade 1 5 10 10 7 
Grade 2 10 5 14 30 Grade 2 38 35 20 27 
Grade 3 30 30 46 45 Grade 3 43 45 30 47 
Grade 4 50 55 20 15 Grade 4 15 10 40 20 
Grades 
2+3+4 
90 90 80 90 
Grades 
2+3+4 
96 90 90 94 
 
AF 39 IC AC IC LMP VB AC VB LMP 
 
AF 50 IC AC IC LMP VB AC VB LMP 
Grade 1 4 11 4 5 Grade 1 10 5 14 6 
Grade 2 20 22 20 20 Grade 2 20 20 20 20 
Grade 3 30 44 26 33 Grade 3 24 25 40 34 
Grade 4 46 22 50 43 Grade 4 46 50 26 40 
Grades 
2+3+4 
96 88 96 96 
Grades 
2+3+4 
90 95 86 94 
 
 
 
B 
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Figure 50: Differences in equally scored adipogenically differentiated MSCs 
(Grade 4), over the same 21 days induction period. A, B) MSCs from donor (AF28 
IC LMP) containing small size fat droplets, mainly associated with LMP-harvested 
MSCs. C, D) MSCs from donor (AF39 VB AC) containing big size fat droplets, mainly 
associated with AC-harvested MSCs. The nucleus is visible in all cases as dark 
brown (A, C) and as spheroid area without fat droplets (B, D). Staining used: Nile red 
(A, C) and Oil red-O (B, D). Olympus inverted microscope was used at x200 
magnification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51: Heterogenic aspect of adipogenesis, using Nile red staining. A) 
MSCs containing different size of fat droplets within the same cell, were observed 
across all donors. B) In all four donors, some MSCs were progressing to Grades 3-4, 
whilst others were remaining at Grades 1-2 within the same culture. Images 
illustrated are from donors AF50 IC AC (A) and AF39 VB LMP (B). Olympus inverted 
microscope was used at x200 magnification. 
 
 
 
 
A B 
    
A B C D 
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Figure 52: Correlation graphics between the Nile red absorbance and the sum 
of grades 2-4 of the semi-quantitative scoring system. Values were analysed per 
group (IC AC, IC LMP, VB AC, VB LMP). A, B, C), showed no statistically significant 
correlation, with the only exception of D), which was statistically significant. 
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4.10.2 Individual analysis of each donor  
 
First donor, AF 28, (14.3y, M). 
 
The overall CVs of the duplicates, following spectrophotometry (OD) for Nile red and 
DAPI were 6.8% and 6.5% respectively, below the cut-off point of 10%, showing 
satisfactory intra-assay accuracy (Table 40). 
 
The first donor exhibited the highest Nile red OD (differentiation) from IC LMP, 
followed by IC AC, VB LMP and VB AC with 1.4-fold, 1.6-fold and 1.8-fold difference, 
respectively. Considering the 6.8% of the overall CV, the differences between the 
values of IC AC, and VB LMP were above the experimental variability (Table 40). 
 
Also DAPI showed a higher OD (proliferation) from IC LMP, followed by VB LMP, VB 
AC and IC AC, with 1.2-fold, 1.2-fold and 2-fold difference, respectively. Similarly to 
Nile red, considering the 6.5% of the overall CV, the differences of IC AC, VB AC, 
and VB LMP, with respect to IC LMP, were above the experimental variability (Table 
40). 
 
Comparing Nile red/DAPI ratios (IC AC 0.3, IC LMP 0.21, VB AC 0.14, VB LMP 
0.16), IC AC-harvested MSCs presented the highest adipogenic differentiation/cell, 
compared to IC LMP,  VB LPM and VB AC by 1.4-fold, 1.9-fold and 2.1-fold 
difference, respectively. Overall, this donor presented a higher adipogenesis/cell from 
ICBM (Figure 53). 
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Table 40: First donor, variability between duplicates of adipogenenic assay. 
ODs in duplicates, were calculated from a 9 spot reading (3x3), for Nile red and 
DAPI. Mean, SD and CV were calculated per single condition. 
 
AF 28 Nile red, Optical density in 48well-plate (x2) 
 1st well 2nd well MEAN SD CV (%) 
IC AC 168.44 174.11 171.28 4.01 2.34 
IC LMP 229.11 253.56 241.33 17.28 7.16 
VB AC 127.44 139.78 133.61 8.72 6.53 
VB LMP 136.00 159.56 147.78 16.66 11.27 
   Total CV Mean 6.82 
      
AF 28 DAPI, Optical density in 48well-plate (x2) 
 1st well 2nd well MEAN SD CV (%) 
IC AC 611.00 533.33 572.17 54.92 9.60 
IC LMP 1174.00 1150.11 1162.06 16.89 1.45 
VB AC 890.00 969.78 929.89 56.41 6.07 
VB LMP 883.11 1004.00 943.56 85.48 9.06 
   Total CV Mean 6.54 
 
 
 
 
 
 
 
 
Figure 53: First donor, optical absorbance of Nile red, DAPI and their ratio. 
Levels of fluorescence were determined, at 21 days of adipogenic induction, 
calculating the difference of spectrophotometric measurements between pre and post 
Nile red and DAPI staining. Nile red/DAPI ratios demonstrated a higher 
adipogenesis/cell for both IC AC and IC LMP by 2.1-fold and 1.9-fold, compared to 
VB AC and VB LMP, respectively. The text box indicates donor's details. Column-
bars graphic shows mean values with SD. 
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Second donor, AF 29, (15.6y, M). 
 
In this case also, the overall CVs of the duplicates for Nile red and DAPI, following 
spectrophotometry (OD) were 2.6% and 6.6%, respectively, below the cut-off point of 
10%, showing satisfactory intra-assay accuracy (Table 41). 
 
The second donor exhibited the highest Nile red OD (differentiation) from VB AC, 
compared to IC LMP, IC AC and VB LMP by 3.1-fold, 3.4-fold and 21.4-fold 
difference respectively. Considering the 2.6% of the overall CV, the differences of IC 
LMP, IC AC, and VB LMP, were all above the experimental variability (Table 41). 
 
Similarly, DAPI OD (proliferation) was higher from VB AC, compared to IC LMP, IC 
AC and VB LMP by 2.1-fold, 3-fold and 4.2-fold difference, respectively. Considering 
the 6.6% of the overall CV, also in this case, the differences of between the values of 
IC LMP, IC AC, and VB LMP were all above the experimental variability (Table 41). 
 
Comparing Nile red/DAPI ratios, (IC AC 0.22, IC LMP 0.17, VB AC 0.25, VB LMP 
0.05) VB AC-harvested MSCs presented the highest adipogenic differentiation/cell, 
compared to IC AC, IC LMP and VB LMP by 1.1-fold, 1.5-fold and 5-fold difference, 
respectively. Overall, this donor presented a consistent adipogenic outcome from 
ICBM with both harvesting methods, whereas VBBM exhibited a higher 
adipogenesis/cell, but only from AC-harvested MSCs (Figure 54). 
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Table 41: Second donor, variability between duplicates of adipogenic assay. 
ODs in duplicates, were calculated from a 9 spot reading (3x3), for Nile red and 
DAPI. Mean, SD and CV were calculated per single condition. 
 
AF 29 Nile red, Optical density in 48well-plate (x2) 
 1st well 2nd well MEAN SD CV (%) 
IC AC 106.78 104.67 105.72 1.49 1.41 
IC LMP 108.44 121.44 114.94 9.19 8.00 
VB AC 358.67 360.33 359.50 1.18 0.33 
VB LMP 16.89 16.78 16.83 0.08 0.47 
   Total CV Mean 2.55 
      
AF 29 DAPI, Optical density in 48well-plate (x2) 
 1st well 2nd well MEAN SD CV (%) 
IC AC 511.00 441.78 476.39 48.95 10.27 
IC LMP 634.67 723.00 678.83 62.46 9.20 
VB AC 1385.00 1486.22 1435.61 71.57 4.99 
VB LMP 334.33 343.67 339.00 6.60 1.95 
   Total CV Mean 6.60 
 
 
 
 
 
 
 
Figure 54: Second donor, optical absorbance of Nile red, DAPI and their ratio. 
Levels of fluorescence were determined, at 21 days of adipogenic induction, 
calculating the difference of spectrophotometric measurements between pre and post 
Nile red and DAPI staining. Nile red/DAPI ratios demonstrated a higher 
adipogenesis/cell for both IC AC and VB AC, compared to IC LMP and VB LMP, by 
1.3-fold and 5-fold deference, respectively. The text box indicates donor's details. 
Column-bars graphic shows mean values with SD. 
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Third donor, AF 39, (15.3y, F). 
 
Similarly to the other two donors, in this case the overall CVs of the duplicates for 
Nile red and DAPI, following spectrophotometry (OD) were 3.7% and 9.6%, 
respectively, below the cut-off point of 10%, showing satisfactory intra-assay 
accuracy (Table 42). 
 
The third donor exhibited the highest Nile red OD (differentiation) from VB AC 
followed by IC AC, VB LMP and IC LMP with 1.1-fold, 1.7-fold and 2.4-fold 
difference, respectively. Considering the 3.7% of the overall CV, the differences 
between the values of IC LMP, IC AC, and VB LMP were all above the experimental 
variability (Table 42). 
 
Similarly, DAPI OD (proliferation) was higher from VB AC followed by IC LMP, IC AC 
and VB LMP with 1.8-fold, 1.8-fold and 2.1-fold difference, respectively. Considering 
the 9.6% of the overall CV, the differences of IC LMP, IC AC, and VB LMP, with 
respect to VB AC, were all above the experimental variability. However, the 
difference between IC AC and VB LMP, were within the experimental variability 
(Table 42).  
 
Comparing Nile red/DAPI ratios (IC AC 0.25, IC LMP 0.11, VB AC 0.15 VB LMP 
0.11), IC AC-harvested MSCs presented the highest adipogenic differentiation/cell, 
compared to VB LMP,  VB AC and IC LMP by 1.4-fold, 1.7-fold and 2.3-fold 
difference, respectively. Overall, this donor exhibited the highest adipogenesis/cell 
from IC AC (Figure 55). 
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Table 42: Third donor, variability between duplicates of adipogenic assay. ODs 
in duplicates, were calculated from a 9 spot reading (3x3), for Nile red and DAPI. 
Mean, SD and CV were calculated per single condition. 
 
AF 39 Nile red, Optical density in 48well-plate (x2) 
 1st well 2nd well MEAN SD CV (%) 
IC AC 209.11 228.44 218.78 13.67 6.25 
IC LMP 92.78 103.89 98.33 7.86 7.99 
VB AC 232.11 232.22 232.17 0.08 0.03 
VB LMP 137.33 136.00 136.67 0.94 0.69 
   Total CV Mean 3.74 
      
AF 39 DAPI, Optical density in 48well-plate (x2) 
 1st well 2nd well MEAN SD CV (%) 
IC AC 919.78 806.11 862.94 80.37 9.31 
IC LMP 814.67 943.67 879.17 91.22 10.38 
VB AC 1461.78 1678.22 1570.00 153.05 9.75 
VB LMP 790.56 696.67 743.61 66.39 8.93 
   Total CV Mean 9.59 
 
 
 
 
 
 
 
 
Figure 55: Third donor, optical absorbance of Nile red, DAPI and their ratio. 
Levels of fluorescence were determined, at 21 days of adipogenic induction, 
calculating the difference of spectrophotometric measurements between pre and post 
Nile red and DAPI staining. Nile red/DAPI ratios demonstrated a higher adipogenic 
differentiation/cell from IC AC, compared to VB LMP,  VB AC and IC LMP by 1.4-fold, 
1.7-fold and 2.3-fold, respectively. The text box indicates donor's details. Column-
bars graphic shows mean values with SD. 
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Forth donor, AF 50, (17y, M). 
 
In the fourth donor, the overall CVs of the duplicates, following spectrophotometry 
(OD) for Nile red and DAPI were 5.8% and 5.4% respectively, below the cut-off point 
of 10%, showing satisfactory intra-assay accuracy (Table 43). 
 
The last donor exhibited similar Nile red OD (differentiation) from both anatomic 
regions, presenting a slightly higher outcome from ICBM-harvested MSCs. In 
particular IC LMP presented the highest outcome followed by IC AC, VB AC and VB 
LMP with 1.2-fold difference, in each case. Moreover, considering the 5.8% of the 
overall CV, the differences of IC AC, VB AC, and VB LMP, with respect to IC LMP, 
were above the experimental variability. However, the differences between IC AC, 
VB AC, and VB LMP, were within the experimental variability (Table 43). 
 
Likewise, DAPI OD (proliferation) presented similar outcomes from both anatomic 
sites, however, VB LMP showed slightly higher values, compared to VB AC, IC AC 
and IC LMP, by 1.2-fold, 1.3-fold and 1.3-fold difference, respectively. Considering 
the 5.4% of the overall CV, the differences of VB AC, IC AC and IC LMP, with 
respect to VB LMP, were above the experimental variability. However also in this 
case, the differences between VB AC, IC AC and IC LMP, were within the 
experimental variability (Table 43).  
 
Comparing Nile red/DAPI ratios, (IC AC 0.15, IC LMP 0.17, VB AC 0.13, VB LMP 
0.11) IC LMP-harvested MSCs presented the highest values of adipogenesis/cell 
compared to IC AC, VB AC and VB LMP, by 1.1-fold, 1.3-fold and 1.6-fold difference, 
respectively. Overall this donor exhibited the highest adipogenesis/cell from ICBM, 
for both harvesting methods used (Figure 56). 
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Table 43: Forth donor, variability between duplicates of adipogenic assay. ODs 
in duplicates, were calculated from a 9 spot reading (3x3), for Nile red and DAPI. 
Mean, SD and CV were calculated per single condition. 
 
AF 50 Nile red, Optical density in 48well-plate (x2) 
 1
st
 well 2
nd
 well MEAN SD CV (%) 
IC AC 198.11 209.22 203.67 7.86 3.86 
IC LMP 233.33 229.89 231.61 2.44 1.05 
VB AC 200.22 177.33 188.78 16.18 8.57 
VB LMP 174.78 200.33 187.56 18.07 9.63 
   Total CV Mean 5.78 
      
      
AF 50 DAPI, Optical density in 48well-plate (x2) 
 1
st
 well 2
nd
 well MEAN SD CV (%) 
IC AC 1278.89 1414.22 1346.56 95.70 7.11 
IC LMP 1284.89 1462.00 1373.44 125.24 9.12 
VB AC 1479.22 1485.67 1482.44 4.56 0.31 
VB LMP 1722.00 1848.67 1785.33 89.57 5.02 
   Total CV Mean 5.39 
 
 
 
 
 
 
 
 
Figure 56: Forth donor, optical absorbance of Nile red, DAPI and their ratio. 
Levels of fluorescence were determined, at 21 days of adipogenic induction, 
calculating the difference of spectrophotometric measurements between pre and post 
Nile red and DAPI staining. Nile red/DAPI ratios showed a higher adipogenic 
differentiation/cell for both IC LMP and IC AC by 1.6-fold and 1.2-fold, compared to 
VB LMP and VB AC, respectively. The text box indicates donor's details. Column-
bars graphic shows mean values with SD. 
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4.10.3 Adipogenesis, overall comparison  
 
Regarding Nile red OD, donors AF29 and AF39 presented the highest OD from 
VBBM, while donors AF28 and AF50 presented the highest OD from ICBM. In terms 
of DAPI OD three donors (AF29, AF39, AF50) presented the highest OD from VBBM 
and only donor AF28 showed high OD from ICBM. The overall performance of all 
four donors is illustrated in Figure 57. 
 
The main conclusions from the summary of Nile red and DAPI ODs, at 21 days post-
induction, were related mainly to DAPI OD showing a statistically significant higher 
outcome from VB AC compared to IC AC-harvested MSCs (p=0.0078). Moreover, IC 
LMP showed a statistically significant result, compared to IC AC (p=0.039). With 
regards to Nile red OD, no statistically significant results were observed, apart from 
the trend of IC LMP to show higher adipogenesis by 1.3-fold difference, compared to 
VB LMP (Figure 57). 
 
The overall Nile red/DAPI ratios, (IC AC 0.24, IC LMP 0.17, VB AC 0.15, VB LMP 
0.14), showed a superior adipogenic differentiation/cell from IC with both harvesting 
techniques. In particular adipogenesis/cell from IC AC presented the highest values 
compared to VB AC, IC AC and IC LMP, however was statistically significant only  
compared to VB LMP (p=0.039). Concluding, overall ICBM, exhibited a higher 
adipogenesis/cell, compared to VBBM (Figure 57).  
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Figure 57: Summarized data from all 4 donors. Nile red and DAPI ODs and their 
ratios. Average values of OD from Nile red and DAPI, showed a statistically 
significant difference, in predisposition to proliferation (DAPI), between VB AC- and 
IC AC-harvested MSCs (**, p=0.0078) and for IC LMP, compared to IC AC (*, 
p=0.039). Nile red/DAPI ratios demonstrated a higher adipogenesis/cell from IC AC, 
which was statistically significant, compared to VB LMP (*, p=0.039). Values were 
processed with Wilcoxon T test and represented as Box & Whiskers graphics. Mean 
and median are illustrated as "+" and "bar" symbols, respectively. 
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4.11 ELISA assays 
4.11.1 Introduction 
 
The purpose of this chapter was to quantify the serum concentrations and examine 
the differences in the pro-inflammatory cytokines (IL-6, IL-18, PCT), anti-
inflammatory cytokine (IL-10), and biochemical parameters (leucocytes, lymphocytes, 
neutrophils, platelets, prothrombin time, partial thromboplastin time, and 
haemoglobin) following AIS, over a week period from surgery and among three 
different approaches (antero-posterior, posterior with costoplasty and posterior). 
Furthermore, it was analysed the impact of the duration of surgery and gender on the 
4 cytokines over one week period in each different approach, as well as the 
differences on the biochemical parameters among the three different approaches 
during the same time period. 
 
Validation of the ELISA assay performance 
 
The ELISA assays were performed in duplicates throughout all the experiments, 
using 4 kits for every single cytokine tested, for a total of 16x96-well-plates (1.264 
readings). Given the high number of tests performed and the use of different ELISA 
kits per single molecule, intra-assay and inter-assay coefficient of variation (CV) were 
assessed to establish kits' accuracy. CV is defined as the ratio of the standard 
deviation (SD) to the mean, which is then multiplied by 100 to allow expression as a 
percentage. Intra- and inter-assay CVs were calculated at two different stages: 1) 
between the known values of the standard curves, to assess whether kits are 
performing similarly and 2) between the OD of the patients' samples examined, as 
showed in Tables 46,48,50,52. 
 
Cut-off points per assay were established by manufactures as follows: IL-6 high 
sensitivity (intra-assay CV 7%, inter-assay CV 10%), IL-6 (intra-assay CV 4.5%, 
inter-assay CV 6.5%), IL-10 (intra-assay CV 5%, inter-assay CV 7.5%), IL-18 (intra-
assay CV 11%, inter-assay CV 10%), PCT (intra-assay CV 10%, inter-assay CV 
12%) (Appendix 8.). 
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ELISA assay performance (spectrophotometry) 
 
Standard curves were generated as per manufacturer instructions (Appendix 8.2). 
Best fit curves were created for all ELISA kits, showing consistent results across the 
different kits testing for the same molecule. Data were processed with GraphPad 
Prism software and a four parameter logistic (4-PL) curve was generated for IL-6, IL-
10, IL-18. Due to limitations of GraphPad Prism functions, the 4-PL model was 
working better by plotting the OD on the x-axis against the concentration on the y-
axis. Contrarily for PCT, the best fit line was determined linearizing the data by 
plotting the log of the OD on the y-axis, against the log of the concentrations on the 
x-axis. Following 1.264 readings, the optical densities were analyzed and the overall 
and intra- and inter-experimental CVs were 5.4% for both, showing satisfactory 
performance (Figure 58). Furthermore, for the diluted samples the concentration, 
determined from the standard curve, was multiplied by the dilution factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: Examples of standard curve calibration for ELISA. Standard curves 
between OD and IL concentrations for molecules IL-6, IL-10, IL-18 were generated 
by a 4-PL model, while for PCT were linearized by logarithmic transformation. 
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4.11.2 Differences of IL-6, IL-10, IL-18, and PCT over one week period, in three 
different surgical approaches 
 
IL-6 analysis  
 
The overall intra- and inter-assay CVs of the duplicates, following spectrophotometry 
(OD) were 5.7% and 5.6%, close to the cut-off point of 4.5% and 6.5%, respectively 
showing satisfactory assay accuracy (Table 45a). Moreover, no statistically 
significant difference was observed in pre-operative IL-6 concentration, between pre- 
and post-anaesthetic induction (Table 45c). 
 
Friedman non-parametric tests were conducted to examine for differences in IL-6 
serum levels for each surgical approach. Over the period of study, IL-6 
concentrations showed statistically significant differences, among groups and time 
points compared, as showed in Figure 59, Tables 44, 45b (ANOVA: posterior; 
Friedman=44.76, p<0.0001, antero-posterior; Friedman=28.38, p<0.0001, posterior-
costoplasty; Friedman=21.34, p=0.0007).  
 
 
 
 
 
 
 
 
 
 
Figure 59: IL-6 concentration over time, comparison between different 
approaches. IL-6 concentration was significantly elevated mainly at the end of the 
surgery (T2) and the next 24 hours (T3), in the antero-post, compared to the other 
approaches. Graphic was presented as mean with SEM. 
 
In the posterior approach, multiple comparisons demonstrated significantly higher 
concentrations of IL-6 levels at the end of surgery (T2), 24 hours (T3), and 2 days 
(T4) post-operatively, compared to (T0) and 2 hours intra-operatively (T1), all 
p<0.001 (Table 44a). 
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Similarly, in the antero-posterior approach significant differences over time were also 
found at T2 and T3, where IL-6 concentrations were significantly elevated as 
compared to T0 and T1, all p<0.001 (Table 44a). Finally, in the posterior-costoplasty 
approach, IL-6 concentration was significantly higher at T2, T3, and T4 compared to 
T0, all p<0.05 (Table 44a).  
 
Table 44: A) Outcome of Friedman non-parametric tests between the time points of 
each approach and B) outcome of Kruskal-Wallis tests between all three approaches, 
for every time point. 
 
A T0 vs T1 T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. - 0.0002 0.0009 - - 0.0506 - - - - - - - - - 
Post.-Cost. - 0.0108 0.0352 0.0058 - - - - - - - - - - - 
Posterior - <0.0001 <0.0001 <0.0001 - 0.0108 0.0031 0.0108 - - - - - - - 
 
 
 
A series of Kruskal-Wallis tests were then used to identify possible differences 
among the three approaches at each time point, which were observed at T1, T2, and 
T3 (Table 44b). Specifically, IL-6 level in antero-posterior approach was significantly 
higher than in posterior-costoplasty approach, at T1. At T2, IL-6 level was 
significantly higher in antero-posterior, compared to the other approaches. Moreover, 
IL-6 level in the antero-posterior approach remained at higher levels, compared to 
the posterior approach at T3, all p<0.05 (Table 44b). 
 
Therefore, the results indicated that IL-6 concentration was significantly elevated at 
the end of the surgery (T2) and the level remained elevated at T3 and/or T4 in 
different approaches. In addition, participants who underwent the antero-posterior 
approach demonstrated higher levels of IL-6 at T1, T2, and T3.  
 
 
 
 
B T0 T1 T2 T3 T4 T5 
Posterior vs. Ant.-Post. - - 0.0042 0.048 - - 
Posterior vs. Post.-Cost. - - - - - - 
Ant.-Post. vs. Post.-Cost. - 0.0206 0.0437 - - - 
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Table 45: Overall outcome from IL-6 ELISA assay. A) OD with intra- and inter-
assay CV, B) final concentrations in pg/ml, C) comparison of pre- and post-
anaesthetic induction. 
 
A 
 
IL-6 Optical density in 96well-plate 
Antero-Post. Approach 
(n=6) 
Post.-Costoplasty Approach 
(n=5) 
Posterior approach    
(n=12) Intra-assay   
overall CV 
(%) Median SD 
Intra-assay 
CV (%) 
Median SD 
Intra-assay  
CV (%) 
Median SD 
Intra-assay 
CV (%) 
Time 0 0.088 0.006 5.448 0.105 0.011 8.650 0.110 0.003 3.952 6.017 
Time 1 0.170 0.004 3.590 0.043 0.001 1.746 0.062 0.002 5.051 3.462 
Time 
"Turn" 
0.589 0.026 6.372 - - - - - - 6.372 
Time 2 2.066 0.132 6.680 0.375 0.017 5.278 0.424 0.024 6.074 6.011 
Time 3 1.246 0.056 5.341 0.405 0.025 7.348 0.587 0.019 6.122 6.270 
Time 4 0.776 0.034 5.567 0.685 0.038 4.446 0.497 0.017 3.520 4.511 
Time 5 0.129 0.013 8.051 0.227 0.013 6.242 0.182 0.008 5.421 6.571 
Time 6 0.178 0.011 6.173 0.298 0.024 6.672 0.169 0.010 6.212 6.352 
Inter-assay overall CV 
(Mean) 
5.903   5.769   5.193  
Total Inter-assay CV 
(Mean) 
5.622    
Total Intra-assay CV 
(Mean) 
5.696 
 
 
B 
IL-6 Final concentration (pg/ml) 
Antero-Post. Approach  
(n=6) 
Post.-Costoplasty Approach 
(n=5) 
Posterior approach 
(n=12) 
Median SD Mean Median SD Mean Median SD Mean 
Time 0 0.042 0.035 0.044 0.114 0.217 0.215 0.124 1.424 0.575 
Time 1 10.834 5.140 10.811 2.798 1.139 3.130 3.952 4.347 4.893 
Time 
"Turn" 
41.367 87.318 76.162 - - - - - - 
Time 2 229.846 63.154 222.340 22.357 55.410 53.460 25.852 60.142 46.746 
Time 3 115.317 105.138 164.196 24.829 46.642 53.870 41.196 56.950 58.319 
Time 4 62.307 24.583 58.190 52.295 18.419 53.069 33.610 38.202 42.941 
Time 5 8.176 11.804 13.893 11.934 6.270 13.452 11.627 10.400 13.645 
Time 6 8.103 0.789 8.103 16.649 8.071 16.649 7.574 3.062 8.375 
 
 
C     Optical density in 96well-plate  Final concentration (pgr/ml) (n=4) 
IL-6 Median SD CV (%)  IL-6 Median SD Mean 
Time 0a* 0.106 0.004 3.971  Time 0a* 0.087 0.067 0.097 
Time 0* 0.130 0.010 7.776  Time 0* 0.234 0.364 0.382 
 
* IL-6 of Time 0a and Time 0, were measured with a high sensibility ELISA kit. The 
intra-assay CVs of the duplicates, following spectrophotometry (OD) were close the 
cut-off point of the intra-assay CV 7% of the kit, showing satisfactory assay accuracy. 
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IL-10 analysis  
 
The overall intra- and inter-assay CVs of the duplicates, following spectrophotometry 
(OD) were both 6.4%, close to the cut-off point of 5% and 7.5%, respectively showing 
satisfactory assay accuracy (Table 47a). Moreover, no statistically significant 
difference was observed in pre-operative IL-10 concentration, between pre- and post-
anaesthetic induction (Table 47c). 
 
Friedman non-parametric tests were conducted to examine for differences in IL-10 
serum levels for each surgical approach. Over the period of study, IL-10 
concentrations showed statistically significant differences, only in posterior and 
antero-posterior approaches, as showed in Figure 60, Tables 46, 47b, (ANOVA: 
posterior Friedman=29.38, p<0.0001, antero-posterior Friedman=13.56, p<0.019, 
posterior-costoplasty Friedman=9.2, p=0.1015).  
 
 
 
 
 
 
 
 
 
 
Figure 60: IL-10 concentration over time, comparison between different 
approaches. IL-10 concentration was significantly elevated mainly at the end of the 
surgery (T2) and the next 24 hours (T3), in the antero-post and posterior approaches. 
Graphic was presented as mean with SEM. 
 
In the posterior approach, multiple comparisons demonstrated significantly reduced 
concentration of IL-10 at T3 and T4, compared to T0 and T1. Furthermore, the IL-10 
level at T3 was also lower, compared to T2, all p<0.05 (Table 46a). Similarly, in the 
antero-posterior approach, IL-10 level at T4 was significantly lower, compared to T2, 
p=0.014 (Table 46a).  
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A series of Kruskal-Wallis tests were then conducted to identify possible differences 
among the three approaches at each time point. Specifically, IL-10 level in the 
posterior approach was significantly lower at T3, than in the antero-posterior 
approach, p=0.006 (Table 46b).  
Therefore, it was found that IL-10 concentration was reduced at the baseline at T3 
and T4 in the posterior approach, whereas the reduction of IL-10 concentration was 
only observed in the antero-posterior approach at T4, compared to T2. Furthermore, 
participants who underwent antero-posterior approach showed a higher level of IL-
10, than did those in the posterior approach.  
Table 46: A) Outcome of Friedman non-parametric tests between the time points of 
each approach and B) outcome of Kruskal-Wallis tests between all three approaches, 
for every time point. 
 
A T0 vs T1 T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. - - - - - - - - - - 0.0136 - - - - 
Post.-Cost. - - - - - - - - - - - - - - - 
Posterior - - 0.0008 0.0108 - - 0.002 0.0233 - 0.0072 - - - - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B T0 T1 T2 T3 T4 T5 
Posterior vs. Ant.-Post. - - - 0.0055 - - 
Posterior vs. Post.-Cost. - - - - - - 
Ant.-Post. vs. Post.-Cost. - - - - - - 
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Table 47: Overall outcome from IL-10 ELISA assay. A) OD with intra- and inter-
assay CV, B) final concentrations in pg/ml, C) comparison of pre- and post-
anaesthetic induction. 
 
 
B 
IL-10 Final concentration (pg/ml) 
Antero-Post. Approach  
(n=6) 
Post.-Costoplasty Approach 
(n=5) 
Posterior approach 
(n=12) 
Median SD Mean Median SD Mean Median SD Mean 
Time 0 0.766 0.166 0.828 0.766 0.646 1.046 0.713 0.766 1.042 
Time 1 1.806 3.657 2.992 0.757 1.516 1.407 0.958 2.124 1.526 
Time 
"Turn" 
2.616 7.269 5.271 - - - - - - 
Time 2 4.977 7.994 7.288 1.210 0.929 1.387 1.029 5.602 4.423 
Time 3 1.152 3.347 2.429 0.477 0.765 0.732 0.291 0.136 0.287 
Time 4 0.412 0.337 0.502 0.258 0.278 0.392 0.322 0.194 0.324 
Time 5 0.544 0.103 0.548 0.494 0.190 0.473 0.532 0.156 0.524 
Time 6 0.249 0.202 0.249 0.277 0.162 0.277 0.149 0.070 0.135 
 
 
C      Optical density in 96well-plate  Final concentration (pgr/ml) (n=4) 
IL-10 Median SD CV (%)  IL-10 Median SD Mean 
Time 0a 0.017 0.001 3.825  Time 0a 0.528 0.051 0.528 
Time 0 0.019 0.001 7.277  Time 0 0.633 0.031 0.633 
 
 
 
 
 
A 
IL-10 Optical density in 96well-plate 
Antero-Post. Approach 
(n=6) 
Post.-Costoplasty Approach 
(n=5) 
Posterior approach   
(n=12) Intra-assay   
overall CV 
(%) Median SD 
Intra-assay 
CV (%) 
Median SD 
Intra-assay 
CV (%) 
Median SD 
Intra-assay 
CV (%) 
Time 0 0.022 0.002 11.403 0.022 0.001 3.928 0.021 0.001 3.859 6.397 
Time 1 0.078 0.007 9.065 0.037 0.004 9.205 0.045 0.001 2.378 6.883 
Time 
"Turn" 
0.119 0.011 5.945 - - - - - - 5.945 
Time 2 0.208 0.005 3.826 0.068 0.005 7.770 0.061 0.002 5.005 5.534 
Time 3 0.068 0.003 5.115 0.045 0.002 5.398 0.038 0.002 4.549 5.021 
Time 4 0.037 0.001 2.615 0.031 0.001 3.565 0.033 0.002 5.569 3.917 
Time 5 0.028 0.005 15.396 0.030 0.001 4.044 0.029 0.002 8.703 9.381 
Time 6 0.037 0.004 8.979 0.038 0.004 9.315 0.032 0.002 6.695 8.330 
Inter-assay overall CV 
(Mean) 
7.793   6.175   5.251  
Total Inter-assay CV 
(Mean) 
6.406    
Total Intra-assay CV 
(Mean) 
6.426 
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IL-18 analysis  
 
The overall intra- and inter-assay CVs of the duplicates, following spectrophotometry 
(OD) were both 5.4%, below the cut-off point of 5% and 7.5%, respectively showing 
satisfactory assay accuracy (Table 49a). Moreover, no statistically significant 
difference was observed in pre-operative IL-18 concentration, between pre- and post-
anaesthetic induction (Table 49c). 
 
The results of the Friedman non-parametric tests for IL-18 indicated significant 
differences over time periods only in the posterior and antero-posterior approaches, 
as showed in Figure 61, Tables 48, 49b, (ANOVA: posterior Friedman=36.17, 
p<0.0001, antero-posterior Friedman=21.62, p<0.0006, posterior-costoplasty 
Friedman=9.9, p=0.078).  
 
 
 
 
 
 
 
 
 
 
Figure 61: IL-18 concentration over time, comparison between different 
approaches. IL-18 showed a similar trend between all the approached, with 
significant differences only within different time-points of the posterior and antero-
posterior approach. No significant difference were observed comparing all three 
approaches. Graphic was presented as mean with SEM. 
 
Multiple comparisons demonstrated significantly elevated concentration of IL-18 in 
the posterior approach, at T5 in relation to T0, T1, T2, and T3, all p<0.05 (Table 48). 
Furthermore, the IL-18 level at T4 was also significantly higher than that at T2, 
p=0.016 (Table 48). Similarly, in the antero-posterior approach, a significantly higher 
IL-18 level was observed only at T5, compared to T2, p=0.0001 (Table 48).  
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A series of Kruskal-Wallis tests were then conducted to test for differences among 
the three approaches at each time point. However, no significant differences were 
found at any time point. 
Therefore, in all the approaches IL-18 slightly dropped after the surgery (T2), for after 
reach the highest level at five days after surgery (T5). Moreover, only the posterior 
and the antero-posterior approaches showed statistically significant results at T5, 
compared to the end of surgery (T2). No significant differences were found among 
the three approaches at any time point.  
Table 48: Outcome of Friedman non-parametric tests between the time points of 
each approach. 
A T0 vs T1 T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. - - - - - - - - - - - 0.0001 - - - 
Post.-Cost. - - - - - - - - - - - - - - - 
Posterior - - - - 0 . 0 0 8 - - - 0.0048 - 0.0159 <0.0001 - 0.0233 - 
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Table 49: Overall outcome from IL-18 ELISA assay. A) OD with intra- and inter-
assay CV, B) final concentrations in pg/ml, C) comparison of pre- and post-
anaesthetic induction. 
 
 
B 
IL-18 Final concentration (pg/ml) 
Antero-Post. Approach 
(n=6) 
Post.-Approach/Costoplasty 
(n=5) 
Posterior approach    
(n=12) 
Median SD Mean Median SD Mean Median SD Mean 
Time 0 35.723 10.660 36.776 43.966 18.190 48.361 30.725 15.836 33.287 
Time 1 36.348 6.067 37.388 44.015 18.018 45.547 32.396 9.374 33.324 
Time 
"Turn" 
31.655 5.084 32.395 - - - - - - 
Time 2 20.706 6.731 23.043 33.941 11.248 36.945 22.717 9.624 24.667 
Time 3 33.721 3.542 33.690 41.847 13.005 44.672 36.685 9.230 36.448 
Time 4 35.728 21.550 44.162 46.495 18.298 51.079 39.730 10.464 39.295 
Time 5 55.262 12.263 57.153 52.981 18.894 55.869 48.600 18.848 52.597 
Time 6 46.224 8.729 46.224 36.246 0.372 36.246 40.524 10.758 43.369 
 
 
C     Optical density in 96well-plate  Final concentration (pgr/ml) (n=4) 
IL-18 Median SD CV (%)  IL-18 Median SD Mean 
Time 0a 0.094 0.001 2.008  Time 0a 25.182 12.497 25.419 
Time 0 0.093 0.001 4.442  Time 0 24.553 17.019 30.901 
 
 
 
 
A 
IL-18 Optical density in 96well-plate 
Antero-Post. Approach 
(n=6) 
Post.-Costoplasty Approach 
(n=5) 
Posterior approach   
(n=12) Intra-assay   
overall CV 
(%) Median SD 
Intra-assay 
CV (%) 
Median SD 
Intra-assay 
CV (%) 
Median SD 
Intra-assay 
CV (%) 
Time 0 0.134 0.009 8.879 0.164 0.007 4.400 0.093 0.001 4.442 5.907 
Time 1 0.112 0.005 4.865 0.137 0.006 4.497 0.099 0.003 3.487 4.283 
Time 
"Turn" 
0.089 0.004 5.143 - - - - - - 5.143 
Time 2 0.064 0.005 6.626 0.109 0.008 6.380 0.068 0.004 6.828 6.611 
Time 3 0.101 0.006 6.802 0.147 0.008 5.066 0.118 0.007 6.071 5.979 
Time 4 0.115 0.005 5.113 0.151 0.012 8.060 0.129 0.005 4.149 5.774 
Time 5 0.173 0.007 3.818 0.173 0.004 2.533 0.156 0.007 3.937 3.430 
Time 6 0.170 0.004 2.761 0.116 0.005 4.734 0.139 0.012 9.519 5.671 
Inter-assay overall CV 
(Mean) 
5.501   5.096   5.491  
Total Inter-assay CV 
(Mean) 
5.362    
Total Intra-assay CV 
(Mean) 
5.350 
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Procalcitonin (PCT) analysis  
 
The overall intra- and inter-assay CVs of the duplicates, following spectrophotometry 
(OD) were 4.2% and 4.4%, below the cut-off point of 10% and 12%, respectively, 
showing satisfactory assay accuracy (Table 51a). Moreover, no statistically 
significant difference was observed in pre-operative PCT concentration, between pre- 
and post-anaesthetic induction (Table 51c). 
The results of Friedman non-parametric tests for PCT revealed significant differences 
over time periods only in the posterior and antero-posterior approaches, as showed 
in Figure 62, Tables 50, 51b, (ANOVA: posterior Friedman=25.71, p=0.0001, antero-
posterior Friedman=17.81, p=0.003, posterior-costoplasty Friedman=5.9, p=0.315).  
 
 
 
 
 
 
 
 
 
 
Figure 62: PCT concentration over time, comparison between different 
approaches. PCT concentration was significantly elevated between the end of the 
surgery (T2) and the next 48 hours (T4), in the antero-post and posterior approaches. 
No significant differences were found among the three approaches. Graphic was 
presented as mean with SEM. 
 
Specifically, multiple comparisons showed significantly elevated PCT concentration 
in the posterior approach, at T2 and T4, compared to T0 and T1, all p<0.05 (Table 
50). In the antero-posterior approach, a significantly higher level in PCT was 
observed at T4, compared to T0, p=0.018 (Table 50). 
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A series of Kruskal-Wallis tests were then conducted to test for differences among 
the three approaches at each time point. However, no significant differences of PCT 
were found at any time point. 
Therefore, the results indicate that PCT concentration was significantly elevated 2 
days after surgery (T4) in both posterior and antero-posterior approaches.  
Moreover, a higher level was also observed at the end of surgery (T2) in the posterior 
approach. No significant differences were found among the three approaches at any 
time point. 
Table 50: Outcome of Friedman non-parametric tests between the time points of 
each approach. 
 
 T0 vs T1 T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. - - - 0.0179 - - - - - - - - - - - 
Post.-Cost. - - - - - - - - - - - - - - - 
Posterior - 0.0008 - 0.0031 - 0.0108 - 0.0338 - - - - - - - 
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Table 51: Overall outcome from PCT ELISA assay. A) OD with intra- and inter-
assay CV, B) final concentrations in pg/ml, C) comparison of pre- and post-
anaesthetic induction. 
 
 
 
B 
PCT Final concentration (pg/ml) 
Antero-Post. Approach   
(n=6) 
Post.-Costoplasty Approach 
(n=5) 
Posterior approach   
(n=12) 
Median SD Mean Median SD Mean Median SD Mean 
Time 0 9.339 3.542 10.920 11.433 1.725 11.366 10.208 2.867 10.340 
Time 1 12.158 5.314 12.686 19.717 23.160 23.206 11.550 5.118 13.505 
Time 
"Turn" 
5.747 5.539 9.249 - - - - - - 
Time 2 36.154 74.577 64.931 30.809 28.928 44.111 33.795 13.131 33.747 
Time 3 21.988 378.350 259.471 11.459 49.973 43.315 16.714 48.332 35.702 
Time 4 41.875 193.822 121.506 38.512 48.722 55.041 36.908 29.626 40.218 
Time 5 13.263 21.745 22.780 17.479 20.046 26.662 17.634 6.760 18.930 
Time 6 11.264 5.057 11.264 5.401 0.488 5.401 5.941 2.717 6.970 
 
 
C     Optical density in 96well-plate  Final concentration (pgr/ml) (n=4) 
PRC MEDIAN SD CV (%)  PRC MEDIAN SD MEAN 
Time 0a 0.037 0.003 5.800  Time 0a 10.893 8.181 13.882 
Time 0 0.037 0.003 7.558  Time 0 11.140 10.698 13.656 
 
 
 
 
A 
PCT Optical density in 96well-plate 
Antero-Post. Approach 
(n=6) 
Post.-Costoplasty Approach 
(n=5) 
Posterior approach           
(n=12) Intra-assay   
overall CV 
(%) Median SD 
Intra-assay 
CV (%) 
Median SD 
Intra-assay 
CV (%) 
Median SD 
Intra-assay 
CV (%) 
Time 0 0.035 0.002 4.922 0.038 0.003 8.319 0.036 0.002 5.575 6.272 
Time 1 0.045 0.004 7.699 0.057 0.002 5.995 0.044 0.003 6.899 6.864 
Time 
"Turn" 
0.036 0.001 1.964 - - - - - - 1.964 
Time 2 0.043 0.002 3.807 0.039 0.001 2.773 0.041 0.002 4.030 3.537 
Time 3 0.065 0.002 2.040 0.049 0.001 2.245 0.058 0.001 2.333 2.206 
Time 4 0.046 0.004 7.123 0.044 0.002 3.995 0.044 0.002 4.177 5.098 
Time 5 0.047 0.001 2.360 0.063 0.004 6.363 0.054 0.002 4.651 4.458 
Time 6 0.048 0.004 7.825 0.035 0.001 1.543 0.037 0.000 0.971 3.446 
Inter-assay overall CV 
(Mean) 
4.718   4.462   4.091  
Total Inter-assay CV 
(Mean) 
4.423    Total Intra-assay CV (Mean) 4.231 
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4.11.3 Relationship between duration of surgery and IL-6, IL-10, IL-18, 
PCT concentrations over one week period, in three different surgical 
approaches 
 
The posterior approach was the most suitable group to perform this analysis, 
showing a series of advantages over the other approaches. In a first place it was 
possible to distinguish a clear cut off between a "fast group " (median time 4h, range 
2-5h) and a "slow group " (median time 6h, range 5.1-11h), which was statistically 
significant, p=0.0006. Moreover, the two groups of 6 donors each, presented similar 
demographics (4/2 M/F, 16 years of age, 6 days LOS). In addition, the posterior 
approach is the most common in the spinal field and it was the most populated group 
in this study, allowing a consistent comparison between the different molecules, with 
only variable, the surgical duration. 
 
IL-6 analysis 
 
The results of Friedman non-parametric tests for IL-6, revealed significant differences 
over time periods in both fast and slow groups of surgery, as showed in Figure 63, 
Table 52 (ANOVA: fast group Friedman=21.24, p=0.0007, slow group 
Friedman=25.05, p=0.0001).  
 
 
 
 
 
 
Figure 63: IL-6 concentration over time, comparison between fast and slow 
duration of surgery in the posterior approach. PCT concentration was 
significantly elevated between the end of the surgery (T2) and the next 48 hours (T4), 
in both groups, however the slow group showed significantly higher values with 
highest 24 hours (T3) post-operatively. Graphic was presented as mean with SEM. 
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Multiple comparisons demonstrated that IL-6 concentration was significantly elevated 
in both groups at T2, T3, and T4, compared to T0, p<0.05. Moreover, in the slow 
group the IL-6 level was also significantly higher at T3, compared to T1, p=0.0103 
(Table 52). A series of Mann-Whitney non-parametric tests showed no significant 
difference between the two groups at any time point.  
In summary, IL-6 concentration was significantly increased at T2 and the level 
remained elevated throughout T4, in both fast and slow groups. Moreover, donors 
who had a longer duration of surgery demonstrated a higher level of IL-6 at T3, than 
did those who had a shorter duration of surgery.  
Table 52: Outcome of Friedman non-parametric tests of fast and slow posterior 
approach, between the different time points (IL-6). 
 
Posterior T0 vs T1 T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Fast - 0.0032 0.0179 0.0058 - - - - - - - - - - - 
Slow - 0.0304 0.0009 0.0179 - - 0.0103 - - - - - - - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 166  
IL-10 analysis 
 
The results of Friedman non-parametric tests for IL-10, revealed significant 
differences over time periods in both fast and slow groups of surgery, as showed in 
Figure 64, Table 53 (ANOVA: fast group Friedman=12.67, p=0.0267, slow group 
Friedman=19.62, p=0.0015).  
 
 
 
 
 
 
 
 
 
 
 
Figure 64: IL-10 concentration over time, comparison between fast and slow 
duration of surgery in the posterior approach. IL-10 concentration was 
significantly reduced in both groups 24 hours (T3) post-operatively, without statistical 
difference between them. The slow group presented a higher level of IL-10 at T1, 
compared to the fast. Graphic was presented as mean with SEM. 
 
Multiple comparisons demonstrated that IL-10 concentration was significantly 
reduced in the fast group at T3, compared to T0, p=0.049. In the slow group, IL-10 
concentration was significantly reduced at T3, compared to T1, p=0.0058 (Table 53). 
A series of Mann-Whitney non-parametric tests showed no significant difference 
between the two groups at any time point. Moreover, donors who had a longer 
duration of surgery demonstrated a higher level of IL-10 at T1 and T3, than did those 
who had a shorter duration of surgery.  
Table 53: Outcome of Friedman non-parametric tests of fast and slow posterior 
approach, between the different time points (IL-10). 
 
Posterior T0 vs T1 T 0  v s  T 2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Fast - - 0.049 - - - - - - - - - - - - 
Slow - - - - - - 0.0058 - - - - - - - - 
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IL-18 analysis 
 
The results of Friedman non-parametric tests for IL-18, revealed significant 
differences over time periods in both fast and slow groups of surgery, as showed in 
Figure 65, Table 54 (ANOVA: fast group Friedman=19.16, p=0.0018, slow group 
Friedman=17.81, p=0.0032).  
 
 
 
 
 
 
 
 
 
 
 
Figure 65: IL-18 concentration over time, comparison between fast and slow 
duration of surgery in the posterior approach. IL-18 showed a similar trend 
between both approached, with significant differences at 5 days post-operatively (T5) 
for both groups. Graphic was presented as mean with SEM. 
 
Multiple comparisons demonstrated that IL-18 concentration was significantly higher 
in the fast group at T5, compared to T0 and T2, p<0.05. In the slow group, IL-18 
concentration was significantly elevated at T5, compared to T2, p=0.0005 (Table 54). 
Therefore, IL-18 concentration was significantly raised above the baseline, 5 days 
after surgery (T5) in both groups. Despite, IL-18 presents the lowest level at T2 for 
both groups, it was not statistically significant. Also, no significant differences were 
found between the two groups at any time point using Mann-Whitney non-parametric 
tests. 
Table 54: Outcome of Friedman non-parametric tests of fast and slow posterior 
approach, between the different time points (IL-18). 
 
Posterior T0 vs T1 T 0  v s  T 2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Fast - - - - 0.0167 - - - - - - 0.0012 - - - 
Slow - - - - - - - - - - - 0.0005 - - - 
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PCT analysis 
 
The results of Friedman non-parametric tests for PCT, revealed significant 
differences over time periods only for the slow groups of surgery, as showed in 
Figure 66, Table 55 (ANOVA: fast group Friedman=9.71, p=0.084, slow group 
Friedman=16.95, p=0.0046).  
 
 
 
 
 
 
 
 
 
 
 
Figure 66: PCT concentration over time, comparison between fast and slow 
duration of surgery in the posterior approach. PCT concentration was  
significantly higher only in the slow group at T2. A significant difference among 
groups was found at T5 with slow group presenting a higher concentration. Graphic 
was presented as mean with SEM. 
 
 
Multiple comparisons demonstrated that PCT concentration was significantly higher 
only in the slow group at T2, compared to T0, p=0.0103 (Table 55). Moreover, a 
series of Mann-Whitney non-parametric tests were conducted and the results 
showed a significative difference only at T5, with the slow group presenting higher 
levels of PCT, than the fast group, p=0.039 (Figure 66). 
Table 55: Outcome of Friedman non-parametric tests of fast and slow posterior 
approach, between the different time points (PCT). 
 
Posterior T0 vs T1 T 0  v s  T 2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Fast - - - - - - - - - - - - - - - 
Slow - 0.0103 - - - - - - - - - - - - - 
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4.11.4 Relationship between gender and IL-6, IL-10, IL-18, PCT 
concentrations over one week period, in three different surgical approaches 
 
Given the gender distribution and the cohort demographics (Tables 1, 2, 9, 10), the 
posterior (8M/4F) and the antero-posterior (3M/3F) approaches were the most 
suitable groups to perform this comparison, considering also that the posterior-
costoplasty approach was composed only by females. Although the size of this 
cohort and the gender distribution represented the limiting factor for this comparison, 
it was important to identify possible gender differences at this stage.     
 
IL-6 analysis 
 
Friedman non-parametric tests were conducted in antero-posterior and posterior 
approach groups to examine for differences in IL-6 levels over one-week time period 
in each gender, as showed in Figure 67. 
 
 
 
 
 
Figure 67: IL-6 concentration over time, comparison between genders in the 
posterior and antero-posterior approach. Although both approaches presented 
significant differences between T2-T4, compared to the base line, no significant 
differences, were detected between genders. Graphic was presented as mean with 
SEM. 
 
Specifically, in the posterior approach, the overall time effect was significant in both 
genders (ANOVA: female Friedman=33.95, p<0.0001, male Friedman=14.24, 
p<0.0001). Moreover, in females IL-6 concentration was significantly increased at T2, 
T3, and T4, compared to T0, all p<0.005. IL-6 level at T2 was also significantly 
higher, compared to T1, p=0.0100. Within the males, the only significantly higher 
level of IL-6 was at T3, compared to T0, p=0.0338 (Table 56).  
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Similarly in the antero-posterior approach, an overall significant time effect was found 
in both genders (ANOVA: female Friedman=14.24, p=0.0001, male Friedman=14.24, 
p<0.0001), with IL-6 concentration presenting a significant increment at T2, 
compared to T0, p=0.0338 (Table 56).  
A series of Mann-Whitney non-parametric tests were conducted to measure the 
differences between genders at each time point. However, no significant differences, 
were detected on either approaches, all p>0.05. 
Therefore, in the posterior approach, IL-6 increased significantly at T2, T3, and T4 in 
females, but within the males an increment was found only at T3. In the antero-
posterior approach, IL-6 presented higher concentrations, compared to posterior 
approach, however both genders showed an elevated level of IL-6 only at T2.  
Table 56: Outcome of Friedman non-parametric tests for both genders in posterior 
and antero-posterior approach, between the different time points (IL-6). 
Posterior T0 vs T1 T 0  v s  T 2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Male - - 0.0338 - - - - - - - - - - - - 
Female - <0.0001 0.0005 0.0014 - 0.0100 - - - - - - - - - 
 
Antero-
Posterior 
T0 vs T1 T 0  v s  T 2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Male - 0.0338 - - - - - - - - - - - - - 
Female - 0.0338 - - - - - - - - - - - - - 
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IL-10 analysis 
 
Friedman non-parametric tests were conducted in antero-posterior and posterior 
approach groups to examine for differences in IL-10 levels over one-week time 
period in each gender, as showed in Figure 68. 
 
 
 
 
 
 
 
Figure 68: IL-10 concentration over time, comparison between genders in the 
posterior and antero-posterior approach. Posterior approach presented an overall 
significant difference only in females, and the antero-posterior approach presented 
significant differences only in males, compared to base line. Were no detected 
significant differences between genders. Graphic was presented as mean with SEM. 
 
Specifically, in the posterior approach, the overall time effect was significant only in 
females (ANOVA: female Friedman=26.52, p<0.0001, male Friedman=6.24, p=0.32). 
Moreover, for females IL-10 concentration was significantly reduced at T3, compared 
to T0, T1 and T2, all p<0.01 (Table 57).  
Contrarily, in the antero-posterior approach, an overall significant time effect was 
found only in males (ANOVA: female Friedman=5, p=0.47, male Friedman=11.95, 
p=0.0084) (Table 57). However, multiple comparisons failed to yield significance 
between any time points, hence it could not be determined the exact time-points.  
A series of Mann-Whitney non-parametric tests were also used to measure gender 
differences at each time point, but no significant differences were found, all p>0.05. 
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Table 57: Outcome of Friedman non-parametric tests for both genders in posterior 
approach, between the different time points (IL-10). 
Posterior T0 vs T1 T 0  v s  T 2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Male - - - - - - - - - - - - - - - 
Female - - 0.0024 - - - 0.0063 - - 0.0024 - - - - - 
 
 
IL-18 analysis 
 
Friedman non-parametric tests were conducted in antero-posterior and posterior 
approach groups to examine for differences in IL-18 levels over one-week time 
period in each gender, as showed in Figure 69. 
 
 
 
Figure 69: IL-18 concentration over time, comparison between genders in the 
posterior and antero-posterior approach. In both approaches and genders IL-18 
dropped at the end of the surgery (T2), however it was not statistically significant. IL-
18 was significantly elevated 5 days after surgery (T5) in both approaches and 
genders. Graphic was presented as mean with SEM. 
 
Specifically, in the posterior approach, the overall time effect was significant in both 
genders (ANOVA: female Friedman=27.8, p<0.0001, male Friedman=14.24, 
p=0.0001). Furthermore, in females, IL-18 concentration was significantly higher at 
T5, compared to T0 and T2, all p<0.001, whereas in males, IL-18 concentration was 
significantly higher at T5, but only compared to T2, p=0.159 (Figure 69, Table 58) 
 
Similarly, in the antero-posterior approach, an overall significant time effect was 
found in both genders (ANOVA: female Friedman=11.76, p=0.0095, male 
Friedman=11.57, p=0.0117). In both groups, the only significantly higher level of IL-
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18 was observed at T5, compared with T2, p<0.05. A series of Mann-Whitney non-
parametric tests were also used to measure gender differences at each time point, 
but no significant differences were found, all p>0.05. 
Therefore, in both approaches IL-18 concentrations dropped at the end of the 
surgery (T2), for both genders, however, it was not statistically significant. Moreover, 
IL-18 was significantly elevated 5 days after surgery (T5) for both approaches and 
genders, mainly compared to T2.  
Table 58: Outcome of Friedman non-parametric tests for both genders in posterior 
and antero-posterior approaches, between the different time points (IL-18). 
Posterior T0 vs T1 T 0  v s  T 2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Male - - - - - - - - - - - 0.0159 - - - 
Female - - - - 0.0005 - - - - - - < 0.0001 - - - 
 
Antero-
Posterior 
T0 vs T1 T 0  v s  T 2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Male - - - - - - - - - - - 0.0338 - - - 
Female - - - - - - - - - - - 0.0159 - - - 
 
 
PCT analysis 
 
Friedman non-parametric tests were conducted in antero-posterior and posterior 
approach groups to examine for differences in PCT levels over one-week time period 
in each gender, as showed in Figure 70. 
Specifically, in the posterior approach, the overall time effect was significant in both 
genders (ANOVA: female Friedman=15.22, p=0.0095, male Friedman=12.33, 
p=0.0052). Furthermore in females, PCT was significantly increased at T2 and T4, 
compared to T0, all p<0.05. In males, however, multiple comparison was not able to 
determine where the differences were (Figure 75, Table 59).  
 
In the antero-posterior approach, an overall significant time effect was found only in 
males (ANOVA: female Friedman=7.76, p=0.168, male Friedman=11.38, p=0.0136), 
however, multiple comparisons were not able to determine where the differences 
were.  
 
Additionally, there were no significant differences between genders at any time points 
using Mann-Whitney non-parametric tests.  
 174  
 
 
 
 
Figure 70: PCT concentration over time, comparison between genders in the 
posterior and antero-posterior approach. PCT levels presented a statistically 
significant increment at the end of surgery (T2) and 2 days post-operatively (T4), only 
in the posterior approach in females. Were no detected significant differences 
between genders. Graphic was presented as mean with SEM. 
  
 
Table 59: Outcome of Friedman non-parametric tests for both genders in posterior 
approach, between the different time points (PCT). 
Posterior T0 vs T1 T 0  v s  T 2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Male - - - - - - - - - - - - - - - 
Female - 0.0147 - 0.0338 - - - - - - - - - - - 
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4.11.5 Differences between biochemical parameters over one week 
period, following three different surgical approaches 
 
Biochemical parameters (leucocytes, lymphocytes, neutrophils, platelets, PT, PTT 
and Hb) were obtained from the Leeds Teaching Hospitals Haematology laboratory, 
to match with the blood samples' (ELISA) time points (Table 60). A comparison 
between the three approaches has not been identified in the current literature. 
Therefore the purpose of this section was to quantify the variation of biochemical 
parameters following AIS, over a week period, among three different approaches 
(antero-posterior, posterior- costoplasty, posterior).  
 
Table 60: Overall biochemical parameters collected over a week period  
 
Blood analysis Approach Time 0 Time 2 Time 3 Time 4 Time 5 
Leucocytes  
Antero-posterior 5.84 9.93 10.86 8.14 6.63 
Post.+Costoplasty 6.01 12.25 11.36 7.51 6.52 
Posterior 5.79 15.43 11.69 12.11 6.67 
       
Lymphocytes 
Antero-posterior 2.21 0.56 0.61 1.17 1.10 
Post.+Costoplasty 2.41 0.82 0.98 1.02 1.23 
Posterior 1.94 1.14 1.24 0.97 1.30 
       
Neutrophils 
Antero-posterior 3.26 8.93 8.17 6.18 4.74 
Post.+Costoplasty 3.29 10.67 8.97 5.45 4.60 
Posterior 3.12 13.65 8.97 6.16 4.67 
       
Platelets 
Antero-posterior 248.33 111.00 104.83 122.33 225.33 
Post.+Costoplasty 266.20 195.60 168.40 191.25 215.50 
Posterior 268.67 195.83 167.00 166.55 293.63 
       
Prothrombin Time 
Antero-posterior 11.67 15.00 17.33 12.80 12.20 
Post.+Costoplasty 12.60 14.00 14.40 13.50 12.00 
Posterior 12.17 14.50 14.08 13.50 13.20 
       
Partial 
Thromboplastin 
Time 
Antero-posterior 33.85 24.52 25.82 29.54 30.34 
Post.+Costoplasty 33.78 28.58 28.00 31.00 33.40 
Posterior 33.02 30.66 27.44 30.89 32.00 
       
Haemoglobin  
Antero-posterior 14.90 8.72 8.63 9.18 10.10 
Post.+Costoplasty 13.80 11.28 10.44 9.30 10.85 
Posterior 14.15 11.14 9.48 9.45 9.71 
 
 
 
 
 
 176  
Leukocytes analysis 
 
Friedman non-parametric tests were conducted to test for leukocyte concentration 
differences over one-week time period. As showed in Figure 71, the results indicated 
significant differences over time in all three approaches (ANOVA: posterior 
Friedman=35.20, p<0.0001, posterior-costoplasty Friedman=14.56, p=0.0057, 
antero-posterior approach Friedman=13.73, p<0. 0082). 
 
 
 
 
 
 
Figure 71: Leukocytes concentration over time, comparison between different 
approaches. Leukocytes concentrations were significantly increased at T2 and T3 
and then dropped to basal level at T5 in all the approaches. No statistical differences 
at any time point were observed among al the approaches. Graphic was presented 
as mean with SEM. 
 
In the posterior approach, multiple comparisons showed higher leukocytes 
concentration at T2 and T3, compared to T0, followed by a drop to a lower level at 
T5, compared to T2 and T3, all p<0.05. In the antero-posterior approach, leukocytes 
only showed a higher level at T3, compared to T0, p =0.0102. Also, in the posterior-
costoplasty approach, leukocytes concentrations were significantly elevated 
compared to baseline (T0), only at T2, p=0.0137 (Table 61).  
 
A series of Kruskal-Wallis tests were then conducted to test for differences among 
the three approaches at each time point, but no significant differences were 
observed, all p>0.05  
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Therefore, it appears that leukocytes concentrations were increased at T2 and T3 
and then dropped to basal level at T5 in the posterior approach. Leukocytes were 
also elevated at T2 and T3 above the baseline in the posterior-costoplasty and the 
antero-posterior approaches, respectively. No differences between approaches were 
found at any time point. 
 
Table 61: Outcome of Friedman non-parametric tests between the time points of 
each approach (Leucocytes). 
 
 T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. - 0.0102 - - - - - - - - - - - - 
Post.-Cost. 0.0137 - - - - - - - - - - - - - 
Posterior < 0.0001 0.0001 - - - - - - - - 0.0030 - 0.0451 - 
 
 
Lymphocytes analysis 
 
A series of Friedman non-parametric tests were conducted to examine whether 
lymphocytes level changed over time in each approach. In the Figure 72, the results 
revealed significant differences of lymphocyte concentrations over time in all three 
approaches (ANOVA: posterior Friedman=25.07, p<0.0001, posterior-costoplasty 
Friedman=12.97, p=0.0114, antero-posterior approach Friedman=19.06, p=0.0008). 
 
 
 
 
 
 
Figure 72: Lymphocytes concentration over time, comparison between 
different approaches. Lymphocytes were significantly decreased between T2-T4 in 
all the  approaches, however the antero-posterior approach presented significantly 
lower levels at T2 and T3, compared to the posterior approach. Graphic was 
presented as mean with SEM. 
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In the posterior approach, lymphocytes were significantly decreased below T0 at T2, 
T3, and T4, all p<0.05. Similarly, in the antero-posterior approach, lymphocytes were 
significantly decreased at T2 and T3, compared to T0, all p<0.05. Lastly, in the 
posterior-costoplasty approach, lymphocytes were lower at T2 and T4, compared to 
T0, all p<0.05 (Table 62a).  
 
A series of Kruskal-Wallis tests were conducted, showing significant differences 
among the posterior and antero-posterior approaches at T2 and T3, with 
lymphocytes being significantly higher in the posterior approach, at both time points, 
all p<0.05 (Table 62b).  
 
Therefore, lymphocytes were decreased at T2, T3, T4 in the posterior approach, at 
T2, T3 in the antero-posterior approach, and at T2, T4 in the posterior-costoplasty 
approach. Moreover, lymphocytes showed significantly lower levels in antero-
posterior approach at T2 and T3, compared to posterior approach. 
Table 62: A) Outcome of Friedman non-parametric tests between the time points of 
each approach and B) outcome of Kruskal-Wallis tests between all three approaches, 
for every time point (Lymphocytes). 
A T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. 0.0006 0.0140 - - - - - - - - - - - - 
Post.-Cost. 0.0270 - 0.0373 - - - - - - - - - - - 
Posterior 0.0011 0.0195 < 0.0001 - - - - - - - - - - - 
 
 
 
Neutrophils analysis 
 
The results from a series of Friedman non-parametric tests, revealed significant 
neutrophils concentrations differences over time in all three approaches (Figure 73). 
(ANOVA: posterior Friedman=42.40, p<0.0001, posterior-costoplasty 
Friedman=16.85, p=0.0021, antero-posterior approach Friedman=12.93, p=0.0116). 
More specifically, as illustrated in Figure 73, Table 63, in the posterior approach, 
neutrophil concentration reached a significantly higher level at T2 and T3 compared 
B T0 T1 T2 T3 T4 T5 
Posterior vs. Ant.-Post. - - 0.0141 0.0296 - - 
Posterior vs. Post.-Cost. - - - - - - 
Ant.-Post. vs. Post.-Cost. - - - - - - 
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to T0, T4, T5 and T0, T5, respectively, all p<0.05. In the antero-posterior approach, 
neutrophil concentration was only significantly increased at T2, compared to T0, 
p=0.0102. In the posterior-costoplasty approach, significantly higher levels were 
found at T2 and T3, compared to T0, all p<0.05 (Table 63).  
The results from a series of Kruskal-Wallis tests suggested no significant differences 
among the three approaches at any time point, all p>0.05. 
 
 
 
 
 
 
 
 
 
 
 
Figure 73: Neutrophils concentration over time, comparison between different 
approaches. Neutrophils were significantly elevated at the end of the surgery (T2) in 
all the approaches, however without significant differences between them. Graphic 
was presented as mean with SEM. 
 
Therefore, neutrophils were significantly elevated at the end of the surgery (T2) in all 
the approaches. In the posterior and posterior-costoplasty approaches, 
concentrations remained elevated at T3. Moreover, no significant differences were 
observed among the three approaches at any time point. 
Table 63: Outcome of Friedman non-parametric tests between the time points of 
each approach (Neutrophils). 
 T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. 0.0102 - - - - - - - - - - - - - 
Post.-Cost. 0.0032 0.0137 - - - - - - - - - - - - 
Posterior < 0.0001 < 0.0001 - - - - - - - 0.0125 0.0006 - 0.0451 - 
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Platelets analysis 
 
A series of Friedman non-parametric tests, revealed significant platelet 
concentrations differences over time in all three approaches (ANOVA: posterior 
Friedman=33.13, p<0.0001, posterior-costoplasty Friedman=16.12, p=0.0029, 
antero-posterior approach Friedman=16.67, p=0.0022) (Figure 74). 
 
 
 
 
 
 
 
 
 
Figure 74: Platelets concentration over time, comparison between different 
approaches. Platelets presented the lowest concentration at T3 in all the 
approaches. The antero-posterior approach presented significantly lower levels of 
platelets, compared to the other approaches. Graphic was presented as mean with 
SEM. 
 
More specifically, in the posterior approach, platelets concentration presented 
significantly lower levels at T3 and T4, compared to T0 and T5, all p<0.005. Similarly, 
in the antero-posterior approach significantly lower levels of platelets were found at 
T2 and T3, compared to T0, all p<0.05. In the posterior-costoplasty approach, 
platelet only showed a lower level at T3, compared to T0, p=0.0014 (Table 64a).  
 
A series of Kruskal-Wallis tests were conducted between the three approaches at 
each time point, showing significant differences of platelets concentration among the 
approaches at T2 (p=0.0415), T3 (0.0414), and T4 (p=0.0161). However, multiple 
comparisons demonstrated a relation only between antero-posterior and posterior-
costoplasty approaches at T4, where platelets concentration was significantly lower 
in the antero-posterior approach, p=0.0189 (Table 64b).  
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In summary, platelets levels were significantly decreased at T3 in all the approaches 
and additionally at T2 and T4, T5 in the antero-posterior approach and posterior 
approach, respectively. Furthermore, antero-posterior approach presented 
significantly lower levels of platelets, compared to the other groups. 
 
Table 64: A) Outcome of Friedman non-parametric tests between the time points of 
each approach and B) outcome of Kruskal-Wallis tests between all three approaches, 
for every time point (Platelets). 
 
A T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. 0.0349 0.0191 - - - - - - - - - - - - 
Post.-Cost. - 0.0014 - - - - - - - - - - - - 
Posterior - 0.0030 0.0002 - - - - - - - - - 0.0018 0.0001 
 
 
 
Prothrombin (PT) analysis 
 
There were significant changes of PT over time in all three approaches using a series 
of Friedman non-parametric tests (ANOVA: posterior Friedman=21.50, p=0.0003, 
posterior-costoplasty Friedman=16.73, p=0.0022, antero-posterior approach 
Friedman=19.52, p=0.0006) (Figure 75). 
In both posterior and antero-posterior approaches, PT was significatively elevated at 
T2 and T3, compared to T0, all p<0.05. Also, in posterior and posterior-costoplasty 
approaches, PT dropped significantly at T5, compared to T3, all p<0.05 (Figure 80, 
Table 65a).  
A series of Kruskal-Wallis tests were then conducted to test for differences among 
the three approaches, detecting a statistically significant higher PT, for the posterior 
approach only at T5, compared to the other two approaches, all p<0.05 (Table 65b). 
Therefore, the results suggested that PT significantly increased to a higher level at 
T2 and T3, compared to T0, in both posterior and antero-posterior approaches, for 
after return to base line quite simultaneously. Moreover, antero-posterior and 
B T0 T1 T2 T3 T4 T5 
Posterior vs. Ant.-Post. - - - - - - 
Posterior vs. Post.-Cost. - - - - - - 
Ant.-Post. vs. Post.-Cost. - - - - 0.0189 - 
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posterior-costoplasty approaches presented a significantly lower PT, compared to 
posterior approach at T5. 
 
 
 
 
 
 
 
Figure 75: PT concentration over time, comparison between different 
approaches. PT was significantly increased at T2 and T3, in all approaches, 
compared to T0. The antero-posterior and posterior-costoplasty approaches 
presented a significantly lower PT, compared to posterior approach at T5. Graphic 
was presented as mean with SEM. 
 
Table 65: A) Outcome of Friedman non-parametric tests between the time points of 
each approach and B) outcome of Kruskal-Wallis tests between all three approaches, 
for every time point (PT). 
A T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. 0.0191 0.0037 - - - - - - - - - - 0.0466 - 
Post.-Cost. - - - - - - - - - - - - 0.0137 - 
Posterior 0.0005 0.0023 - - - - - - - - - - - - 
 
 
 
 
 
 
B T0 T1 T2 T3 T4 T5 
Posterior vs. Ant.-Post. - - - - - 0.0421 
Posterior vs. Post.-Cost. - - - - - 0.0361 
Ant.-Post. vs. Post.-Cost. - - - - - - 
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Partial thromboplastin (PTT) analysis 
 
A series of Friedman non-parametric tests were conducted to examine time effect in 
each approach, showing significant changes of PTT over the time in all three 
approaches (ANOVA: posterior Friedman=24.02, p=0.0001, posterior-costoplasty 
Friedman=14.67, p=0.0054, antero-posterior Friedman=13.33, p=0.0098) (Figure 
76). 
 
 
 
 
 
 
 
 
 
 
Figure 76: PTT concentration over time, comparison between different 
approaches. PTT was lower at T2 and T3 in all the approaches, compared to T0. No 
significant differences were found among the three approaches at any time point. 
Graphic was presented as mean with SEM. 
 
In the posterior approach, PTT was significantly lower at T3, compared to T0 and T5, 
all p<0.005. In both antero-posterior and posterior-costoplasty approaches, PTT was 
significantly reduced at T2 and T3, compared to T0, all p<0.05 (Table 66). Moreover, 
no significant differences among the three approaches at any time point were 
observed using Kruskal-Wallis tests, all p>0.05.  
 
Table 66: Outcome of Friedman non-parametric tests between the time points of 
each approach (PTT). 
 
 T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. 0.0102 0.0349 - - - - - - - - - - - - 
Post.-Cost. 0.0373 0.0373 - - - - - - - - - - - - 
Posterior - 0.0002 - - - - - - - - - - 0.0018 - 
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Haemoglobin (Hb) analysis 
 
Intraoperative blood-loss and Hb concentration are important elements able to 
influence the post-operative outcome, requiring constant peri-operative monitoring. 
Typical blood loss for AIS correction procedures may exceed the 50% of patient's 
total blood volume and is directly related to the number of vertebrae involved, 
surgical techniques utilised, duration of surgery and anaesthetic factors (blood 
pressure, assisted ventilation)232. The intent of this section was to study the variation 
of intra- and post-operative Hb concentrations, in three different approaches. 
However, due to the characteristics of this cohort and the clinical priorities, the Hb 
concentration analysed is the final result following intra-operative and post-operative 
red cells transfusion (intra-operative: from blood bank and/or auto-transfusion from 
cell saver device, post-operative from blood bank only) (Table 67). 
 
Table 67: Blood loss and blood transfusion over time, for all the approaches.  
Posterior approach (Total) T0 (ml) T1 (ml) T2 (ml) T3 (ml) T4 (ml) 
Blood transfusion - 55 75 50 75 
Auto-transfusion (cell saver) - 136 576 - - 
Blood loss - Not recorded 
1.998 
Total 
- - 
      
Posterior approach (Fast) T0 (ml) T1 (ml) T2 (ml) T3 (ml) T4 (ml) 
Blood transfusion - 0 0 86 - 
Auto-transfusion (cell saver) - 221 570 - - 
Blood loss - Not recorded 
1.964 
Total 
- - 
      
Posterior approach (Slow) T0 (ml) T1 (ml) T2 (ml) T3 (ml) T4 (ml) 
Blood transfusion - 100 129 0 129 
Auto-transfusion (cell saver) - 52 689 - - 
Blood loss - Not recorded 
1.752 
Total 
- - 
      
Post.-costoplasty approach T0 (ml) T1 (ml) T2 (ml) T3 (ml) T4 (ml) 
Blood transfusion - 0 240 - 120 
Auto-transfusion (cell saver) - 0 318 - - 
Blood loss - Not recorded 
1.239 
Total 
- - 
      
Antero-posterior approach T0 (ml) T1 (ml) T2 (ml) T3 (ml) T4 (ml) 
Blood transfusion - 0 200 50 50 
Auto-transfusion (cell saver) - 0 653 - - 
Blood loss - Not recorded 
2.478 
Total 
- - 
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The results from a series of Friedman non-parametric tests revealed significative 
changes of haemoglobin concentrations over time in all three approaches (ANOVA: 
posterior Friedman=26.83, p<0.0001, posterior-costoplasty Friedman=17.58, 
p=0.0015, antero-posterior Friedman=14.27, p=0.007) (Figure 77). 
 
 
 
 
 
 
 
 
 
 
Figure 77: Hb concentration over time, comparison between different 
approaches. In all approaches Hb level was significantly reduced between T3 and 
T5. The antero-posterior approach presented the lowest Hb level, at the end of 
surgery (T2) and for the next 24 hours (T3). Graphic was presented as mean with 
SEM. 
 
In particular, the posterior approach, showed significantly lower Hb levels at T3, T4, 
and T5, compared to T0, all p<0.005. Similarly, in the antero-posterior approach, 
significantly lower Hb levels were presented at T3 and T4, compared to T0, all 
p<0.04. Contrarily, the posterior-costoplasty approach presented significantly 
reduced Hb levels only at T4, compared to T0, p=0.001 (Table 68a).  
 
A series of Kruskal-Wallis tests were performed to test for differences of Hb levels 
among the approaches in each time point, presenting statistically significant 
differences only at T2 (Table 68b). At the end of the surgery, the antero-posterior 
approach showed the lowest Hb level, compared to the other two approaches, 
despite the red cells transfusion received, all p<0.05 (Tables 67, 68b). 
 
Therefore in both antero-posterior and posterior approaches, Hb level was 
significantly reduced at T3, T4 and T5, respectively. In the posterior-costoplasty 
approach, Hb level was significantly decreased only at T4. In addition, at the end of 
surgery (T2) and for the next 24 hours (T3), participants who underwent the antero-
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posterior approach demonstrated a significantly lower level of haemoglobin, 
compared to the other two approaches.  
 
Table 68: A) Outcome of Friedman non-parametric tests between the time points of 
each approach and B) outcome of Kruskal-Wallis tests between all three approaches, 
for every time point (Hb). 
A T0 vs T2 T0 vs T3 T0 vs T4 T0 vs T5 T1 vs T2 T1 vs T3 T1 vs T4 T1 vs T5 T2 vs T3 T2 vs T4 T2 vs T5 T3 vs T4 T3 vs T5 T4 vs T5 
Ant.-Post. - 0.0349 0.0052 - - - - - - - - - - - 
Post.-Cost. - - 0.0010 - - - - - - - - - - - 
Posterior - 0.0002 0.0002 0.0018 - - - - - - - - - - 
 
 
 
4.11.6 Cytokines dynamics, inflammatory response and surgical 
outcome, overall comparison 
 
Concerning the cytokine differences over a week period, in the antero-posterior 
approach IL-6 and IL-10 presented significantly elevated concentrations at T2 and 
the level remained elevated at T3 (Figures 60, 61). Contrary, IL-18 slightly dropped at 
T2, in all the approaches, for after reach the highest level at T5, however only the 
posterior and the antero-posterior approaches showed statistically significant results 
at T5, compared to T2. PCT, level was significantly elevated at T3 and T4 in both 
posterior and antero-posterior approaches. PCT kinetics were similar to IL-6 and IL-
10, but PCT concentration became higher at T3, T4 time-points, instead of T2 and T3 
of IL-6 and IL-10. With respect to the differences among the three approaches at 
each time point, IL-6 level was significantly higher in the antero-posterior, compared 
to the other approaches. IL-10 was significantly higher in antero-posterior, but only 
compared to posterior approach and IL-18 and PCT showed no significant 
differences at any time point.  
 
The duration of surgery affected the kinetics of all the cytokines examined. In 
particular, although IL-6 did not show any significant difference between the two 
groups at any time point, concentration was higher in the slow group from T2 to T4. 
Moreover, IL-10 presented higher levels at T1 and T3 in the slow group and both 
B T0 T1 T2 T3 T4 T5 
Posterior vs. Ant.-Post. - - 0.0274 - - - 
Posterior vs. Post.-Cost. - - - - - - 
Ant.-Post. vs. Post.-Cost. - - 0.0220 - - - 
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groups gave a higher pick at T2. Similarly to IL-6, IL-18 concentration presented very 
similar kinetics for both groups, with no significant differences between them. In both 
groups IL-18 was significantly raised at T5. Lastly, although PCT concentration was 
high at T2 for both groups, the increment was significant only in the slow group. 
Furthermore, the slow group presented a significative higher PCT concentration at 
T5, compared to the fast group. Concluding, regardless the degree of significance, all 
cytokines presented higher concentrations in the slow group of surgery.  
 
Concerning the comparison between genders and cytokine concentrations, IL-6 in 
the posterior approach increased significantly from T2 to T4 in females, contrary 
males presented only a pick at T3. In the antero-posterior approach, IL-6 presented 
overall higher concentrations, compared to posterior approach with both genders 
showing a pick only at T2. IL-10 concentrations, although appeared higher in the 
posterior approach at T1 and T2 in females, inversely in the antero-posterior 
approach appeared higher in males at T1 and T2. Similarly to IL-6, the overall IL-10 
concentration was higher in the antero-posterior approach, compared to posterior 
approach. IL-18 concentrations, similarly to previous comparisons, presented a 
characteristic drop at T2 in both genders and approaches, which however it was not 
statistically significative. Moreover, IL-18 was significantly elevated at T5 for both 
approaches and genders, compared to T2. PCT levels presented a statistically 
significant increment at T2 and T4, only in the posterior approach in the female 
group. Furthermore, similarly to IL-6 and IL-10, PCT concentrations were higher in 
the antero-posterior approach, compared to posterior approach. In none of the cases, 
were detected significant differences on either genders between approaches. 
Leukocytes concentrations in the posterior approach were increased at T2 and T3 for 
after return to basal level at T5. In the posterior-costoplasty and the antero-posterior 
approaches leukocytes increased at T2 and T3, respectively, compared to T0. 
Contrarily, lymphocytes were decreased at T2 to T4 in the posterior approach. 
Similarly, they were decreased at T2, T3 and at T2, T4 in the antero-posterior and 
posterior-costoplasty approaches, respectively. Moreover, lymphocytes presented 
significantly lower levels in the antero-posterior approach, compared to posterior 
approach. Neutrophils were significantly elevated at T2 in all the approaches and in 
both posterior and posterior-costoplasty approaches, concentrations remained 
elevated at T3. Moreover, with the exception of lymphocytes, no significant 
differences were observed among the three approaches at any time point, 
concerning leukocytes and neutrophils. 
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Regarding coagulation markers, platelets levels were significantly decreased at T3 in 
all three approaches and at T2 and T4, T5 of the antero-posterior approach and 
posterior approach, respectively. As expected, the antero-posterior approach 
presented the lowest level of platelets, compared to the other approaches. PT 
increased significantly at T2 and T3, from baseline in both posterior and antero-
posterior approaches. Moreover, antero-posterior and posterior-costoplasty 
approaches presented a significantly lower PT at T5, compared to posterior 
approach. PTT was significantly decreased at T3 in all three approaches. 
Furthermore, the antero-posterior and posterior-costoplasty approaches, presented a 
lower level of PTT at T2. Moreover, no significant differences were observed among 
the three approaches at any time point. 
 
Hb level was significantly reduced, in both antero-posterior and posterior 
approaches, at T3, T4 and T5, respectively. Hb level of the posterior-costoplasty 
approach, was significantly decreased only at T4. As expected at T2 and T3, the 
antero-posterior approach showed the lowest level of Hb, compared to the other 
approaches. 
 
With regards to spinal infections, from a cohort of 23 patients studied, two developed 
a late spinal infection (few months after the discharge), which did not present any 
apparent signs or symptoms during their in-hospital stay. Donor AF22 was tested 
positive for staphylococcus aureus, however, for donor AF26 it has not been possible 
to identify the pathogen despite the clinical signs of infection. Both donors were 
treated successfully with six weeks of antibiotics. Although their cytokines, in addition 
to clinical and biochemical parameters were investigated, in an attempt to identify 
any possible elements for early signs of infections, it was not possible to reach a 
clear conclusion. Both clinical and biochemical parameters were within the 
physiologic ranges and despite cytokine levels presented at few time-points higher 
concentrations, compared to the average, this element in isolation was not sufficient 
to use it as early predictive marker of infection (Tables 69, 70). 
 
Concerning the spinal fusion, it was ascertained radiologically, considering fused a 
spinal segment which present bridging callus across the treated vertebrae on two 
orthogonal views on plain X-ray films. As it was expected, given the young age, all 
patients presented satisfactory healing at 12 months following AIS correction, 
regardless the approach performed.  
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Table 69: Comparisons between median concentrations of cytokines, with the 
single concentration of the two infected donors. Differences were calculated for 
every time-point. Concentrations are expressed in pg/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Posterior-Costoplasty Posterior 
IL-6 
Median 
values 
AF22 
values 
Fold-
difference 
Median 
values 
AF26 
values 
Fold-
difference 
Time 0 0.1 0.0 -0.1 0.1 0.1 0.0 
Time 1 2.8 2.7 -0.1 4.0 2.1 -1.8 
Time 2 22.4 70.4 48.0 25.9 5.5 -20.3 
Time 3 24.8 17.6 -7.2 41.2 43.7 2.5 
Time 4 52.3 37.7 -14.6 33.6 23.5 -10.1 
Time 5 11.9 22.3 10.4 11.6 Discharged 
Time 6 16.6 10.9 -5.7 7.6 Discharged 
       
IL-10       
Time 0 0.8 0.6 -0.2 0.7 0.6 -0.1 
Time 1 0.8 0.8 0.0 1.0 0.7 -0.3 
Time 2 1.2 0.3 -0.9 1.0 1.2 0.2 
Time 3 0.5 0.6 0.1 0.3 0.4 0.1 
Time 4 0.3 0.2 -0.1 0.3 0.1 -0.2 
Time 5 0.5 0.5 0.0 0.5 Discharged 
Time 6 0.3 0.2 -0.1 0.1 Discharged 
       
IL-18       
Time 0 44.0 43.1 -0.8 30.7 51.0 20.2 
Time 1 44.0 45.6 1.5 32.4 39.7 7.3 
Time 2 33.9 33.9 0.0 22.7 33.6 10.9 
Time 3 41.8 45.7 3.8 36.7 37.2 0.5 
Time 4 46.5 44.7 -1.8 39.7 42.6 2.8 
Time 5 53.0 64.5 11.5 48.6 Discharged 
Time 6 36.2 36.5 0.3 40.5 Discharged 
       
PCT       
Time 0 11.4 12.7 1.3 10.2 10.2 0.0 
Time 1 19.7 7.6 -12.1 11.6 8.5 -3.0 
Time 2 30.8 29.4 -1.4 33.8 58.2 24.4 
Time 3 11.5 10.4 -1.0 16.7 23.1 6.4 
Time 4 38.5 38.5 0.0 36.9 38.5 1.6 
Time 5 17.5 16.3 -1.2 17.6 Discharged 
Time 6 5.4 5.1 -0.3 5.9 Discharged 
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With regards to the cohort demographics and surgical outcome, the antero-posterior 
group presented an equal gender distribution and as it was expected the surgical 
time was longer, compared to the other approaches. Given the surgical complexity, 
these donors spent more time in intensive or higher dependency care units and 
required a longer in hospital stay before discharged (Table 70). The posterior-
costoplasty group, considering also that costoplasty was mainly performed as an 
aesthetic correction rather than a functional necessity, was made only by females. 
Furthermore, the duration of surgery was similar to posterior approach, donors 
presented the shorter length of hospital stay and they did not require intensive or 
higher dependency care (Table 70). Lastly, the posterior approach was the most 
populated and gender distribution presented 1:2 M/F ratio. Moreover, appeared that 
the faster group of surgery, had higher requirements of intensive dependency care 
(Table 70). Additionally, for all three approaches were used similar amounts of 
pedicle screws and a similar number of vertebrae were involved in the correction 
(Table 70).  
 
Table 70: Demographics and outcomes for the three different approaches. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 F/M Age 
HDU/ICU 
LOS 
(days) 
Total 
LOS 
(days) 
Duration of 
Surgery 
(hours) 
Infections 
N. of 
screws 
Number of 
vertebrae 
involved 
Antero-posterior 3F/3M 14.7 3 8.5 10 0 15 11 
Post.-costoplasty 5F 15.9 0 4 5.6 1 16 10 
Posterior (Total) 8F/4M 15.8 1.5 6 5.1 1 16 10 
Posterior (Fast) 4F/2M 15.9 2 6 4.1 1 16 11 
Posterior (Slow) 4F/2M 15.6 0 6 6.1 0 18 13 
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5. Discussion 
 
This thesis is composed by two main units, the comparison of MSCs populations 
from ICBM and VBBM, isolated using two different processing methods (density 
gradient concentration and red cells lysis) and the immuno-inflammatory response 
following surgery. 
 
The purpose of the MSC component of the study, using a well-established 
methodology and a robust cohort, was to determine whether the VB, a well known 
hematopoietic stem cells reservoir229-231, could provide comparable MSCs' numbers, 
with those in IC, in donor-matched samples. Hence, providing an additional source of 
MSCs for grafting augmentation during spinal procedures. Moreover, a second 
hypothesis tested was whether VB-MSCs had a similar or even better proliferation 
and differentiation potentials compared to IC-MSCs. Furthermore, the third 
hypothesis tested in the study, was to investigate the effectiveness of red cells lysis 
technique (AC) compared to density gradient concentration technique (LMP) for 
MSCs isolation for both ICBM and VBBM. 
 
The potential benefit of these findings, would be to minimize the need for IC harvest, 
in many cases, and to provide an additional source of MSCs both for patients 
requiring extensive grafting (spinal revision surgery, extended spinal instrumentation) 
and for those with limited availability of ICBM due to anatomic variability or in case 
they had previous irradiation of the pelvis (due to cancer), where may not be an 
adequate volume of ICBM to complete the spinal fusion.  
 
Spinal arthrodesis is the ideal treatment for severe or progressive spinal conditions 
like spinal instability following extensive spinal decompression, spondylolisthesis, and 
several degenerative diseases. The success of the operation, often depends from the 
quality of the bone fusion; its failure (pseudoarthrosis) may lead to failure of 
metalwork, possible revision surgery, higher risk of infection, and pain2, 98.  
 
Among the factors that spinal surgeons can control to maximize the surgical 
outcome, is a robust bone fusion through bone graft augmentation. Currently, in their 
armamentarium there are mainly bone morphogenetic proteins, allograft scaffolds 
and autograft possibilities8-12. The first is an expensive alternative, which continue to 
show promising results, however, their application present limitations, are not devoid 
of complications and also several aspects of their mechanisms of action need to be 
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further clarified8-12. Corticocancellous autograft is the most common solution for bone 
graft augmentation and IC harvesting is considered the "gold standard" source. 
However, harvesting can become laborious, generate post-operative pain and could 
predispose patient to post-operative complications8,11. 
 
A valid alternative is represented by allograft material, especially when used in 
combination with BM-MSCs showing spinal fusion rates similar to autograft8,11-13. 
Furthermore, in terms of therapeutic concentration of MSCs and bone healing, it was 
reported by Hernigou et al, that grafting over 50.000 MSCs in bone defects was able 
to ensure a particularly effective bone healing13. Considering VB enumeration assays' 
results, the present study demonstrated that VBBM is comparable to ICBM, able to 
provide sufficient concentration of MSCs to use in graft augmentation. 
 
Despite the fact that VBBM is a well known hematopoietic stem cells source, from 
cadaveric donors229,231, for the last 50 years, and is used routinely in transplantation 
field230; its use as autologous bone graft in spinal surgery is not yet considered as a 
routine procedure despite the great benefits it can offer.  
 
On technical ground, while aspiration from IC takes only a few minutes, aspiration 
from pedicle adds virtually no extra time, because pedicles have to be approached as 
part of the procedure for the pedicle screws implantation. Additionally, the practical 
difference between both procedures, is that VBBM harvesting can be virtually 
extended as far as the metalwork goes. BM can be aspirated from both pedicles of 
each vertebra, without adding extra time or resulting more painful for the patient in 
the post-operative period, as it does for IC aspirate, in case of multiple aspirations for 
optimal MSCs concentration with low haemodilution.  
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5.1 Bone Marrow: Harvesting 
 
BM-MSCs from 19 donors were isolated using two different methods and selected 
though their ability to adhere on plastic surface under standard culture conditions219. 
MSCs were able to proliferate from single cells into colonies presenting the expected 
fibroblastic-like morphology with long spiky tentacles and growing together in a 
radial-growth pattern. CFU-F, flow cytometry and trilineage differentiation assays 
were performed in order to confirm the MSC nature of the harvested cells, fulfilling 
the ISCT criteria69, for the definition of MSCs.  
 
Consistency of anatomic structures involved, aspiration and isolation techniques are 
deemed as the most important aspects of a study, because they can influence the 
quality of all the forthcoming results. Isolating the maximum number of cells with the 
minimum blood dilution is crucial, therefore, 1-4ml of BM has been described as the 
optimum aspiration volume170,173,229. However, bigger quantities (8-10ml) with similar 
results, in terms of cell concentration, were also reported7,53,173. Haemodilution is a 
well documented condition, however in a clinical scenario, the priority is to harvest 
the highest number of MSCs per singe aspirate using the most effective technique. 
To a certain extent the haemodilution factor can be overcame intraoperatively, using 
bone marrow aspirate centrifugation devices, to concentrate the MSCs obtaining a 
high quality sample233-235 and allowing direct MSCs application into the defect area. In 
this study 10ml of BM were harvested, from IC and VB, in order to fulfil the 
experimental requirements. Considering also the high BM cellularity, due to the 
young age of the subjects51,173, a sufficient number of cells was isolated. 
 
Additionally, concerning the safety of the BM harvesting procedure, 10ml of BM is far 
below the recommended aspiration volumes based on the bone marrow 
transplantation guide lines, which recommend a total volume of 1,000-1,200 ml from 
adult patients and 500ml from children (15-20ml/kg in adults and 10-15ml/kg in 
children). Moreover, following bone marrow aspiration, abnormalities were 
documented with skeletal scintigraphy, CT and MRI, mainly in patients undergoing 
conspicuous aspirations (1000ml approx.) for transfusion purposes. Signal changes 
in MRI, showing oedema, hyperaemia and proliferative activity were eventually 
detected at the aspiration sites 4 weeks after harvest236 and the great majority of 
those donors experienced prolonged discomfort. Although, tissue repair was 
achieved, commonly after a year in a significant percentage of cases signal 
abnormalities were still persisting236, however, without necessary a pathological 
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relevance. Nevertheless, the documentation of these findings is important for 
differential diagnosis purposes237. In this study, only 5 patients reported a transient 
mild discomfort from the IC, lasted 3-4 days. However, this discomfort could be also 
caused by the intra-operative positioning and not necessarily from the aspiration 
procedure itself. Moreover, all patients recovered satisfactorily as expected, during 
the in-hospital stay and the follow-up period.  
 
Many studies have reported significant MSC heterogeneity in vitro, identifying three 
main factors:  
1) harvesting technique used51, culture aspects68 (cell seeding density, media used) 
and donor's related factors51,238,239 (age, gender, health status and different anatomic 
architecture of the cancellous bone where the cells where harvested); 
2) existence of different subpopulations185,221,240 within the BM-MSCs' aspirate, 
however not all of them may have a therapeutic relevance241;  
3) most recently, through studies investigating gene expression profiles and cellular 
markers241-243, became more clear that native micro-environment from the donor site 
(topography), is one of the most important aspects, particularly concerning MSCs' 
differentiation241,242,244.  
 
Furthermore, it is important to consider that despite the different micro-environment 
of every native tissue245, MSCs (including BM-MSC harvested from different 
bones246) are generally studied using identical methods for harvesting, selection 
expansion and induction. This, raises the question whether important 
subpopulations242,247 of MSCs are lost, due to the ways they are isolated and 
expanded.  
 
The mechanisms of higher osteogenicity/chondrogenicity of VBBM MSCs versus 
ICBM MSCs have not been analyzed here, however a variation in the 
genetic/epigenetic factors regulating the differentiation, could be proposed. A 
distinctive epigenetic signature has been reported explaining the variable 
differentiation potential between MSCs from BM and adipose tissue268. Moreover, to 
better explain the MSCs' function, Hox codes248 could play an important role in 
determining a "genetic identification profile" unique to every MSC-type based on its 
function and topography. 
 
In this study, despite the restricted age range and the same harvesting technique 
used, it was not possible to limited the donor-to-donor CV, which was ranging 
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between 85%-89% for both anatomic sites (85%IC AC, 89%IC LMP, 87%VB AC, 
86%VB LMP). The interindividual variation in MSCs/ml of BM, it was reported by 
different authors and was consistent with previous studies11,239 for both anatomic 
regions.  
 
5.2 Bone Marrow: Comparison between LMP and AC 
 
Two different methods were used to isolate potential MSCs from bone marrow. The 
first method (LMP), has been well characterised and uses density gradient 
centrifugation to separate the mononuclear layer from BM, which is next isolated 
through further washes and centrifugation. The second alternative method, uses AC 
salt to lyse the erythrocytes contained in the BM sample, selecting the leucocytes 
which are concentrated through centrifugation in the cell pellet.  
 
Despite the well documented effectiveness of AC in ICBM54-56, all available studies in 
the literature comparing IC vs VB, were using density gradient concentration 
technique (Table 44). Furthermore, LMP is able to isolate only MSCs that can "fit" 
within its density features (1.077 ± 0.001 g/ml), which is similar to MNC (monocytes 
and lymphocytes) density (≤ 1.077 g/ml)54-56. Moreover, LMP is characterized by a 
higher number of steps, compared to AC57 and is a more operator-dependent 
technique, introducing potentially more variability. 
 
Sufficient evidence is available from several authors55,56,216,217, showing a significative 
loss of MSCs following use of LMP from ICBM, compared to AC. A possible 
explanation of these results, could be related to the presence of at least two 
subpopulations185,221,240 of MSCs. Other authors suggested that MSCs may have a 
different grade of maturation, presenting different size/weight and level of activity, at 
the moment of aspiration58. Thus, LMP is not able to "hold trapped" within the 
interlayer all different MSCs and therefore a part of them, most likely the heaviest 
cells, are lost within the discarded component54,55,57 (erythrocytes and granulocytes).  
 
Contrarily, AC isolates MSCs using the principle of red cells lysis concentrating all 
leucocytes and not only MNCs. Hence, the potential loss of MSCs following AC 
procedure is significantly lower. Taking into account these findings, it appears more 
accurate to use AC for comparisons between different anatomic sites, and 
suboptimal the use of LMP. Up to date, there are several studies, comparing both 
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cells isolation methods from ICBM56,57, but no data exist analysing VBBM using both 
techniques.  
 
5.3 Comparison of MSCs findings with the literature 
 
Summarising the enumeration assays findings of this study, cells count (total 
cells/ml), presented a statistically higher number of cells when AC was used for both 
IC (20x106/ml) and VB (15x106/ml), compared to LMP (IC 7.23x106/ml, VB 5x106/ml). 
Moreover, prevalence (CFU-F/106) of MSCs, showed that both IC and VB yielded 
slightly higher number of colonies when LMP was used (IC 40/106, VB 57/106), 
compared to AC (IC 34/106, VB 44/106), but without statistical significance. Most 
importantly from a clinical perspective, concentration of MSCs (CFU-F/ml), was 
statistically higher when AC was utilized for both IC (916/ml) and VB (840/ml), 
compared to LMP (IC 357/ml, VB 417/ml). However, no statistically significant 
difference was found between anatomic sites. 
 
Comparison of these results with the current literature (Table 71) shows slightly 
higher total cells concentrations from ICBM, however, a clear trend was not 
observed, with respect to the anatomic site. Nevertheless, regarding MSCs 
concentration, authors Ahrens, et al62, McLain, et al52, Defino, et al172, and Woo-Kie, 
et al68, similarly to this study, showed higher MSCs/ml from VBBM. However, the 
difference was not always statistically significant, because they all used LMP.  
 
A critical determinant of BM-MSCs capacity to enhance bone healing, is the ability to 
generate quickly a sufficient number of proliferating colonies able to promote 
chondrogenesis and osteogenesis. Risbud, et al171, measured the CFU-F size from 
both IC and VB donor-matched samples, classifying colonies in three different sizes 
(small, medium, large), showing a statistically significant higher number of smaller 
colonies in VB, whilst IC presented a more uniform distribution of bigger colonies. 
This could suggest that VB-MSCs may have better mitogenic properties, justifying 
the higher number of smaller colonies. Furthermore, heterogeneous groups of MSCs 
and a statistically significative faster doubling rate of VB-MSCs has been also 
observed by authors Defino, et al172 and Barbanti Brodano G, et al173. In this thesis a 
statistically significant difference in colonies size was showed between IC and VB, 
but only when AC was used; which confirms further the presence of more 
subpopulations which are not entirely selected by LMP.  
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Concerning gender-related differences in BM-MSCs, despite several reports and the 
recently discovered androgenic receptors on both genders' MSCs242, given the 
uneven gender distribution of this cohort, due to the demographics of scoliosis, it was 
not possible to perform robust statistics in this respect. Nevertheless, in this study, 
but also from the IC vs VB comparison studies examined (Table 71), no significant 
difference between genders were observed. 
 
With regards to the left or right side for the ICBM and VBBM aspiration, as it was also 
investigated by other authors7,242, there is no anatomic basis to suggest a possible 
difference. Hence, this information was not recorded in this study. 
 
Concerning donors' age, BM-MSCs are involved in the bone remodeling process not 
only following an injury, but also physiologically during the entire life span, therefore it 
is expected that their concentrations and functions are adapted accordingly. Also 
aging is associated with a significant age-related decline in MSCs concentration per 
single aspirate in both genders250 and additionally with a significant decrement of BM 
osteoblastic progenitors in women, but not in men250. Scope of this research was to 
eliminate the age variability factor by restricting the age range. There are not well 
codified data on this subject, however the experience of Leeds MSCs group is 
consistent with previous studies reporting an age-related decline51,173. 
 
Different weaknesses have been observed, analysing the current literature (Table 
71). Generally, the number of patients recruited was relatively limited68,170-173. 
Moreover, the BM harvesting technique and the anatomic site were not always 
constant, with the exception of only one study where BM-aspiration was performed 
consistently for the same vertebra68. Furthermore, despite the evidence of better 
results with AC56,57,216, all the studies used LMP method for cells isolation52,62, 
68,170,171,173. In addition, in two studies VBBM and ICBM was not donor-matched62,173. 
In the great majority of the studies, donor’s age and gender were given, however 
health status was rarely reported. 
 
To complicate matters further, comparisons among BM harvested from patients and 
from cadavers were made, increasing the variability of the results62,173. Considering 
also, BM variability, based on the donors age238,239, none of the studies performed a 
further analysis of the results in age-groups, despite the broad age range of patients 
analysed (~3-80 years old).  
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Papers listed 
in chronologic order 
Elements examined  
per paper 
Table 71: Overview of the literature, comparing ICBM and VBBM.  
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5.4 Flow cytometry, discussion 
 
Currently the use of MSCs in orthopaedics to promote bone healing is being 
progressed and developed due to the unique characteristics of these cells, in terms 
of proliferation, differentiation and growth factor secretion at the application site (e.g. 
osseous defects).  
 
CFU-F assay represent the most common method for MSCs analysis, however is a 
lengthy procedure and as it was highlighted from other authors225,227, by being a 
plastic adherence–based cultivation method, may select only a portion of the MSCs 
population, leading to the loss of some poorly adherent, but highly potent MSCs.  
Flow cytometry is a faster method and is based on extra- and intra-cellular markers 
detection. It was performed with the aim to confirm and study further MSCs nature, 
as per ISCT criteria69,222, in addition to differentiation and CFU-F assays.  
 
Although AC- and LMP-harvesting methods are commonly accepted for BM-MSCs 
sample preparation, for flow cytometric characterization little data exist regarding the 
effects of these procedures226 on the physical and biochemical properties of the 
MSCs. Furthermore, from the literate review performed, a comparison between 
harvesting methods, was reported by few authors224,226,251 based only on ICBM-
MSCs, but not on VBBM-MSCs. Additionally, to increase the complexity, it is 
established that different subpopulations of BM-MSCs exist223,225,251 and also is 
known that there is an intra-donor variability regarding BM-MSCs harvested from 
different anatomic sites51 of the same donor. Despite CD271 represent an ideal 
marker for the identification of all the subpopulation of MSCs, its use is mainly 
indicated for fresh-harvested MSCs, as shown in previous publications191,193,223,224 and 
not in frozen MSCs used in this study. 
 
Moreover, on a technical ground, MSCs' size can influence the light scatter signals 
(large cells will refract more light, leading to high forward scattered light and vice 
versa)224. Also, changes in the cell membrane (smoothness) due to the sample 
preparation technique used, can influence the index of the light's refraction224. 
Additionally, side-scattered light can be also affected by the internal complexity of the 
cells224. Hence, the aim of the flow cytometry was also to investigate whether ICBM-
MSC differs from VBBM-MSCs especially when different isolation methods were 
employed.  
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Moreover, studying the ALP intracellular marker187,188 and MSCA1 extracellular 
marker182-186, it was possible to investigate to some extent the osteogenic 
predisposition of MSCs. This method can provide a "proof of principle" that the whole 
BM-MSCs population can be directly phenotypically characterized, without 
necessarily utilising cell-culture techniques. 
 
All the MSCs standard characterization markers (CD105, CD90, CD73), presented a 
similar MFI pattern with CD90 showing always the highest intensity, for both VB and 
IC, regardless the harvesting method used. Moreover, CD90 from IC AC-harvested 
MSCs, was the only marker to present a statistically significant higher MFI (p=0.048), 
compared to IC LMP. 
 
Regarding the overall outcome from all 4 donors, the intracellular ALP187,188 staining, 
presented a higher MFI from LMP-harvested MSCs from both anatomic sites and the 
highest outcome from ICBM by 1.34-fold, compared to VBBM. Whereas the 
extracellular marker MSCA1182-186, presented the opposite outcome with the highest 
MFI from AC-harvested MSCs, equally from both anatomic sites. For the number of 
donors examined, it was not observed any statistically significant difference between 
anatomic sites or harvesting method used, in terms of osteogenic predisposition in 
non-osteogenically differentiated MSCs.   
 
SUSD2 extracellular marker for an additional MSCs characterization181-183, presented 
similar results for both VB and IC. Nevertheless, LMP-harvested MSCs from VBBM 
presented a slightly higher MFI by 1,24-fold, however without any statistic 
significance. 
 
Although different techniques were used (flow cytometry, CFU-F and calcium 
assays), in order to study MSCs' function and osteogenic ability, it was not always 
possible to perform a direct comparison between techniques. Moreover, whilst flow 
cytometry analyses mainly the presence of markers, colourimetric assays used, are 
based on cellular cultures, which are more dynamic, however can influence MSCs' 
behavior. In addition, MSCs proliferation rate and MSCs confluency, is one of the 
most important elements which can influence osteogenic differentiation252 in vitro. 
Moreover, for same amount of incubation time, VB-MSCs were growing slightly faster 
compared to IC, as it was also observed from other authors171-173, therefore VB 
cultures could had virtually "more time" to produce a higher calcium concentration. 
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5.5 Trilineage differentiation, discussion 
 
The aim of the trilineage differentiation, was to prove retrospectively, the 
tripotenciality of the isolated MSCs, as per ISCT's position statement69,222 and also to 
compare mainly the osteo-chondral capacity of BM-MSCs from VB and IC. In order to 
understand better the VBBM potential in a clinical setting, the MSCs' tripotenciality 
has to be compared as a whole, especially the chondro-osteogenesis axis and not 
only focusing on the osteogenic capacity on MSCs, as often happens. 
 
However, before the final conclusions in this chapter, it is of paramount importance to 
highlight briefly the different embryogenic steps, regarding the enchondral 
ossification of the spine, in order to better appreciate the deep relation between the 
three components of the differentiation assays performed, especially between 
chondrogenesis and osteogenesis.  
 
The development of the axial skeleton is derived from a synchronised migration of 
sclerotomal cells both along a rostral to caudal and towards the midline directions, 
surrounding the spinal cord and notochord and forming a long mesenchymal column 
through the process of the endochondral ossification253. This process, takes place in 
3 stages (pre-cartilage, chondrification, and ossification), involving the gradual 
replacement of a temporary structure with a permanent one and is completed at 
about 25 years of age253. A less extensive version of the last two steps of the same 
process, is reactivated every time that a traumatic or surgical fracture occurs.  
 
During this complex process, a sequence of events in chondrocyte behaviour 
coordinated with the actions of blood vessels, osteoclasts, osteoblasts and other 
factors (receptors, signalling molecules, transcription factors and cytoskeletal 
components regulating the chondrocytes' behaviour) occur, in such a way to prepare 
the cartilage matrix for the "invasion" by the cells of the ossification front253,254.  
 
Chondrocytes, following proliferation, pass through a transition stage called ‘pre-
hypertrophic, to hypertrophic, increasing their volume and secreting, at the same 
time, extracellular matrix. Hypertrophic chondrocytes then die, via apoptosis or other 
unspecified mechanism, allowing to the invading elements of the ossification front 
(blood vessels, osteoclasts, osteoblasts and bone marrow cells), to colonise and 
mineralise the extracellular cartilaginous matrix, transforming it into bone254. 
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Osteogenic induction for calcium assay, matrix mineralization AR assay and ALP 
activity was performed during 14 days instead of 21200-202. This decision was based 
on a pilot experiment performed before setting the differentiation assay, using the 
same cell density, but 2 different induction periods of 14 and 21 days. After 2 weeks 
the cell-layer reached confluency and cells started to lift off from the well, risking to 
alter the outcome of the assay. Hence, due to the continuous proliferation in 
combination with the mineralisation, which appear to have potential to continue even 
beyond the 21 days period, it was decided that 14 days of induction it was a safe 
period able to guarantee valid results, without compromising the outcome of the 
assay. 
 
The ALP activity data of this study, supported also by AR and calcium assays, 
showed an overall superior osteogenic capacity from VBBM, compared to ICBM. 
Matrix mineralization is a result of continuous mineral deposition due to ALP activity, 
which has a critical role in osteogenesis. Moreover, ALP is involved in the cleavage 
of calcium phosphate groups and also contributes to a better colonization and 
consequent mineralization of the scaffolds in vitro254.  
 
With regards to chondrogenesis, it was performed using a three-dimensional-type of 
culture during 21 days of induction, compacting together a large number of cells in a 
spheroid-like shape following micro-centrifugation in eppendorf tubes. GAG 
accumulation was used as a marker of chondrogenesis and was evaluated 
spectrophotometrically and through pellet staining. For pellet cryo-preservation and 
sectioning OCT was employed. It is physically less stable, compared to paraffin or 
resin embedded sections, however it was preferred as provides a satisfactory 
definition of the fine details of the specimen206,207. Additionally, it is faster/simpler to 
set up, does not involve dehydration and also preserves better the antigenicity of the 
specimen, therefore the detection of antigens under microscope for future studies207.   
All 4 donors, showed statistically higher GAG concentrations from VB-MSCs, 
compared to IC-MSCs (VBBM: AC 44.3μg/ml, LMP 43.5μg/ml, ICBM: AC 11.7μg/ml, 
LMP 22.8μg/ml). 
 
Adipogenic differentiation presented also a certain donor-to-donor heterogeneity and 
variability within the same well. Despite the homogeneous culture condition in the 
well, a small subset of MSCs did not show any fat droplets accumulation even at 21 
days of induction. The concentration of differentiated MSCs within the well, appeared 
to be higher in the outer perimeter rather than the centre of the well, presenting areas 
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with a higher concentration of adipogenic MSCs and others less differentiated. 
Possibly, communication between adipocytes may had a role in this pattern of growth 
or merely it was for mechanical reasons due to the initial location of the cells when 
seeded on the well. 
 
Moreover, based on Nile red/DAPI ratios, ICBM showed a higher adipogenesis/cell 
for both harvesting methods used, compared to VBBM. Even though adipogenesis 
assay is not an deal method to measure MSCs-proliferation, VBBM presented a 
certain predisposition to proliferation, based on DAPI outcome, which was higher 
compared to ICBM. Regarding the harvesting method used, LMP appeared to be 
related to higher predisposition to proliferation for both VB and IC-harvested MSCs, 
showing a smaller size of fat droplets. Contrarily, AC appeared to be related to an 
increment of adipogenesis for both anatomic sites, also associated to bigger fat 
droplets size. 
 
Oil red-O semi-quantitative scoring system which provides a visual method of 
adipogenic quantification, it was attempted in this study, however, it was proven to be 
subjective (operator dependent), time consuming and not always correlating between 
Oil red-O and Nile red OD measurements. Additionally, given the heterogeneity of 
the cultures, it was not always straightforward to establish the appropriate grade. 
Furthermore, semi-quantitative scoring system does not take into account the 
intracellular variability of the fat droplets (different size droplets in the same cell), 
hence, this can influence the final scoring decision.  
 
Alternatively, spectrophotometric measurement of adipogenesis, using Nile red/DAPI 
dyes, it was faster, not operator dependent and also it was not influenced by the 
morphologic characteristics of the fat droplets or the heterogeneity of the cultures. 
Moreover, the dual examination of the same wells, through fluorescent imaging and 
spectrophotometric readings, offered an additional level of control, regarding the 
MSCs' fat content. 
 
Despite the thorough tissue culture techniques, all the trilineage differentiations 
shown a certain heterogeneous distribution of the staining within the same well, 
which was believed to be due to the heterogenic nature of MSCs238,256.  
In the available literature examined (Table 44), a complete trilineage differentiation 
assay was performed only in one study173 showing better differentiation from VBBM 
for all three lineages. Osteogenic assay was performed in five studies, showing 
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better osteogenic performance from VB in two studies68,173, even results in one171 and 
better performance from IC in two170,172. Adipogenic and chondrogenic differentiation 
was performed only in one study173 showing higher outcome from VBBM, however, 
without reporting a detailed analysis of the results. A better VB osteogenesis, was 
also supported by a higher runx-2, osteocalcin and alkaline phosphatase gene 
activity68,171,172, which may be related to better bone healing results in vivo. 
Furthermore, the LMP outcomes from the literature are similar to the LMP-results of 
the present study. However, the use of AC-harvested MSCs added a more define 
perspective, offering a more realistic outcome considering the better efficiency of AC 
in isolating more MSCs.  
 
An additional element for reflection, is whether VB-MSCs are genuinely more 
osteogenic/chondrogenic, compared to IC, or maybe VBBM contains more 
subpopulations of MSCs257 which are possibly contributing to the higher VBBM 
performance. A supportive element towards this idea, in an attempt to explain the 
different results between AC and LMP; could be related to AC ability to isolate more 
efficiently the different subpopulations contained in the VBBM. Nonetheless, authors 
who compared single-cell expanded populations of donor-matched MSCs, from 
different tissues, showed that MSCs' differentiation ability were influenced by their 
tissue of residence255. Additionally, in these studies, all cultures were compatible with 
the ISCT criteria. Regardless the fact that the question on VBBM performance is still 
open, VBBM offers a series of advantages from a biological and technical 
perspective, for the spinal surgeon, compared to ICBM. 
 
Nowadays becomes more clear that the ISCT definition of MSCs, despite the fact 
that represents a milestone in MSCs' field, its unable to "capture" the subtle 
differences in otherwise similar behaving MSCs. On the other hand, MSCs' 
tripotenciality is classically tested retrospectively, following in vitro exposure of MSCs 
to specific culture supplements, which are far from simulating the physiological 
environment. Also these methods, despite the considerable amount of knowledge 
provided, are not supplying information as to what MSCs look like in their naturally 
residence tissues. To address this issue, in addition to what already exist, better 
surface phenotype markers, potentially subdividing MSCs based on their subtle 
characteristics, together with improved experimental methods such as microarray, 
transgenic animal technologies, human and animal genomes, could provide precious 
information towards this direction, in the years to come.  
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5.6 Immuno-inflammatory component of the study: discussion 
 
The purpose of the immuno-inflammatory component of the study, was to analyse 
the post-operative responses of the three most common approaches of AIS operation 
and correlate the pro-inflammatory (IL-6, PCT, IL-18) and the anti-inflammatory (IL-
10) cytokines with clinical and biochemical parameters, during a week period. 
Moreover, the second aim was to analyse the effects of surgical duration and gender, 
in the three different approaches.  
 
Based on the current literature review performed in this thesis, focusing mainly on the 
immuno-inflammatory aspect of the spinal surgery, the great majority of authors 
analysed the host defence response in adult polytrauma patients, associated 
eventually with spinal injuries91-93. Moreover, other authors investigated the local and 
systemic effects of herniated discs101-107 and only few studies analysed the immuno-
inflammatory response following AIS correction via posterior approach99,100,102,261. 
However, despite the pioneering work performed and the essential information 
provided, none of the studies analysed the antero-posterior and the posterior-
costoplasty approaches, especially under the prism of IL-18 and PCT in addition to 
IL-6 and IL-10. Considering the above, the potential benefit of this component of the 
thesis, could be to provide new insight in a field where still little is known. 
 
In patients undergoing scoliosis operation, surgical trauma is known to produce a 
transient impairment of immuno-competence affecting both the cellular and humoral 
arms of the immune system99,100,261. Nevertheless, in order to interpret better 
cytokines' behavior, data needed to be correlated with the biochemical parameters. 
Specifically, surgical stress in the antero-posterior approach resulted to be higher, 
followed by the posterior-costoplasty and next by the posterior approach. This 
outcome was consistent with author Suzuki et al99, showing a transient reduction of 
lymphocytes concentrations between T2-T4, followed by a gradual return to the base 
line concentrations. Moreover, during the same period of time, leukocytes and 
neutrophils showed in contrast, an increment between T2-T3, however without 
differences between the approaches. Both these responses were in balance, 
showing a well maintained biological homeostasis91,99. 
IL-6 was selected as the most consolidated and reliable marker for the measurement 
of the magnitude of a surgical insult91. Moreover, it is a major mediator of the acute-
phase response and presents a long half-life which makes IL-6 less transient and 
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readily measurable. In this study, consistently with other authors163,261, IL-6 was 
increased 2 to 4 hours intra-operatively (T1), reached a peak within 6 hours (T2) and 
then maintained a plateau for up to 24-36 hours (T3,T4), followed by a gradual 
decrement to baseline between T5-T6. Similar to PCT, in the antero-posterior 
approach, IL-6 first reached its peak at T2 and then started decreasing gradually 
without presenting a plateau. Contrarily to PCT and IL-18, IL-6 increment in the 
antero-posterior approach it was statistically significant, compared to the other 
approaches, possibly also due to the discectomies performed (average 4), which 
could had contributed to the IL-6 increment101-107.  
 
IL-10 was selected as one of the most consolidated and reliable antiinflammatory 
markers, producing mainly immunosuppressive123 and also protective effects against 
conspicuous cytokine release during a shock123. In the antero-posterior and posterior 
approaches, IL-10 level increased 2 to 4 hours intra-operatively (T1), reached a peak 
within 6 hours (T2), followed by a rapid decrement to baseline between T3-T4. 
Contrarily posterior-costoplasty approach, following a mild peak of IL-10 at T1, 
started decreasing gradually, returning to baseline at T3. Similarly to IL-6, IL-10 
presented a statistically significant higher concentration, compared to the other 
approaches. IL-10 kinetics correlated with the severity of the operation and was 
consistent with other authors163,266. Moreover, the fast return to baseline could be 
explained due to the lack of other mechanisms (infection, shock) which could have 
triggered the IL-10 de novo synthesis, as suggested by author Peronnet et al267. 
 
PCT increases prevalently following bacterial infection, thus, it was selected as an 
element of differential diagnosis between a bacterial from another infection (virus)150-
157. In contrast with current literature265, suggesting that PCT levels did not increase 
following elective spinal surgeries in infection-free patients, this study provided 
additional evidence suggesting that non-infectious inflammatory stimuli, like major 
spinal surgery, when extremely severe can increase PCT levels150-157. In this study, 
PCT level increased 2 to 4 hours intra-operatively (T1), reached a peak within 6 
hours (T2) and then maintained a plateau for up to 24-48 hours (T3,T4), followed by 
a gradual return to baseline between T5-T6. These findings were consistent with the 
literature146-149, with the only variation of the antero-posterior approach where PCT 
concentration reached its peak at 24 hours (T3) and started decreasing gradually 
afterwards without presenting a plateau. This different behaviour of the antero-
posterior approach, was consistent throughout the majority of the experiments 
performed, confirming the higher immuno-inflammatory stress, compared to the other 
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two approaches. However, no statistically significant differences were detected 
between the approaches.  
 
IL-18 was selected as an early predictive factor in case of lethal postoperative 
sepsis137 or respiratory complications like interstitial lung disease and pneumonia 139, 
which could be an important post-operative complication particularly in posterior-
costoplasty and antero-posterior approaches. However, this cohort of patients did not 
present such complications, hence, although all approaches and genders presented 
significantly elevated levels at T5, compared to T2, it was not correlated to any 
clinical symptoms, including the two donors presenting late onset spinal infection. 
Furthermore, all approaches presented similar concentrations throughout, with a 
characteristic drop at T2, which it was not statistically significative. 
 
Blood loss, transfusion requirements and clotting profile during spinal fusion for AIS 
remain a concern, despite the anaesthetic protocols258,259, the use of cell saver 
devices and tranexamic acid to control bleeding260. The two arms of the coagulation 
cascade165,166, external (PT) and intrinsic (PTT) pathways, behaved in an inversely 
proportional manner, with PT presenting a mild increment at T2 and T3, whilst 
contrarily PTT was decreased at the same time points in all three approaches. Also 
in this case, antero-posterior approach, presented the highest PT and the lowest 
PTT, followed by the other two approaches, but without any statistic significance 
between the lesser two. Moreover, concerning the platelets concentration, as it was 
expected, the antero-posterior approach presented a significative lower concentration 
at T2-T4, compared the other two. Also, the surgical stress often induced a 
hypercoagulable state, which was more frequent within the antero-posterior group. 
The outcomes were consistent with author Bosch et al262, although in his study 
analysed only the posterior approach. 
 
Concerning the comparison between genders and cytokine concentrations, although 
were not statistically significant differences between genders in the posterior and 
antero-posterior approach, few trends observed deserve further discussion. IL-6 
contrarily to the current literature91,97,263,264, suggesting elevated levels in males due 
to the estrogens down-regulation of the IL-6 function, in this study however, no 
gender-related differences were observed. Nevertheless, a high IL-6 concentration 
throughout all donors was observed between T2-T4, consistent with the 
literature100,102,261. IL-18, presented for both approaches and genders similar 
concentrations throughout, with a characteristic drop at T2, which however, it was not 
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statistically significant. IL-10 concentrations, although appeared higher in the 
posterior approach at T1 and T2 in females, and in males at T1 and T2 in the antero-
posterior approach, the variation was not statistically significant. PCT levels 
presented higher concentrations at T2 and T4, only in the posterior approach in the 
female group, however, no differences were observed between the genders. 
Furthermore, the antero-posterior approach presented always higher concentrations 
of IL-6, IL-10 and PCT. 
 
AIS correction is never an emergency operation, hence there is often time to optimise 
patients pre-operatively and adapt the anaesthetic procedure accordingly, in order to 
prevent post-operative complications, especially in patients with significant 
comorbidities. Based on patients' necessities and individual decision of the 
anaesthetist involved, different drugs were used intra-operatively258,259 (propofol, 
remiphentanil, ketamine, phentephedrine, vecuronium, diazepam, ondansetron 
dexamethasone, midazolam). Additionally, antibiotics, as per trust protocol, 
(gentamicin, Flucloxacillin) and tranexamic acid to control bleeding260, were also 
administered during the procedure. Moreover, according to post-operative patients' 
clinical responses, further medication was prescribed (fentanyl pump, paracetamol, 
diclophenac, tramadol, morphine, ibuprofen)259,260. As a result of all the poly-therapy 
prescribed, the intra- and post-operative clinical signs were affected and all appeared 
to be similar and within physiological ranges for all three groups, hence they did not 
show substantial differences which could have been used for comparisons. 
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5.7 Limitations of the MSCs component of the study 
 
In this study the cells used for culture, enumeration, differentiation assays and flow 
cytometry, were cryopreserved rather than used fresh. This decision was made 
considering the prolonged duration of the surgeries, the lengthy MSCs-harvesting 
and culturing procedures, and logistic issues related to the hospital and laboratories. 
Nonetheless, consistent procedures of cryopreservation/thawing during the whole 
study were applied to minimise bias. 
 
A relatively small cohort of patients (n=4) was used for both flow cytometry and 
differentiation assays. Despite the low number of donors, 4 different conditions were 
tested per donor (IC AC, IC LMP, VB AC, VB LMP), for a total of 16 sets of 
experiments. Cells were expanded for differentiation assays with scope to use them 
also for flow cytometry, in order to integrate the outcomes. However, during the 
planning phase of the experiments, leading role had mainly the degree of their 
complexity and the high cost of reagents for both differentiation assay and flow 
cytometry. This resulted in the need to downsize the number of donors to a minimum. 
Nevertheless, similar strategies were observed in other studies comparing ICBM with 
VBBM (Table 71). 
 
In spite the use of same donors for both CFU-F and flow cytometry, was not possible 
to perform direct comparisons between colony numbers from CFU-F and MSCs' 
count from flow cytometry. Thawed P3 expanded MSCs were used for flow 
cytometry, whereas for CFU-F assay, fresh-frozen leucocytes (AC) and MNC (LMP) 
were cultured. Moreover, these two sets of experiments and the MSCs' samples 
used, were not performed in a synchronized manner to allow direct comparisons. 
Ideally, direct comparisons between CFU-F assay and flow cytometry, should give 
more accurate results, when are performed in tandem, using the same sample of 
fresh-harvested MSCs. 
 
Although the importance of gene analysis for better comparison of the different 
behaviour between VB- and IC-MSCs, at the current stage of this research, 
information on gene expression was not performed. It has to be acknowledged 
however, that indirectly the findings of this research confirmed the higher osteogenic, 
chondrogenic and proliferation ability of VBBM, especially from AC-harvested MSCs.  
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Inevitably, time was a limiting factor in these experiments and despite the important 
information that RT-PCR could have added to this work, it could not be completed at 
the current stage. It would be interesting to confirm from a genetic perspective why 
VB-MCS are more osteogenic and or whether are present more subpopulations 
between them which are more efficiently selected by AC. These unanswered 
questions, remain to be addressed in future studies.   
 
 
5.8 Limitations of the immuno-inflammatory component of the study 
 
Blood samples were collected in different time-points within a week period, thus any 
variation of cytokines which may occurred beyond that period of time were not taken 
into account. Furthermore, due to patients' clinical priorities and their in-hospital 
management, blood samples were not obtained at a standard time during the day, 
hence, values may be influenced by any diurnal variation of cytokines that might 
exist. Additionally, scoliosis surgery is an uncomfortable experience for the great 
majority of the patients, which are often becoming emotionally vulnerable. Hence, in 
those circumstances, patients' dignity and clinical necessities were prioritised, 
becoming challenging to keep always a rigorous timetable of peripheral blood 
sampling. 
 
Concerning the biochemical parameters, it must be noted that data derived from the 
hospital laboratory. As these tests were carried out based on the individual patients’ 
needs, measurements did not cover with the same consistency the last time point 
(T6), as measured for the cytokines. Moreover, ideally for the immuno-inflammatory 
component of the study, serial blood samples should be taken for up to two weeks 
following an operation. However, the average duration of the in-hospital stay, was 
approximately 6 days, ranging between 4-24 days, restricting consequently the 
peripheral blood sampling. Therefore, the analyses were performed excluding T6 
data. However despite this, approximately a third of the patients' blood samples were 
obtained at T6 time-point showing consistent trend over time, compared to patients 
with the missing data, hence despite the incomplete data set, it was possible to 
finalise the overall analysis. 
 
This study could potentially be limited with regards to the number of patients 
recruited, although the trends showed by these molecules, to a certain extent  
implied that the sample size was sufficient for analysis. However, a more even 
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gender distribution throughout the cohort could have provided a more define picture 
between genders. Moreover, with a significative bigger cohort of patients and ideally 
a serial blood samples taken up to two weeks, more infection cases could have been 
included in the study and possibly early markers and correlations between infected 
patients, cytokines and biochemical parameters could have been identified. 
 
Samples were stored at −80°C, and the possibility of protein variation cannot be 
excluded. However, this potential effect, if present, it should be extremely low and the 
cytokines' concentration in this study, to a certain extent, were consistent to other 
studies used similar cryopreservation protocols100,102,163.  
 
In this study it was applied the internal control concept (T0-base line values pre-
operatively) as control group, mainly for two reasons. Firstly, given the lack of 
international agreement on the physiological concentration range of cytokines and 
the variety of factors that can affect their levels among an apparently healthy cohort, 
it was considered more reasonable to use the preoperative sample as base line 
value. Second, this research is focused on minors and peripheral blood sampling can 
be often an uncomfortable experience for them. It was not conceived from the 
authors as a necessary step at this stage, to recruit an external control group of 
healthy minors, merely for blood sampling without any clinical reason. ,. 
 
Cytokines were measured in peripheral blood only and not in drained blood nor from 
the cell saver devices. This reduced the amount of information gathered, on the 
amount of cytokines released locally. Nonetheless, scope of this study was to 
analyse the systemic effect of the cytokines on the human body and correlate with 
the clinical outcome. 
 
Furthermore, anaesthetic drugs and post-operative pain management may have 
affected the cytokines levels. However, given the fact that all patients were treated 
applying the same clinical protocols, was not possible to analyze separately the 
effects of a single drug on the cytokines' concentration taken in exam. 
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6. Future study  
 
Would be interesting to investigate further the genetic setup of VB and IC MSCs, in 
an attempt to clarify whether their differences are related to different subpopulations 
of MSCs or a different embryogenic background based on their anatomic location. 
Moreover, another practical aspect requiring further investigation could be whether 
different vertebrae of the same donor present comparable MSCs concentrations. In 
addition could be interesting to identify whether any correlation exists between the 
volume of the vertebras and their MSCs content. 
 
From a transitional point of view, the MSCs findings of this research could be used 
intra-operatively together with the technology currently available (MSCs 
concentrators, portable flow cytometry), to monitor prospectively the MSCs numbers 
yielded from every anatomic site, allowing consistent MSCs concentrations and 
potentially standardising better the clinical outcome. 
 
Concerning the immuno-inflammatory component of this research, will be useful to 
study bigger groups with an even gender distribution and ideally be able to monitor 
cytokines, biochemical and clinical data for two weeks period of time. This will 
determine better their kinetics and in particular of those patients undergoing longer 
and more aggressive procedures. The intra-operative cell saver device is commonly 
used in spinal field. However, still little is know regarding its impact on the 
biochemical parameters and cytokines in different surgical approaches, based on its 
efficiency and erythrocytes preparation prior retransfusion. 
 
The great majority of research performed in the spinal field, is based on the posterior 
approach. Consecutively, the protocols related to the post-operative management, as 
well as the use of antibiotics, are both based on the posterior approach. Moreover, 
also for more traumatic and prolonged procedures (antero-posterior approach), 
presenting longer immunosuppression periods post-operatively, the protocols are still 
following the posterior approach model. The transitional aspect of the immuno-
inflammatory component of this research could be to review and possibly amend the 
current protocols, in an attempt to optimise and better adapt them into individual 
patients' requirements, based on a number of elements, like: type and duration of 
surgery, metabolic conditions, age and other factors predisposing for infection. 
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8. Appendices 
 
8.1 Regression mean imputation for missing data recovery. Regression 
trends were generated based on mean scores over time for the known values (blood 
parameters). Formulas were generated accordingly, using IBM SPSS software, in 
order to calculate the missing data and allowed GraphPad Prism software to perform 
the statistic analysis. A) Posterior approach, B) Antero-posterior approach, C) 
Posterior approach and costoplasty 
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8.2 Materials, consumables and equipment 
 
For samples collection and processing, the following laboratory consumables and 
equipment were used, in addition to what had been already described in the relative 
sessions of the manuscript. : 
Media and Reagents 
 
Media / Reagents  Product code Company  
Dulbecco's modified eagle's medium 
DMEM(1X) + GlutaMAX
TM
-I 
61965-026 Gibco
®
, Invitrogen 
Stem macs MSC expansion media  130-091-680 Miltenyi Biotec  
Dulbecco's phosphate buffered saline 
DPBS(1X)  
14190-094 Gibco
®
, Invitrogen 
Dimethyl sulfoxide (DMSO)  M81802 Sigma  
Trypsin/EDTA solution  15400-054 Invitrogen  
Penicillin/Streptomycin solution  14140 Gibco
®
,
 
Invitrogen  
Lymphoprep
TM
 1114545 Axis-Shield  
Ammonium chloride (NH4Cl) 12125-02-9 Vickers Laboratories 
Boric acid B0252 Sigma 
Tryphan blue  T8154 Sigma  
Methylene blue stain  66720 Fluka  
Fetal calf serum (FCS)  A3059-500g Sigma 
Formaldehyde  BP531-500 Fischer Scientific  
DNAse  D4513 Sigma 
Disodium tetracarbonate decahydrate 106308-0500 Merck 
Calcium assay kit 17667 Senitial Diagnostics 
Sulfated glycosaminoglycan assay kit B1000 Blyscan™ 
Quantikine ELISA Human IL-6 
Immunoassay 
D6050 R&D Systems 
Quantikine ELISA Human IL-6 
Immunoassay 
HS600B R&D Systems 
Quantikine ELISA Human IL-10 
Immunoassay 
HS100C R&D Systems 
Human IL-18 Immunoassay 7620 MBL International corporat. 
Human procalcitonin RAB0037 Sigma-Aldrich 
As2P A8960 Sigma-Aldrich 
Sodium Pyruvate 100x concentrated stock 
5mL 
S8636 Sigma-Aldrich 
PBS 14190-169 Gibco LifeTech 
BSA 7906 Sigma-Aldrich 
Proline P5607 Sigma-Aldrich 
Dexamethasone D1756 Sigma-Aldrich 
Papain  P4762 Sigma-Aldrich 
TGFβ3  243-B3-002 R&D System 
ITS+ (1:100 50μL) 12521 Sigma-Aldrich 
Beta-2-Glycerophosphate  G6251 Sigma-Aldrich 
Fast blue RR Salt FBS25-10CAP Sigma-Aldrich 
Naphthol AS-MX phosphate alkaline 
solution 
855-20ML Sigma-Aldrich 
Citrate concentrated solution 83273-250ML-F Sigma-Aldrich 
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Isobutylmethylxantine I5879 Sigma-Aldrich 
Hydrocortisone H2270 Sigma-Aldrich 
Horse Serum 06750 Stem Cell Technologies 
Oil Red  O0625 Sigma-Aldrich 
 
Plastic devices 
 
Equipment Product code Company  
Inverted microscope  DMIL090-135.001 Leica Microsystems 
Inverted microscope CKX41 Olympus 
Digital camera  C-7070  Olympus 
Mechanical freezer -80°C ULTF 80 Dairel 
Mechanical freezer -150°C MDF-C2156 VAN Sanyo 
Liquid nitrogen NA NA 
Centrifuge PK 130 R ACL 
Centrifuge 5810 R Eppendorf 
Centrifuge Z 206 A Hermle 
Multiskan EX photometer VWR-14230-392 Thermo Scientific 
Biological safety cabinet, class II AC2-4E1 ESCO 
Incubated at 37 
o
C, 5% CO2  50100783 Sanyo 
Haemocytometer BS.748 Hawksley 
37 
o
C water bath  Grant 
Plastic-ware  Product code Company  
Pasteur pipettes sterile 1ml 1170915 Gilson 
Pipette tips (1000 μl)  F167104 Gilson 
Pipette tips (200 μl)  F167103 Gilson  
Pipette tips (10 μl)  F167101 Gilson  
Stripette (25 ml)  4251 Corning  
Stripette (10 ml)  4101 Corning  
Stripette (5 ml)  4051 Corning  
96 well plate (round bottom)  3799 Corning  
6 well plates  3516 Corning  
Flask (25 cm2)  430639 Corning  
Flask (75 cm2)  430641 Corning  
Petri-dish (10cm diameter)  430167 Corning  
Cryovials (2 ml)  72.380 Sarstedt 
Cryovials (1.2 ml) 72.377.005 Sarstedt 
Cryo boxes 
93.872.625 and 
93.876.281 
Sarstedt 
Syringe (10 ml)  302188 BD  
Syringe (50 ml)  300867 BD  
Centrifuge tubes (15 ml)  430790 Corning  
Centrifuge tubes (50 ml)  430828 Corning  
Vacuette (K2EDTA) 4ml 454023 GBO  
Vacuette (z serum clot activator) 6ml 456092 GBO 
MF-millipore
TM
 membrane (0.45 μm)  SLHA033SS Millex – HA 
Freezing container,nalgene86mm tall X C1562-1EA Sigma 
13G match-ground bevel tip introduction 
needle 5'' 
306-131 Stryker 
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8.3 Differentiation assay, optimization of chondro-pellets staining 
technique 
 
 
 
 
 
 
Toluidine blue staining of chondro-pellets under different conditions. A, B) 
Toluidine blue was adjusted on pH2.5 and 4 and both were incubated for 10min. C, 
D) Toluidine blue was adjusted to pH2.5 and 4, respectively and both were incubated 
for 30min. A better colour appearance was observed for the combination of pH4 at 
30min. of incubation (D). (The staining optimization was performed on a secondary 
selection pellets, Magnification 64X.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B  pH 2.5, 30min C  pH 4, 30min D A pH 2.5 10min pH 4, 10min 
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AF28 IC AC 
POI POI 
POI POI 
POI 
POI 
POI 
POI 
POI 
AF28 IC LMP 
POI POI 
POI 
POI 
POI 
POI POI 
8.4 Flowcytometry, histograms of the BM-MSCs markers   
 
For all four donors, antigens and fluorochromes used, are illustrated in each 
histogram. Histograms were gated between 102-105 being deemed as positive 
staining. Population of interest (POI) was stained positively for markers APL, CD105, 
CD90, CD73, SUSD2, MSCA1, and negatively for CD14, CD19, CD34, HLA-DR and 
CD45 confirming MSCs' nature. 
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AF28 VB LMP 
POI POI POI 
POI 
POI 
POI 
POI POI 
 
 
 
AF28 VB AC 
POI POI POI 
POI POI POI 
POI 
POI 
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AF29 IC AC 
POI 
POI 
POI 
POI POI POI 
POI POI 
AF29 IC LMP 
POI POI 
POI 
POI 
POI 
POI 
POI POI 
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AF29 VB AC 
POI POI 
POI POI POI 
POI 
 
POI 
AF29 VB LMP 
POI POI POI 
POI POI 
POI 
POI POI 
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AF39 IC AC 
POI 
POI 
POI 
POI POI 
POI 
POI POI 
AF39 IC LMP 
POI POI POI 
POI POI 
POI 
POI POI 
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AF39 VB AC 
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POI 
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POI 
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POI 
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AF50 IC AC 
POI POI POI 
POI POI POI 
POI 
POI 
POI 
AF50 IC LMP 
POI POI 
POI 
POI 
POI POI POI 
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AF50 VB AC 
POI  POI   POI  
POI POI 
POI 
POI 
POI 
AF50 VB LMP 
POI POI 
POI 
POI 
POI 
POI 
POI 
POI 
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8.5 Children information sheet and Assent form (13-16 years old) 
Patient information sheet and Consent form (16-17 years old) 
Parental information sheet and Parental agreement / Consent form 
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CHILDREN INFORMATION SHEET 
 
Study title: The role of Stem Cells in Fracture Healing  
 
“Collection of Bone Marrow and Blood” 
 
PART 1  
 
(Please read part 1 and if you agree continue on reading part 2) 
 
You are being invited to take part in a RESEARCH study! 
 
Please take the time to read the following information carefully  
and discuss it with your family, friends, and your General Practitioner if you wish. 
 What research means?  
Research is when doctors try to understand new things about a disease or about something 
special! 
 
 Why are we doing this research? 
We would like to study the behaviour of some special cells of our body (stem cells), under 
specific conditions such as scoliosis surgery.  
We believe that those cells have a different behaviour in young people, compared to adults, 
and for this reason we need your help!   
 
 What is the procedure that is being tested? 
In this research we need to study the behaviour of those special cells during your scoliosis 
operation. You will not be required to take any additional medicine, and we will not be 
testing any device on you! 
 
 Why have I been invited to take part in this research? 
We are looking for children-young people (above the age of 13years) that are having 
surgery like yours (scoliosis correction). In this project we need to study 30 children.   
 
 Do I have to take part in your research? 
Your parents or guardians have to say it’s OK for you to be in the study. After they decide 
that, you get to choose if you want it as well. If you don’t want to be in the study, there is 
no problem, no one will mind. If you want to be in the study now and change your mind later, 
that’s also OK. You can stop at any time. This will not affect the standard of care that you 
receive. 
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 What will happen to me if I take part? 
You will be involved only during the first week of your stay in the hospital.  
You will not lose any of your time, for us.  
The total research program will last one year, but this time is necessary only for us 
doctors to study all the collected information. The only thing that we will ask you to do is, 
to allow us to take and analyse a small sample of your blood that will be collected during the 
standard blood tests that you would have anyhow during your stay in the hospital. 
 
 What will I be asked to do? 
If you decide to be a part of this study, you will have to write your name to a special paper 
called Assent form. Then nothing of the standard things that would happen anyhow during 
your stay with us will change. We will collect the small sample of blood that we need, during 
the time that we will collect blood for our routine tests. There will be no more needles. You 
will not lose any additional time from school. 
 
 What other medicines could I have instead? 
In this research we don’t use medicines. Our study is related only to the blood tests. 
 
 Is there anything else to be worried about if I take part? 
No, don’t worry, none of the aspects of this research can give you trouble/problems. 
 
 What are the possible benefits of taking part? 
We cannot promise the study will help you, but the information we get will help other 
children and in the future. You will have the opportunity to help us out in our work and be 
an important member of our research team. 
 
 Contact details 
If something is not clear or if you would like more information please ask us. 
 
Take your time to decide whether you wish or do not wish to take part. 
 
Contact Prof. Peter V. Giannoudis on 0113 392 2750, for any further information. 
 
Thank you for reading this. 
 
If you agree please read now Part 2
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PART 2 
 
What is the study about? 
 
In our body there are special cells everywhere, which help to make different parts 
of our body such as, bone, cartilage, muscle, tendon or ligament.  
 
We are doing this study on children, and we would like to ask for your help, because we 
want to know if there are any differences between adults and children, in surgery, such   
as a scoliosis operation. 
 
We are need to find how these cells influence the process of fixing problems.  
Our research aims to understand how these cells work. 
 
 
 
Why is the study being done? 
 
These cells help to heal different parts of the body, but just how they work is still not 
understood.  
 
So, with your help we would like to understand how these cells think and work, in a  
young person like yourself !!!  
 
 
Why have I been chosen? 
 
You suffer from a condition called scoliosis (means that the back is curved to the side), 
which may need surgery, like the operation you are having. 
 
We are doing this study on children with the same age as yourself, and we would need  
to involve around 30 different young people with scoliosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This is the theatre 
where the surgeon will 
fix your back bone! 
Curved Spine              Straight Spine 
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What will happen to me in the study? 
 
You will be asked to allow us to take an extra small amount of blood (few extra drops) 
during the normal tests, which are routinely made before, during, and after your operation. 
 
During the operation, the surgeon will take a very small piece of bone marrow from the 
area of the surgery, like a little a bread crumb that will be also analysed.  
This piece is not going to give you any pain or problems. 
 
You will not be asked to have any more needles. 
We will collect the few extra drops of blood just before your surgery, during the surgery 
and at the first day, the third, the fifth and the seventh day after your surgery while you 
are still in the hospital. 
 
 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part in this study, but we do hope you will. 
Take your time to think and discuss with any body you want, and feel free to decide.  
Whatever is your decision, will not change the way we take care of you! 
 
 
What do I have to do? 
 
Apart from agreeing to take part to this study, nothing else. 
What we need to collect for the study (the blood samples), will be collected during the 
time we would have to take blood as in all people that have surgery like yours. 
 
 
 
What are the possible benefits and risks of taking part? 
 
There are no side effects or risks. Asking you to give us a very small extra quantity  
of your blood, (just a few drops), will not put you at risk. 
 
You will not benefit directly from taking part in this research and all other aspects of  
your care will be the same as if you did not take part. 
 
Helping us, we could help other children like you, in the future! 
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Will I need to take time out off school, and if so how much time? 
 
This research will not make you miss any additional time from school! It is related only  
with the minimum necessary time spent in hospital for your good recovery after the 
surgery. 
 
 
 
 
Would this affect my social life? 
 
The goal of this surgery is to help you to get a better social life and, the aim of this 
research is to help other people like you in the future! 
  
 
 
 
When will the study begin and possibly finish?  
 
This is a pilot study and will last one year, starting on June 2012. 
After the evaluation of all the data collected we will think about the possibility to 
expand the study in more people and hospitals. 
 
 
What will happen to the results of the study? 
 
At the end of the study, the results will be published in a clinical scientific journal. They 
will be also discussed in big meetings of doctors that are very interested to learn such 
things. 
 
 
What happens when the research project stops? 
 
As the study is not related with any type of drugs, and you are not under a special 
treatment, you must not worry if the study is going to end. 
 
What happens if new information from this research comes along? 
 
Sometimes during a research study, new things are found. If this happens we will   
inform yourself and your family or guardians. 
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What if something goes wrong? 
 
This research can not cause you damage, for this reason there are no special  
compensation arrangements if you are harmed by taking part. If you are harmed due to 
someone’s negligence, then you may have grounds for legal action but you may have to pay 
for it.  
Regardless of this, if you wish to complain about any aspect of the way you have been 
approached or treated during the course of this study, the normal NHS complaints 
procedure will be available to you. 
 
 
 
Will my taking part in this study be kept confidential? 
 
Other people will not know if you are in our study.  We will put all the information  
we learn about you, together with information regarding other children-young people,  
so no one will know what details came from you.  When we tell other people about our  
research, we will not use your name, so no one can tell who we are talking about.  
 
 
 
What will happen to any samples I give you? 
 
The collection and storing of all samples is done in such a way as to ensure maximum  
safety. After their examination in the laboratory, are neutralised and discharged  
under special conditions, respecting particular rules.  
 
 
 
 
Where will the study take place? 
 
This project is being organised by Doctors of this hospital (Leeds General Infirmary)  
and Leeds Institute Molecular Medicine under the supervision and support of Leeds 
University. 
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Who has reviewed this study? 
 
This study has been reviewed by the independent ethics committee called the Leeds  
(East) Research Ethics Committee. This committee control if this research is ethical and 
correct respecting the rights and the well-being of patients. We have received approval 
from this committee to do this study. 
 
 
 
Who will lead the study? 
  
Prof. Peter V. Giannoudis is the principal investigator. He is the director of the 
Department of Trauma and Orthopaedic Surgery, Leeds General Infirmary. 
 
If you need to ask more information about this study or if you decide you don’t  
want to be in the study any more, please feel free to contact Prof. Peter V. Giannoudis     
on 0113 392 2750. 
 
NOTES 
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
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CHILDREN ASSENT FORM 
 
Title of Study: The role of Stem Cells in Fracture Healing  
 
“Collection of Bone Marrow and Blood” 
 
 
Patient Name: …………………….……………………………………..…………………………. 
Patient Identification Number: ………………………………………..…………………………… 
 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name!  
If you do want to take part, you can write your name below  
 
Child’s agreement  
I agree to participate in the study I have been told about. 
Name:…….………………………………………...........………………….….. Date: …………........……. 
Investigator/Sub-investigator 
I have explained the study to the above named participant and he/she has indicated his/her willingness to participate 
Name (BLOCK CAPITALS): …………............………………………………….……………………….. 
Signed: …….................……………………………… ……..…………………. Date:….........…..……….. 
Thank you for your help. 
Please circle all you agree (or if unable, to be completed by parent / guardian on their behalf) 
1. Have you read all (or had read to you) the information about this study? Yes No 
2. Has somebody else explained this project to you? Yes No 
3. I have had the opportunity to ask questions about the study and to discuss it with my family  
    and friends if I so wish to. 
Yes No 
4. Do you understand what this study is about? Yes No 
5. I understand that all information collected in the study will be held in confidence and that, if  
    it is presented or published as scientific paper, all personal details will be removed. 
Yes No 
6. I agree for the data collected to be used for teaching, study and research in order to help  
    more patients in the future. 
Yes No 
7. Have you asked all the questions you want? Yes No 
8. Have you had your questions answered in a way you understand? Yes No 
9. Do you understand that it’s ok to stop taking part, in the study, at any time? Yes No 
10. Are you happy to take part? Yes No 
 Collection of Bone Marrow & Blood – Parental Information Sheet for a Child or Young Person   
Version 1.1 – 23-03-2012 
 A24 
PATIENT INFORMATION SHEET 
Regarding Investigation for a Young Person over 16 to 17 years old 
 
 
Study title: Biological properties of Mesenchymal Stem Cells in Fracture Healing 
“Collection of Bone Marrow and Blood” 
  
PART 1  
(Please read part 1 and if you agree continue on reading part 2) 
 
 
You are invited to participate in a RESEARCH study. 
 
You are selected as a possible participant, because you are within the age range that we are interested to study. 
Before reaching any decision, it is important to understand why the research is being done, and what it will 
involve. 
Please read the following information carefully, and  discuss it with your relatives, partner, friends, and if you 
wish your GP. 
 
Take your time to decide whether or not you wish to take part in our study. 
 
 What is the purpose of the study? 
Special cells of the human body known as Mesenchymal Stem Cells (MSCs) are involved in the production of 
bone, cartilage, muscle, tendon and ligaments. These cells have been found in all tissues to date, but exactly how 
they work is still not well understood. The purpose of this research is to find if there are any differences between 
the behaviour of young people’s and adult’s MSCs under specific conditions such as surgery. 
 
 What is the medicine, device or procedure that is being tested?  
In this research we need to study only the behaviour of Mesenchymal Stem Cells (MSCs). Will not be required to 
take any kind of medicine for the purposes of the study, and we will not be testing any device or procedure! 
 
 Why have I been invited to take part in the study? 
You have been selected as a possible participant because you suffer from Idiopathic Scoliosis which after a 
certain point of its evolution is treated surgically.  
Secondly you are in the age range that we are interested to study (between 13 to 17 years old). 
In order to achieve statistically valid results we need to study about 30 children/young people of the same age. 
 
 Do I have to take part? 
Of course, the decision to participate or not, is absolutely yours. Should you decide to participate in the study 
and change opinion afterwards, this will not represent a problem. You can withdrawal from the study at any 
time, and this will not affect the standards of care that you receive. 
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    What will happen to me if I take part in the study? 
You will be involved only during the first week of your stay into the hospital and,you will not lose any 
more of your time, for the purposes of the study. 
 The whole study will last for one year, in order to recruit the necessary number of cases and to analyse 
the collected data. 
The only thing that we need is your permission/consent to take a small sample of your  blood during the 
normal blood tests, with no additional punctures or procedures than the standard ones, as well as a small 
sample of bone marrow during the surgery from the area of the operation. 
 
    What will be asked to do? 
Apart from donating a small quantity of blood and bone marrow for the research purposes, there are no 
other requirements or tests that will be needed.  
You will not lose any additional time from school/college due to this research.   
Before you will be recruited in the study, we will give you a copy of this information sheet and you will be 
asked to authorise us by signing a special consent form. 
 
    What other medicines could I have instead? 
In this research we don’t use medicines, thus we do not anticipate any side effects or complications. Our 
study is related only to the analysis of small samples of bone marrow and blood from your organism. 
 
    Is there anything else to be worried about, if I take part in the study? 
No, none of the aspects of this research can create any problem to you. 
 
    What are the possible benefits of taking part in the study? 
We cannot promise that the study will help you directly. However, the information we will get after our 
analysis, might help other children and people in the future. It will also be an opportunity for you  to 
participate to a scientific research study approved by the Leeds Research Ethics Committee and the 
Research and Development department of this NHS Trust. 
 
    Contact details 
If something is not clear or if you would like more information, please don’t hesitate to ask us. 
Take your time to decide whether you wish or do not wish to take part in the study. 
Contact Prof. Peter V. Giannoudis on  0113 392 2750. 
 
 Thank you for reading this.  
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PART 2 
 
What is the purpose of the study? 
 
Special cells of the human body known as Mesenchymal Stem Cells (MSCs) are involved in the production 
of bone, cartilage, muscle, tendon and ligaments. These cells have been found in all tissues, but exactly 
how they work is still not well understood.  
There is great interest in the use of MSCs as a way of repairing damaged tissues.  
Our research aims to improve our understanding of how these cells work in health and in disease. 
More specifically, we would like to study if these cells have a different behaviour between adults and 
children/young people, in case of major surgery, such as a scoliosis operation. 
 
Why have I been chosen? 
 
You suffer from idiopathic scoliosis, which after a certain point of its evolution is treated surgically. 
Also, we are conducting this study on children/young people within the age range between 13 to 17 years 
old.  
To undergo this sort of lengthy and complex surgery, albeit quite safe, does cause these stem cells to come 
into action so as to protect patients during surgery and mobilise natural healing.  
We want to know what happens to these stem cells during surgery and what triggers them into action. 
In order to achieve a statistically valid result of our research program we need to study approximately 30 
children. 
 
 
 
What will happen to me if I take part in the study? 
 
You will be asked to donate a small extra amount of blood (few extra grams for every withdrawal) which 
is routinely taken before, during and after the operation.  
The plan is to take small samples of peripheral blood (just 3 ml more, than the standard quantity of blood 
collection) before the start of the operation, intra-operatively, at the end of the surgery and four more 
times later (1
st
, 3
rd
, 5
th
 and 7
th
 day after the surgery).  
Blood samples are taken before and after surgery routinely, as standard of care, in this type of operation. 
We would like to obtain smalls additional amounts of blood in the same samplings for our research. 
Withdrawing this extra small amount of blood does not influence the final result of the operation of your 
child or his/her recovery. 
During surgery similar blood samples are often taken as part of intra-operative monitoring. At that setting 
we would like also to obtain a small additional amount for our research. This additional sample will not 
cause you any further discomfort, as it is already part of the normal procedure and will not delay healing 
in any way. 
Also, during surgery (from the field of the surgical area) in the bony part of the operation, when the 
metalwork is inserted we shall take a very small piece of bone marrow aspirate, so in this way we are able 
to study the biology of these stem cells.  This will not in any way harm your child who will feel absolutely 
no discomfort whatsoever over and above a routine scoliosis operation. This bone marrow normally leaks 
out and is washed out and discarded during the operation.  
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Do I have to take part?  
 
It is up to you to decide whether or not you would like to participate. There is absolutely no obligation at 
all to take part in this study although being quite harmless to you; we do hope you will agree to join our 
research team. If you decide to take part, you will be given this information sheet to keep and be asked to 
sign a consent form. You are still free to withdraw at any time without giving a reason. This will not affect 
the way we take care of you..  
 
 
What do I have to do? 
 
Apart from donating a small quantity of blood, and bone marrow (only once), for research purposes, there 
are no other requirements/tests. 
It is very important, when you are giving your medical history to the doctor, to inform if you are regularly 
taking any medicine. Taking certain types of medication, may mean that we will have to exclude you from 
this study. 
 
 
What are the possible benefits and risks of taking part? 
 
You will not benefit directly from taking part in this research and all other aspects of your care will be the 
same as if you did not take part. 
Although there may be no direct benefit to you, this will be of great value to future scoliosis patients and 
other people of any age that undergo major surgery. 
 
What are the side effects of taking part? 
 
There are no side effects. Asking to give us a very small amount of your blood, (just a few drops), will not 
put yourself at any type of risk. 
 
What other medicines could I have instead? 
 
We do not require you to take any kind of research related medications. Our study is related only with the 
bone marrow and blood samples and the specific tests that we will run for analysis. 
 
Is there anything else to be worried about if I take part? 
 
No, none of the aspects of this research can cause problems to you. 
 
 
Will I needs to take time out of school/college, and if so how much time? 
 
This research will not require taking any time out of school/college! It is related only with the first week of 
the total period of staying in the hospital at the time of the scoliosis surgery. The whole period of time 
spent in the hospital is the minimum necessary for your good recovery after such major surgery, and is not 
related with the research study.  
 
Would this affect my social life? 
 
Not at all, as it will not affect your recovery and will not cause any additional problems or discomfort. 
The aim of this research is to help other people and children/young people like you in the future. The goal 
of scoliosis surgery is to improve the quality of life and your social aspect.. 
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When will the study begin and possibly finish?  
 
This is a pilot study, and will last one year, starting in June 2012. 
The duration of the study depends principally on the evaluation of all the data collected after acquiring 
samples from 30 patients, and not on the future availability of any of these patients. 
 
What will happen to the results of the study? 
 
They will be analysed very carefully, published in a major scientific journal so that the rest of the world 
will appreciate its significance not only in scoliosis surgery but other comparable major operations. 
 
 
Will my taking part in this study be kept confidential? 
 
Although you will be an important part of the study, as soon as the samples are withdrawn from you, all 
information that may identify you will be removed so that you cannot be recognised or linked  to the 
research material. 
 
 
What will happen to any samples you give? 
 
The collection and storing of all samples is done in a way that ensures maximum safety. After examination 
in the laboratory they are neutralised and discarded under special conditions, respecting particular rules, 
within the trust guide lines.  
 
 
What if something goes wrong? 
 
If you are harmed by taking part in this research (again this is not expected to be the case by any means), 
there are no special compensation arrangements. If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it. Regardless of this, if you wish to 
complain about any aspect of the way you  have been approached or treated during the course of this 
study, the normal NHS complaints procedure is available to you. 
 
 
What happens when the research project stops? 
 
Considering that this study is not related to any type of drugs, and you are not under any type of special 
treatment, you must not worry if the study is going to end. 
 
What happens if new information about the research medicine comes along? 
 
Sometimes during a research study, new things can be discovered or new related evidence can become 
available. If something relevant to this study becomes available which affects the design or the subject of 
this project we will inform you in accordance to the changes occurred. 
 
 
Where will the study take place? 
 
This project is being organized by Doctors of this hospital (Leeds General Infirmary) and researchers of 
the Leeds Institute of Molecular Medicine, with supervision and support from the University of Leeds. 
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Who has reviewed this study? 
 
This study has been reviewed by the independent ethics committee called the Leeds (East) Research Ethics 
Committee. This committee is appointed to determine that research studies are ethical and do not impair 
the rights or well-being of  patients. Also the Research and Development department of the Leeds 
Teaching Hospitals NHS Trust has also reviewed and approved this study.  
 
  
Who will lead the study? 
  
Prof. Peter V. Giannoudis is the principal investigator. He is the chairman of the Academic Department of 
Trauma and Orthopaedic Surgery, of the School of Medicine of the University of Leeds, and is also a 
Honorary Consultant at the Leeds Teaching Hospital NHS Trust, based at the Leeds General Infirmary. 
If you require further information about this study, or if you decide that you don’t want to participate in 
the study any more, please do not hesitate to contact Professor Peter Giannoudis on 0113-39-22750, 
0113-39-23290. 
 
 
 
NOTES 
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------
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PATIENT CONSENT FORM  
Regarding Investigation for a Young Person aged between 16 to 17 years of age. 
 
Study title: Biological properties of Mesenchymal Stem Cells in Fracture Healing 
 
“Collection of Bone Marrow and Blood” 
 
Patient’s Name: ………………………………………………………..…………………………. 
Patient’s Identification Number: …..………………………………..…………………………… 
 
Patient or Legal Representative  (BLOCK CAPITALS):  
Name: ……………………………………………………………….........……….………….…..……….... 
 
Signed: ………………..……………………………………...........………..…….. Date: …………………. 
 
Investigator/Sub-investigator (BLOCK CAPITALS): 
I have explained the study to the above named participant and he/she has indicated his/her willingness to participate 
 
Name: ………………………….…………………………………………….………………….........…….. 
 
Signed: ………...........…………………………………………..…………………. Date: ………..………. 
Thank you for the help 
Please circle as appropriate 
1. I have read (or had read to me) and understand the patient information sheet for the above 
study. 
Yes No 
2. I have had the opportunity to ask questions about the study and to discuss it with family and 
friends, if I so wish to. 
Yes No 
3. I understand the purpose of the study, and how I will be involved. Yes No 
4. I understand, and accept, that if I take part in the study I may not gain direct personal 
benefit, but many more people will benefit from it. 
Yes No 
5. I understand that all information collected in the study will be held in confidence and if the 
results will be written into a scientific paper, all personal details will be removed. 
Yes No 
6. I give permission for those responsible doctors, to have access to my medical notes, where it 
is relevant to my taking part in the research. This is on the understanding that no personal 
details which might identify me, will be presented or published without my permission. 
Yes No 
7. I agree for the data collected to be used in future for teaching, study and research for the 
benefit of all patients. 
Yes No 
8. I confirm that I will be taking part in this study of my own free will, and I understand that I 
am free to withdraw from the study at any time without giving a reason and without 
affecting future care or legal rights. 
Yes No 
9. I have spoken to Mr. Fragkakis Evangelos Yes No 
10. I agree to take part in this research study. Yes No 
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PARENTAL INFORMATION SHEET 
Regarding Investigation or Treatment for a Child or Young Person 
 
 
Study title: Biological properties of Mesenchymal Stem Cells in Fracture Healing 
“Collection of Bone Marrow and Blood” 
  
PART 1  
(Please read part 1 and if you agree continue on reading part 2) 
 
 
Your child has been invited to take part in a RESEARCH study. 
 
She/he was selected as a possible participant, because she/he is within the age range that we are interested to 
study. 
Before reaching any decision, it is important to understand why the research is being done, and what it will 
involve. 
Please read the following information carefully, and to discuss it with your partner, friends, relatives, and if you 
wish your GP. 
 
Take your time to decide whether or not you wish your child to take part in our study. 
 
 What is the purpose of the study? 
Special cells of the human body known as Mesenchymal Stem Cells (MSCs) are involved in the production of 
bone, cartilage, muscle, tendon and ligaments. These cells have been found in all tissues to date, but exactly how 
they work is still not well understood. The purpose of this research is to find if there are any differences between 
the behaviour of children’s and adult’s MSCs under specific conditions such as surgery. 
 
 What is the medicine, device or procedure that is being tested?  
In this research we need to study only the behaviour of Mesenchymal Stem Cells (MSCs). Your child will not be 
required to take any kind of medicine for the purposes of the study, and we will not be testing any device or 
procedure! 
 
 Why has your child been invited to take part in the study? 
Your child was selected as a possible participant because she/he suffers from Idiopathic Scoliosis which after a 
certain point of its evolution is treated surgically.  
Secondly your child is in the age range that we are interested to study (above the age of 13 years). 
In order to achieve statistically valid results we need to study about 30 children of the same age. 
 
 Does she/he have to take part? 
Of course, the decision to allow your child to participate or not, is absolutely yours. Should you decide to let 
your child participate in the study and change opinion afterwards, this will not represent a problem. Your child 
can withdrawal from the study at any time, and this will not affect the standards of care that your child receives. 
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    What will happen to my child if she/he takes part in the study? 
She/he will be involved only during the first week of her/his stay into the hospital and, will not lose any 
more of her/his time, for the purposes of the study. 
 The whole study will last for one year, in order to recruit the necessary number of cases and to analyse 
the collected data. 
The only thing that we need is your permission/consent to take a small sample of your child’s blood 
during the normal blood tests, with no additional punctures or procedures than the standard ones, as well 
as a small sample of bone marrow during the surgery from the area of the surgery. 
 
    What does she/he have to do? 
Apart from donating a small quantity of blood and bone marrow for the research purposes, there are no 
other requirements or tests that will be needed.  
She/he will not lose any additional time from school due to this research.   
Before your child will be recruited in the study, we will give you a copy of this information sheet and you 
will be asked to authorise us by signing a special consent form. 
If you agree for your child to participate in this study, will be given to your child  a specially prepared 
document with a brief description of the study in simple terms. She/he will have to agree with the overall 
plan and write her/his name in a special form called Assent form. 
 
    What other medicines could she/he has instead? 
In this research we don’t use medicines, thus we do not anticipate any side effects or complications. Our 
study is related only to the analysis of small samples of bone marrow and blood from your child. 
 
    Is there anything else to be worried about, if she/he takes part in the study? 
No, none of the aspects of this research can create any problem to your child. 
 
    What are the possible benefits of taking part in the study? 
We cannot promise that the study will help your child directly. However, the information we will get after 
our analysis, might help other children and people in the future. It will also be an opportunity for yourself 
and your child to participate to a scientific research study approved by the Leeds Research Ethics 
Committee and the Research and Development department of this NHS Trust. 
 
    Contact details 
If something is not clear or if you would like more information, please don’t hesitate to ask us. 
Take your time to decide whether you wish or do not wish to take part in the study. 
Contact Prof. Peter V. Giannoudis on  0113 392 2750. 
 
 Thank you for reading this.  
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PART 2 
 
What is the purpose of the study? 
 
Special cells of the human body known as Mesenchymal Stem Cells (MSCs) are involved in the production 
of bone, cartilage, muscle, tendon and ligaments. These cells have been found in all tissues, but exactly 
how they work is still not well understood.  
There is great interest in the use of MSCs as a way of repairing damaged tissues.  
Our research aims to improve our understanding of how these cells work in health and in disease. 
More specifically, we would like to study if these cells have a different behaviour between adults and 
children, in case of major surgery, such as a scoliosis operation. 
 
Why has your child been chosen? 
 
Your child suffers from idiopathic scoliosis, which after a certain point of its evolution is treated 
surgically. 
Also, we are conducting this study on children with the same age range as your child’s.  
To undergo this sort of lengthy and complex surgery, albeit quite safe, does cause these stem cells to come 
into action so as to protect patients during surgery and mobilise natural healing.  
We want to know what happens to these stem cells during surgery and what triggers them into action. 
In order to achieve a statistically valid result of our research program we need to study approximately 30 
children. 
 
 
 
What will happen to my child if she/he takes part? 
 
Your child will be asked to donate a small extra amount of blood (few extra grams for every withdrawal) 
which is routinely taken before, during and after the operation.  
The plan is to take small samples of peripheral blood (just 3 ml more, than the standard quantity of blood 
collection) before the start of the operation, intra-operatively, at the end of the surgery and four more 
times later (1
st
, 3
rd
, 5
th
 and 7
th
 day after the surgery).  
Blood samples are taken before and after surgery routinely, as standard of care, in this type of operation. 
We would like to obtain smalls additional amounts of blood in the same samplings for our research. 
Withdrawing this extra small amount of blood does not influence the final result of the operation of your 
child or his/her recovery. 
During surgery similar blood samples are often taken as part of intra-operative monitoring. At that setting 
we would like also to obtain a small additional amount for our research. This additional sample will not 
cause to your child any further discomfort, as it is already part of the normal procedure and will not delay 
healing in any way. 
Also, during surgery (from the field of the surgical area) in the bony part of the operation, when the 
metalwork is inserted we shall take a very small piece of bone marrow aspirate, so in this way we are able 
to study the biology of these stem cells.  This will not in any way harm your child who will feel absolutely 
no discomfort whatsoever over and above a routine scoliosis operation. This bone marrow normally leaks 
out and is washed out and discarded during the operation.  
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Does she/he have to take part? 
 
It is up to you to decide whether or not you would like your child to participate. There is absolutely no 
obligation at all for your child to take part in this study although being quite harmless to her/him; we do 
hope you will agree to join our research team. If you decide to take part, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still free to request for your child 
to withdraw at any time without giving a reason. This will not affect the standard of care that your child 
receives.  
 
 
What does she/he has to do? 
 
Apart from donating a small quantity of blood, and bone marrow (only once), for research purposes, there 
are no other requirements/tests. 
It is very important, when you are giving her/his medical history to the doctor, to inform if she/he is 
regularly taking any medicine. Taking certain types of medication, may mean that we will have to exclude 
your child from this study. 
 
 
What are the possible benefits and risks of taking part? 
 
Your child will not benefit directly from taking part in this research and all other aspects of her/his care 
will be the same as if she/he did not take part. 
Although there may be no direct benefit to your child, this will be of great value to future scoliosis patients 
and other people of any age that undergo major surgery. 
 
What are the side effects of taking part? 
 
There are no side effects. Asking to give us a very small amount of your blood, (just a few drops), will not 
put your child at any type of risk. 
 
What other medicines could she/he have instead? 
We do not require your child to take any kind of research related medications. Our study is related only 
with the bone marrow and blood samples and the specific tests that we will run for analysis. 
 
Is there anything else to be worried about if she/he takes part? 
No, none of the aspects of this research can cause problems to your child. 
 
 
 
Will she/he needs to take time out of school, and if so how much time? 
 
This research will not require taking any time out of school! It is related only with the first week of the 
total period of staying in the hospital at the time of the scoliosis surgery. The whole period of time spent in 
the hospital is the minimum necessary for her/his good recovery after such major surgery, and is not 
related with the research study.  
 
Would this affect her/his social life? 
 
Not at all, as it will not affect her/his recovery and will not cause any additional problems or discomfort. 
The aim of this research is to help other people and children like yours in the future. The goal of scoliosis 
surgery is to improve the quality of life and social aspect of your child. 
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When will the study begin and possibly finish?  
 
This is a pilot study, and will last one year, starting in June 2012. 
The duration of the study depends principally on the evaluation of all the data collected after acquiring 
samples from 30 patients, and not on the future availability of any of these patients. 
 
What will happen to the results of the study? 
 
They will be analysed very carefully, published in a major scientific journal so that the rest of the world 
will appreciate its significance not only in scoliosis surgery but other comparable major operations. 
 
 
 
Will her/his taking part in this study be kept confidential? 
 
Although your child will be an important part of the study, as soon as the samples are withdrawn from 
her/him, all information that may identify your child will be removed so that she/he cannot be linked or 
recognised to the research material. 
 
 
What will happen to any samples that she/he gives you? 
 
The collection and storing of all samples is done in a way that ensures maximum safety. After examination 
in the laboratory they are neutralised and discarded under special conditions, respecting particular rules, 
within the trust guide lines.  
 
 
What if something goes wrong? 
 
If your child is harmed by taking part in this research (again this is not expected to be the case by any 
means), there are no special compensation arrangements. If she/he is harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have to pay for it. Regardless of 
this, if you wish to complain about any aspect of the way your child has been approached or treated 
during the course of this study, the normal NHS complaints procedure is available to you. 
 
 
 
What happens when the research project stops? 
 
Considering that this study is not related to any type of drugs, and your child is not under any type of 
special treatment, you must not worry if the study is going to end. 
 
 
What happens if new information about the research medicine comes along? 
 
Sometimes during a research study, new things can be discovered or new related evidence can become 
available. If something relevant to this study becomes available which affects the design or the subject of 
this project we will inform you in accordance to the changes occurred. 
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Where will the study take place? 
 
This project is being organized by Doctors of this hospital (Leeds General Infirmary) and researchers of 
the Leeds Institute of Molecular Medicine, with supervision and support from the University of Leeds. 
 
 
 
Who has reviewed this study? 
 
This study has been reviewed by the independent ethics committee called the Leeds (East) Research Ethics 
Committee. This committee is appointed to determine that research studies are ethical and do not impair 
the rights or well-being of  patients. Also the Research and Development department of the Leeds 
Teaching Hospitals NHS Trust has also reviewed and approved this study.  
 
 
  
Who will lead the study? 
  
Prof. Peter V. Giannoudis is the principal investigator. He is the chairman of the Academic Department of 
Trauma and Orthopaedic Surgery, of the School of Medicine of the University of Leeds, and is also a 
Honorary Consultant at the Leeds Teaching Hospital NHS Trust, based at the Leeds General Infirmary. 
If you require further information about this study, or if you decide that you don’t want to participate in 
the study any more, please do not hesitate to contact Professor Peter Giannoudis on 0113-39-22750, 
0113-39-23290. 
 
 
 
NOTES 
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
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PARENTAL AGREEMENT - CONSENT FORM  
to Investigation for a Child or Young Person 
 
Study title: Biological properties of Mesenchymal Stem Cells in Fracture Healing 
 
“Collection of Bone Marrow and Blood” 
Patient’s Name: ………………………………………………………..…………………………. 
 
Patient’s Identification Number: …..………………………………..…………….……………… 
 
Parents or Legal Representative  (BLOCK CAPITALS):  
Name: ……………………………………………………………………….………….…..……….... 
Relationship to the child: ………………….………………………………………………………... 
 
Signed: ………………..……………………………………………..…….. Date: …………………. 
 
Investigator/Sub-investigator (BLOCK CAPITALS): 
I have explained the study to the above named participant and he/she has indicated his/her willingness to participate 
 
Name: ………………………….…………………………………………….……………………….. 
 
Signed: …………………………………………………..…………………. Date: …......……..……
Please circle as appropriate 
1. I have read the parental information sheet for the above study, and confirm that I have 
parental responsibility for this child.  
Yes No 
2. I have had the opportunity to ask questions about the study and to discuss it with family and 
friends, if I so wish to. 
Yes No 
3. I understand the purpose of the study, and how my child will be involved. Yes No 
4. I understand, and accept, that if my child takes part in the study he/she may not gain direct 
personal benefit, but many more children will benefit from it. 
Yes No 
5. I understand that all information collected in the study will be held in confidence and if the 
results will be written into a scientific paper, all personal details will be removed. 
Yes No 
6. I give permission for those responsible doctors, to have access to my child’s medical notes, 
where it is relevant to her/his taking part in the research. This is on the understanding that 
no personal details which might identify him/her, will be presented or published without my 
permission. 
Yes No 
7. I agree for the data collected to be used in future for teaching, study and research for the 
benefit of all patients. 
Yes No 
8. I confirm that my child will be taking part in this study of his/her own free will, and I 
understand that we are free to withdraw from the study at any time without giving a reason 
and without affecting future care or legal rights. 
Yes No 
9. I have spoken to Mr Fragkakis Evangelos Yes No 
10. I agree to take part in this research study. Yes No 
Thank you for the help 
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